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Palliative care
A century ago, death was typically quite sudden, and the leading causes were infections, accidents, 
and childbirth.1,2 At that time, a healthy person who became sick either recovered or died, and there 
was no medical involvement or any medical involvement lasted only for a very short period of time.2 
Today, due to improved public health and medical treatments, the overall trend worldwide is towards 
increasing longevity, with ageing of populations as one of its consequences.1-3 As a result, sudden 
death is less common, and more chronic diseases such as cancer, dementia and chronic organ failure 
shape the last years of life for a large part of the population.2 In the Netherlands, the annual absolute 
number of deaths for the last decade was 136 724.4 Six out of ten of these deaths were preceded by 
end-of-life decisions, such as intensive symptom control and withholding or withdrawal of medical 
interventions, and in one out of four of these deaths, an elderly care physician, formerly called nursing 
home physician, was the attending physician.5,6 The primary aim of the care in the last phase of life 
of these often older patients is to optimize quality of life, which is the basic philosophy of palliative 
care.1 Palliative care is defined by the World Health Organization as “an approach that improves 
the quality of life of patients and their families facing the problem associated with life-threatening 
illness, through the prevention and relief of suffering by means of early identification and impeccable 
assessment and treatment of pain and other problems, physical, psychosocial and spiritual. Palliative 
care provides relief from pain and other distressing symptoms; affirms life and regards dying as 
a normal process; intends neither to hasten or postpone death; integrates the psychological and 
spiritual aspects of patient care; offers a support system to help patients live as actively as possible 
until death; offers a support system to help the family cope during the patients illness and in their 
own bereavement; uses a team approach to address the needs of patients and their families, including 
bereavement counselling, if indicated; will enhance quality of life, and may also positively influence 
the course of illness; is applicable early in the course of illness, in conjunction with other therapies 
that are intended to prolong life, such as chemotherapy or radiation therapy, and includes those 
investigations needed to better understand and manage distressing clinical complications.”7 
Palliative care for the needs of a patient with an incurable disease has to be viewed as a continuum of 
care, starting at diagnosis and with death as the end-point.2 At the end of this continuum of palliative 
care, palliative sedation can be administered as a medical intervention.8,9 
Palliative sedation 
If one or more symptoms in a dying patient cause unbearable suffering and conventional modes of 
treatment are not effective or fast-acting enough and/or if these modes of treatment are accompanied 
by unacceptable side-effects (so-called refractory symptoms), an indication arises to administer 
palliative sedation.10-13 Palliative sedation is defined as “the deliberate lowering of a patient’s level 
of consciousness in the last stages of life.”10 The objective of palliative sedation is to alleviate the 
patient’s discomfort caused by refractory symptoms.10-13 Palliative sedation should be applied 
proportionately; the dose of sedative should be individually titrated.10-13 The term ‘‘palliative 
sedation’’ encompasses two distinct types of intervention: brief or intermittent sedation and 
continuous sedation administered until death (CPS).10 Although both interventions represent stages 
in the ongoing process of providing proportional sedation for refractory symptoms, the distinction 
is made to emphasize the fact that CPS is only to be administered to patients who are near death.10 
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CPS is considered as a last resort intervention; it not only takes away a patient’s suffering until 
the moment of death but also produces an impaired capacity to communicate.8,9 Hence, potential 
positive and meaningful experiences a patient might have are taking away, such as pleasant moments 
shared with family, communication, and the ability to reflect upon himself.13-18 In addition, research 
shows that relatives, nurses and physicians sometimes experience the administration of CPS as a 
burden.19-22 Relatives expressed concerns regarding sedation in approximately half of the cancer 
patients for whom CPS was used in an acute palliative care unit.20 These concerns could be classified 
into three main themes: concerns about the aim of CPS, concerns related to the well-being of the 
patient, and concerns related to the well-being of the relatives themselves. Moreover, relatives 
reported that they were distressed about the inability to communicate with a patient.22 Physicians 
reported, more often than nurses, that they felt they were put under pressure to start continuous 
sedation, mostly by patients and relatives.19,21 
Palliative sedation in the literature 
In 1990, Ventafridda and colleagues were one of the first to describe sedation at the end of life in 
relation to uncontrollable symptoms in terminal cancer patients and noted that more than 50% of 
these patients died under sedation.23 In 1991, Enck introduced the term “terminal sedation” into 
the literature.24 Enck did not specifically define “terminal sedation” but presented studies showing 
that some patients dying with cancer had unrelieved suffering in their final days and that providing 
medication to relieve this suffering could only be accomplished by reducing their consciousness.25 
In the following years, an increase in the number of empirical studies on this topic were carried out, 
and terminal sedation was substituted in the majority of the studies by the term palliative sedation.26 
Recently, a Cochrane review was performed to assess the evidence for the benefit of palliative sedation 
on quality of life, survival and specific refractory symptoms in terminally ill adults during their last 
few days of life.27 This review included 14 studies with a total of 4167 adults, of whom 1137 received 
palliative sedation. The proportion of people in each study receiving palliative sedation ranged from 
12% to 67%. In all the studies, the proportion of people with a cancer diagnosis was greater than 95%. 
The settings of these studies were hospices, palliative care units, hospital oncology wards, and home-
based palliative care; three studies involved more than one setting. The most common indications for 
palliative sedation were delirium, dyspnea, pain, existential distress, anxiety, and mental anguish. 
The most commonly used drug to achieve palliative sedation was midazolam, and the mean duration 
of sedation from initiation to death ranged from 19 hours to 3.4 days. Other reviews on palliative 
sedation report similar findings with respect to indication, duration and medication.13,26,28-31 All 
these reviews emphasize the significant lack of research in this area and the need for more clinical, 
prospective and multicenter research on topics such as the efficacy, establishing proper instruments 
for monitoring, the most adequate frequency and timing of assessment, and the interdisciplinary 
evaluation of sedation depth and symptom control.13,26,27-31
Palliative sedation in the Netherlands
In the Netherlands, one of the first publications on sedation at the end of life was published in 1998 
in the Dutch Journal of Medicine (NTVG).32 The authors described four terminal cancer patients 
with terminal restlessness, emphasizing that interventions directed at problems such as withdrawal 
symptoms, metabolic derangements, urinary and/or faecal retention and intoxication by drugs 
should be considered before starting sedation. A year later in the same journal, the importance of 
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timely assessment of the patient’s preference for end-of-life interventions was brought to attention, 
and a distinction was made between sedation at the end of life and euthanasia, arguing that sedation 
does not shorten life.33 In 2002 and 2003, practice guidelines for sedation at the end of life, released 
by two Comprehensive Cancer Centers, underlined the distinction between sedation and euthanasia 
and described the indication and administration of sedation.34,35 Despite these regional guidelines, 
controversies regarding the clinical practice of sedation arose. These controversies were illustrated 
in 2003, when a Dutch anaesthesiologist administered morphine and midazolam to a suffocating 
terminal patient. After he reported a natural death, he was accused of ‘having given purposefully 
and with malice aforethought a lethal injection to a terminal patient’.36 This led to a legal test case 
that lasted for two years.37 With this test case the public prosecutor wanted to create clarity with 
respect to the grey area between hastening death and ‘normal’ medical treatment.38 The case caused 
great concern in the medical profession, as palliative sedation was estimated at that time to be 
involved in more than 11 000 deaths each year in the Netherlands.4,39,40 Eventually, in 2006, the 
court acknowledged that the doctor’s treatment was considered normal medical treatment within 
professional standards.39,41 Meanwhile, another study brought the Dutch sedation practice to the 
attention of an international audience and the Dutch government.42,43 In this study, physicians 
reported the characteristics of their most recent sedation case. Hastening death was partly the 
intention of the physician in 47% of cases and the explicit intention in 17% of cases. In its response 
to this study, the government urged the medical profession to draft a national guideline on terminal 
sedation, which was launched in 2005 and updated in 2009.10,44,45 The Royal Dutch Medical 
Association (RDMA) guideline describes the conditions in which palliative sedation is good medical 
practice. In addition to defining the professional standard, the guideline also has legal significance. 
In January 2006, the Public Prosecution Service stated that it saw no reason to prosecute physicians 
who comply with the RDMA guideline.46 Although the RDMA guideline gave a comprehensive 
framework for clinical decision-making, the Dutch debate on the practice of palliative sedation 
continued. A Dutch study found that continuous deep sedation was administered increasingly 
more often, whereas the use of euthanasia was decreasing.47 This study suggested that palliative 
sedation was possibly being administered as an alternative to euthanasia. In addition to the area 
of debate concerning the relationship between palliative sedation and euthanasia, other areas of 
debate were present as well.40,48-53 First, research has shown that physicians in the past did not 
always act in accordance with earlier regional guidelines, which served in part as the basis for the 
RDMA guideline.54 Several questions therefore arose. Are physicians sufficiently familiar with the 
RDMA guideline? Is the guideline applied adequately in practice? Another area of debate relates 
to specific elements of the guideline. When can a symptom be classified as ‘refractory’? And do all 
physicians have the necessary skills to make that judgement? Should it not be compulsory to consult 
an expert for a second opinion? To what extent is existential suffering an indication for palliative 
sedation? And regarding the requirement that continuous sedation can only be administered if death 
is expected within one to two weeks, the question has been raised whether it is possible to estimate 
time to death.55-64 Although in 2009 the text of the renewed guideline on these issues was adjusted, 
and matters such as acute and intermittent sedation, withdrawal of artificial hydration and use of 
midazolam were clarified, the revision could not answer all questions on the topic. For example, 
the way in which the patient’s comfort should be assessed remained unanswered. Meanwhile, the 
estimated frequency of CPS has risen from 5.6% of all deaths in 2001 to 12.3% in 2010.47,65 
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The practice of palliative sedation by elderly care physicians
The available studies on palliative sedation involving elderly care physicians indicate that the most 
common refractory symptoms are pain, dyspnea, delirium, and anxiety.19,40,43,47,51,54,65-73 The 
drugs most often administered are benzodiazepines, and in most cases the duration of continuous 
deep sedation is 7 days or less. In general no life-shortening effect is reported, and artificial hydration 
is mostly withheld. However, most of these patient-based studies on palliative sedation involving 
elderly care physicians were published before the introduction and the revision of the RDMA 
guideline, and data were obtained mostly from limited samples. Furthermore, these studies often 
neglected to consider the characteristics of nursing home patients separately, who often are elderly 
patients without cancer.74 
Unanswered topics: determinants, practice and outcome 
In palliative care, the early identification, assessment and treatment of physical, psychosocial and 
spiritual problems is important in maintaining quality of life.7 However, little is known about the 
early identification of patients at high risk for CPS. Hence, to improve the practice of palliative care 
and CPS in particular, determinants need to be identified that can predict the need for CPS at the end 
of life. The identification of these determinants could improve advance care planning and quality 
of life for high-risk patients in a terminal phase; this planning will enhance the patient’s autonomy 
by informing the patient or the patient’s representative early in the palliative trajectory about the 
indication and preconditions for CPS.75,76 Additionally, the identification of these determinants helps 
physicians to become aware of high-risk patients early in the palliative trajectory and therefore could 
enable physicians to respond more rapidly to these patient’s symptoms. Effective interventions in 
these patients could possibly prevent a refractory state for such symptoms, thereby possibly limiting 
the future need for CPS. 
Secondly, elderly care physicians are often involved in end-of-life decision making, including CPS. 
For 2005, it was estimated that elderly care physicians administered continuous deep sedation in 
more than 2 000 patients.6,40 Nevertheless, the number of studies on the practice of palliative sedation 
administered by this medical specialty is limited, and these studies have several methodological 
limitations. More insight into the practice of CPS in this medical specialty is essential to contribute to 
the further development of guidelines and clinical practice. Furthermore, although there is no general 
consensus on whether palliative sedation is an appropriate intervention for existential suffering, some 
guidelines and recommendations identify existential suffering as a potential refractory symptom that 
can be treated with CPS under specific conditions.10-13,77-79 However, most patient-based studies on 
existential suffering focus on the frequency of this indication for CPS.21,54,66,68,69,80-90 Therefore, 
little insight has been achieved into the practice of CPS for existential suffering and the degree to 
which the preconditions have been fulfilled.
Finally, there is a need for clinical research on the efficacy of CPS in terms of a person’s well-being 
and control of symptoms.26,27,29,91,92 The purpose of palliative sedation, whether continuous or 
intermittent, is to provide comfort to patients with unbearable suffering.10-13 The gold standard for 
detecting distress is patient self-reporting.93 However, patients who are sedated cannot be consulted 
as palliative sedation produces an impaired capacity to communicate, which places them at a higher 
risk of unrelieved discomfort. Therefore, the monitoring of palliative sedation through professional 
assessments is essential to ensure that the patient becomes comfortable while sedated, that the patient 
receives proportional sedation (not deeper than needed) and to improve communication between 
professionals and the patients’ families.10,12,13,29,79,94 Although it seems intuitive to monitor the 
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level of sedation in a sedated patient, the level of suffering should be the primary parameter to be 
measured.91 Nonetheless, the “how” of monitoring the level of suffering during palliative sedation 
is currently an open question. A recent review on published guidelines on palliative sedation shows 
that only five out of nine guidelines recommend specific assessment methods to monitor palliative 
sedation, and these are mostly focused on the level of consciousness rather than on discomfort.91 
Furthermore, according to a systematic review, only a minority of patient-based studies on palliative 
sedation reported the use of observational scales, and most of these scales were used to monitor 
only the depth of sedation and not the quality.29 The few scales used in these studies to monitor on 
the symptom level were based on evaluations by the attending nurse or physician using a Likert or 
visual analogue scale. Therefore, little is known about the course of discomfort in sedated patients 
and the efficacy of CPS. Moreover, little is known about determinants of inadequate symptom relief 
during CPS. Such determinants could help physicians identify patients who are at risk of higher 
levels of discomfort. In these patients, intensive monitoring and evaluation of the administration of 
CPS could help to achieve more comfort during the administration of CPS.
Research questions
The objectives of this thesis cover the following topics: the determinants, practice and outcome of 
CPS. The objectives are specified in the following research questions:
Determinants:
• Which determinants of the administration of continuous palliative sedation are known in the 
 published literature?
• Are age, gender, diagnosis, use of opioids or psycholeptics, number of medications, functional  
 status, symptom distress and level of consciousness at the time of admission to a hospice or  
 nursing home-based palliative care unit associated with the administration of continuous  
 palliative sedation at the end of life?
Practice:
• What is the practice of continuous palliative sedation by Dutch elderly care physicians? 
• Do Dutch elderly care physicians fulfil the preconditions for administering continuous palliative  
 sedation in cases in which existential suffering is present? 
Outcome:
• What is the course of discomfort in patients admitted to a hospice or nursing home-based 
  palliative care unit receiving continuous palliative sedation?
• Which characteristics of patients admitted to a hospice or nursing home-based palliative care unit  
 determine (dis)comfort during the administration of continuous palliative sedation? 
 
To answer the research questions, we performed a systematic review and designed both a question-
naire and a prospective observational study.
INTRODUCTION
16 Continuous palliative sedation
Outline of the thesis
Chapter 2 shows the results of the systematic review of the literature. This chapter describes what 
was known about the determinants of the administration of CPS and identifies what knowledge was 
lacking. 
Chapter 3 presents the results of the prospective part of our study to investigate which patient- 
related factors at admission to a hospice or nursing home-based palliative care unit are associated 
with receiving CPS later in the terminal phase of life. 
Chapter 4 shows the results of a questionnaire of elderly care physicians on the practice of CPS. 
Chapter 5 focuses on the administration of CPS in cases of existential suffering based on the data 
obtained from the questionnaire. 
Chapter 6 explores the course of discomfort in patients admitted to a hospice or nursing home- 
based palliative care unit receiving CPS using an observer-based scale. In addition, this chapter  
analyses which patient characteristics determine (dis)comfort in the final hours of life.  
Chapter 7 is a general discussion of the clinical implications of this thesis and future directions for 
research.
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Chapter 2
Determinants of the administration of continuous palliative sedation: 
a systematic review.
van Deijck RH, Hasselaar JG, Verhagen SC, Vissers KC, Koopmans RT.
J Palliat Med 2013;16(12):1624-32
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Abstract
Background: 
Little is known about the determining factors related to the administration of continuous palliative sedation. 
Knowledge of these determinants may assist physicians in identifying patients who are at high risk of developing 
refractory symptoms, enable physicians to inform patients, and optimize close monitoring.
Objective: 
The aim of this systematic review was to identify determinants of the administration of continuous palliative 
sedation.
Design: 
A systematic review of PubMed, EMBASE, and CINAHL was performed to identify English, Dutch, and 
German language papers published from January 1990 through April 2011. Inclusion was based on the 
following criteria: patient-based research on continuous palliative sedation, studies investigating determinants 
of palliative sedation and/or comparison between sedated and nonsedated cohorts, and studies using multivariate 
analyses and of fair to good or good methodological quality.
Results: 
In total, eight papers were reviewed. The following nine factors were found to be associated with the 
administration of continuous palliative sedation: younger age, male sex, having cancer, feelings of hopelessness,
dying in a hospital, living in a Dutch speaking community setting, very nonreligious or extremely nonreligious 
physicians, physicians working in ‘‘other hospital’’ specialties, and physicians in favor of assisted death.
Conclusions:
Given the variation in study designs and the limitations of the included studies, the outcomes should be 
interpreted	carefully.	Further	research	is	needed,	particularly	regarding	factors	that	can	be	influenced	and	that	
may alter the course of a patient’s symptoms and the patient’s eventual need for palliative sedation.
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Chapter 2
Introduction
Physicians caring for patients with an advanced disease are often confronted with important end-of-
life decisions during the terminal stages of the disease course. The importance of developing advance 
care plans in the palliative phase has been emphasized; however, many patients and their caregivers 
still do not discuss possible end-of-life scenarios in the final phases of life.1 This lack of planning may 
result in unforeseen situations and difficulties in communication at the bedside when problems arise. 
In particular, a lack of anticipation that continuous palliative sedation may be administered can lead 
to undesirable circumstances. Indeed, when patients and their relatives are suddenly confronted with 
discussions regarding continuous palliative sedation, death, loss of consciousness, and saying goodbye, 
high levels of stress can be experienced.2
Over the past decade there has been considerable discussion concerning the terminology for and 
definition of palliative sedation. Current definitions include the following similarities: 
(1) pharmacological agents used to reduce consciousness, 
(2) reserved for the treatment of intolerable and refractory symptoms, and 
(3) only considered in a patient who has been diagnosed with an advanced progressive illness.3–8 The 
term ‘‘palliative sedation’’ refers to distinct types of interventions: brief or intermittent sedation or 
continuous sedation administered until death.3 Continuous palliative sedation may be superficial or 
deep. In the latter, there is a complete loss of the ability to communicate. The degree of symptom control 
rather than the degree to which consciousness must be reduced determines the dose, combination, and 
duration of the drugs administered.3 Over the past 10 years, continuous palliative sedation has been 
the subject of considerable debate in the field of palliative care. Questions have arisen as to whether 
palliative sedation is a euphemism for euthanasia and about where to draw the boundary between 
sedation for refractory symptoms that are primarily physical and sedation that includes existential 
suffering.9–13 Currently, continuous palliative sedation, if correctly applied, is increasingly accepted as 
a part of medical practice.4 The frequency of palliative sedation has been reported to range from 2.5% 
to 64% among terminally ill patients.14,15 This wide range likely reflects variations in the definition of 
the term and differences in culture and clinical settings.
Although continuous palliative sedation is not an uncommon end-of-life intervention, little is known 
regarding the possible determinants of this intervention. A determinant is an element that identifies or 
determines the nature of something or that fixes or conditions an outcome.16 Knowing the determinants 
of continuous palliative sedation could help physicians to better identify patients who are at high risk of 
developing refractory symptoms and thus optimize the use of close monitoring. Such strategies would 
allow physicians to respond to a patient’s symptoms earlier and to potentially prevent a refractory 
state of such symptoms, thereby possibly limiting the future need for continuous palliative sedation. 
Moreover, in acute situations there is often insufficient time to make well-informed, balanced decisions 
concerning palliative interventions. Thus, the physician must proactively develop a comprehensive 
care plan and establish end-of-life interventions that will meet the patient’s goals, values, needs, and 
preferences. This planning will enhance the patient’s autonomy and inform the patient or the patient’s 
representative about the indication and preconditions for continuous palliative sedation.17,18 The 
objective of this study was to perform a systematic review of published literature to identify possible 
determinants of the administration of continuous palliative sedation.
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Methods
Data sources and search strategy
For this review we searched all articles written in English, Dutch, and German and published from 
January 1990 through April 2011. A computerized search was performed in PubMed, EMBASE, and 
CINAHL. The following search terms and combinations were used: (determinant* OR predict* OR 
correlat* OR characteristic* OR compar* OR associat* OR probability OR survival OR (life AND 
expectancy)) AND ((palliative AND sedation) OR (terminal AND sedation) OR (sedation AND for 
AND terminally AND ill AND patients) OR (end AND of AND life AND sedation) OR (continuous 
AND palliative AND sedation)).
Study selection
To create an initial list of potential studies, the first reviewer (RvD) excluded all studies that reported 
on the following: 
(1) patients who were admitted to an intensive care unit; 
(2) palliative sedation that was restricted to children; 
(3) sedation therapy for invasive procedures and operations; 
(4) sedation therapy in animals; and 
(5) medication administered at low doses to relieve insomnia and/or dyspnea or sedation as an  
 unintended side effect of medication. 
Subsequently, two reviewers (RvD and JH) independently screened all abstracts that were retrieved, 
and these two reviewers then applied the following two inclusion criteria: 
1. The paper had to report on patient-based research on continuous palliative sedation. 
2. The paper had to report on determinants (or terms such as ‘‘associations’’ and ‘‘predictors’’) of 
palliative sedation or on a cohort study on sedated and nonsedated patients in a palliative trajectory.
The two reviewers then compared their lists of selected abstracts to reach a consensus. In cases in 
which there was doubt concerning the inclusion of an article, the full-text article was retrieved. A 
final list of selected papers was compiled after retrieving the full-text articles that met the inclusion 
criteria. These papers were then screened for the presence of multivariate statistical analyses, and 
the methodological quality of the selected papers was assessed using an assessment tool devised by 
Hawker and colleagues.19 Only papers that included multivariate analyses and were of fair to good 
or good methodological quality were included (see Figure 1).
Data extraction
From each selected paper, the following information was extracted: first author, year of publication, 
research design (prospective or retrospective), setting, patient diagnosis, specialty of the physician, 
study population, number of included patients who received palliative sedation, depth of sedation, 
determinants, and outcomes.
Statistical analysis
Because the study design, setting, participants, and reported determinants varied markedly between 
the studies, we chose to describe the studies, their results, and their limitations rather than combining 
or ranking the study data using a meta-analytic statistical approach.
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Results
Study selection
The search initially identified a total of 1088 unique papers. After an initial screening of the abstracts, 
694 papers were excluded, and 394 were deemed eligible for screening by the two reviewers. For 13 
of these papers, the reviewers reached immediate consensus that the papers met the inclusion criteria
(see Figure 1). For an additional 28 papers, the full-text articles were screened, and 9 of these papers 
met the inclusion criteria after a consensus meeting. Finally, after screening for the presence of 
multivariate analysis and fair to good or good methodological quality, 8 of 22 articles were included.
Study characteristics
All of the included studies used a retrospective design. Of the studies that reported on a clinical 
setting, all combined the settings of hospital and home (see Table 1). Other settings included nursing 
homes, hospices, palliative care units, institutions, care homes, and other settings. Nearly all of the 
studies included cancer and noncancer patients. In half of the studies, the specialty of the attending 
physician was reported. The number of patients to whom palliative sedation was administered 
varied from 31 to 1260 (total, 3525 patients). All studies focused on deep palliative sedation. Based on 
Hawker’s method, all of the studies had fair to good methodological quality.19
Determinants
The studies analyzed a total of 14 factors (see Table 2). Five factors were listed in more than one 
study—four factors were listed in two studies and one factor was listed in three studies—and 
nine factors were found in only one study. Five factors showed no significant association with the 
administration of continuous palliative sedation.20,21 Of the remaining nine factors, eight showed 
an increased probability of the administration of continuous palliative sedation. These eight factors 
were patients who were younger; patients who were male; patients with a cancer diagnosis; patients 
with feelings of hopelessness; patients dying in a hospital; and patients whose attending physicians 
were very or extremely nonreligious, working in ‘‘other hospital’’ specialties, or in favor of assisted 
death.14,20,22–25 The factor ‘‘patients living in a Dutch speaking community setting’’ showed a 
decreased probability of receiving continuous palliative sedation.26
Discussion
In this review, we found nine factors associated with the administration of continuous palliative 
sedation. Three studies showed an increased probability of receiving continuous palliative sedation 
among younger patients.14,22,23 An explanation for the association between younger age and the 
administration of continuous palliative sedation could be related to the disease trajectory in such 
patients. Among younger patients, the average disease trajectory tended to be more aggressive, thus 
resulting in a higher likelihood of administering palliative sedation.27 Furthermore, many older 
patients experience spontaneously diminished consciousness in their final days of life, which may 
reduce the apparent need for palliative sedation.28 In addition, because of dementia and inadequate
diagnostic tools, signs of pain and other types of suffering may not be well recognized at the end 
of life among very old patients, which could explain the limited usage of palliative sedation among 
these patients.22 For these reasons, we conclude that the association between age and continuous 
palliative sedation may be the result of an indirect or mediated causal relationship, although the 
mentioned underlying factors have to be identified as determinants in future research.
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With respect to sex, Miccinesi and colleagues stated that it is difficult to explain why male patients are 
more likely to receive palliative sedation.14 A study by Caraceni and colleagues, published after April 
2011, confirmed the result of Miccinesi and colleagues by showing that palliative sedation was more 
frequently indicated in male patients (odds ratio 3.2; 95% confidence interval 1.5–7.0).15 In general, 
women have different trajectories at the end of life than men. Indeed, women tend to live longer and 
have a different disease epidemiology and are more likely to receive care in a nursing home at the 
end of life, which may lead to different medical end-of-life decisions.29 In addition, at the end of life, 
men can become more isolated and receive less social support and tend to be more reticent and less 
willing to discuss emotional and psychological issues, thus making male patients more vulnerable 
than female patients.29,30 Although this review’s findings regarding sex were inconsistent, the 
aforementioned factors could contribute to a patient’s endurance and may exacerbate symptoms 
in male patients, ultimately resulting in the administration of palliative sedation. Therefore, sex, 
although associated, seems to be not an independent determinant but rather a contributing factor 
because of underlying patterns in the health status of and care for male patients.
included cancer and noncancer patients. In half of the studies,
the specialty of the attending physician was reported. The
number of p tients to whom palliative sedation was adminis-
tered varied from 31 to 1260 (total, 3525 patients). All studies
focused on deep palliative sedation. Based on Hawker’s
method, all of the studies had fair to good methodological
quality.19
Determinants
The studies analyzed a otal of 14 fac ors (see Table 2). Five
factors were listed in more than one study—four factors
were listed in two studies and one factor was listed in three
studies—and nine factors were found in on y one study.
Five factors showed no significant association with the
administration of continuous palliative sedation.20,21 Of the
remaining nine factors, eight showed an increas d probability
of the administration of continuous palliative sedation. These
eight factors were patients who were younger; patients who
were male; patients with a cancer diagnosis; patients with
feelings of hopelessness; patients dying in a hospital; and
patients whose attending physicians were very or extremely
nonreligious, working in ‘‘other hospital’’ specialties, or in
fav r of assisted death.14,20, 22–25 The factor ‘‘pati nts living in
a Dutch speaking community setting’’ showed a decreased
probability of receiving continuous palliative sedation.26
Discussion
In this review, we found nine factors associated with the
administration of continuous palliative sedation. Three stud-
ies showed an increased probability of receiving continuous
palliative sedation among younger patients.14,22,23 An expla-
nation for the association between younger age and the ad-
ministration of continuous palliative edation could be related
to the disease trajectory in such patients. Among younger
Table 2. Summary of Determinants of Continuous Palliative Sedation
Determinants
of continuous
palliative sedation
Total
number of
studies (No.) Consistency of outcomes (direction of factor)
Patient factors
Demographic variables
Age 3 All studies show an increased probability of receiving continuous palliative sedation
in younger patients14,22,23
Sex 2 One study shows an increased probability of receiving continuous palliative sedation
in male patients14, one study shows no difference in sex23
Dutch or French-
speaking
1 One study shows a decreased probability of receiving continuous palliative sedation
in the Dutch-speaking community setting26
Factors related to illness
Type of disease
Cancer 2 All studies show an increased probability of receiving continuous palliative sedation
in cancer patients14,23
Symptoms
Hopelessness 1 One study shows an increased probability of receiving continuous palliative sedation
in patients feeling hopeless24
Environmental factors
Place of death
Hospital 2 All studies show an increased probability of receiving continuous palliative sedation
in patients dying in a hospital14,25
Physician
Religious faith 1 One study shows an increased probability of receiving continuous palliative sedation
in patients treated by very or extremely non-religious physicians 20
Specialty of the
physician
2 One study shows an increased probability of receiving continuous palliative sedation
in patients treated by doctors working in ‘‘other hospital’’ specialties23; one study
shows no difference in specialty of the physician20
Attitude toward
assisted death
1 One study shows an increased probability of receiving continuous palliative sedation
in patients treated by doctor in favor of assisted death23
Ethnicity of the
physician
1 One study shows no significant association regarding the ethnicity of the attending
physician and the administration of continuous palliative sedation20
Care
Content of care 1 One study shows no significant association regarding the content of care and the
administration of continuous palliative sedation21
Involvement
General
practitioner
1 One study shows no significant association regarding the involvement of a general
practitioner and the administration of continuous palliative sedation21
Informal caregiver 1 One study shows no significant association regarding the involvement of an informal
caregiver and the administration of continuous palliative sedation21
Treatment
Treatment goal 1 One study shows no significant association regarding the treatment goal and the
administration of continuous palliative sedation21
1628 VAN DEIJCK ET L.
31Determinants, practice and outcome
1
2
3
4
5
6
7
Determinants: review
Van den Block and colleagues used language to differentiate between two communities in Belgium 
and found that although language and culture are strongly related, specific underlying cultural 
factors, e.g., the degree to which curative, technological, and specialist medicine is appreciated, could 
more fully explain the difference between patients living in Dutch speaking and French speaking 
community settings.26
Miccinesi and colleagues suggest that palliative sedation is more commonly performed among 
cancer patients because the clinical condition is more severe in these patients.14 In addition, cancer 
patients may experience a more aggressive disease trajectory, and there could be a higher prevalence 
of refractory symptoms among these patients, thus explaining the association of cancer with a higher 
probability of receiving continuous palliative sedation.27,31 Moreover, the end or terminal stage of 
the disease is better defined in this patient group than in patients suffering from COPD or heart 
failure.32 In this case, the cancer diagnosis itself seems to be the explanatory factor that results in an 
increased likelihood of requiring continuous palliative sedation and therefore can be considered a 
determinant.
Cohen and colleagues indicated that hospital policies that consider continuous palliative sedation to 
be an acceptable alternative to euthanasia may be a possible reason for the increased use of palliative 
sedation in these settings.25 In addition, Cowan and colleagues found that in the state of Tennessee 
in the United States, nursing homes, in contrast to hospitals, are often inadequate with respect to 
the standards of care, protocols, and training that are needed to support palliative sedation. This 
inadequacy may decrease the prevalence of palliative sedation at these care centers, even in cases in 
which sedation may actually be indicated.31 Additionally, when a patient reaches an adequate level 
of symptom control, the patient is discharged from the hospital to receive end-of-life care in a hospice 
or at home. Therefore, it is not surprising that patients who are not discharged from the hospital 
because of complex clinical conditions are presumably more likely to receive palliative sedation 
prior to dying.14 It is likely that factors other than being an inpatient determine the administration 
of palliative sedation, e.g., the patient’s symptoms and symptom severity and attitudes toward 
euthanasia.23
Seale and colleagues reported an increased probability of receiving continuous palliative sedation 
in patients treated by very or extremely nonreligious physicians.20 It would seem advisable that 
doctors become more aware of how broader sets of values, such as those associated with religiosity 
or a nonreligious outlook, may enter into their decision making in end-of-life care.20
Maessen and colleagues reported an association between patients’ feelings of hopelessness and 
continuous palliative sedation.24 However, Maessen and colleagues provided no interpretation of 
this finding, and no odds ratio was reported.24 In addition, because patients’ proxies retrospectively
answered questions about feelings of hopelessness, an under- or overestimation bias may have been 
present; thus, caution should be used in interpreting this finding. 
Seale and colleagues provided no interpretation of their finding that palliative sedation was more 
likely to be reported by physicians working in ‘‘other hospital’’ specialties.23 Because the term 
‘‘other hospital specialties’’ was not clearly defined, the implications of the outcome of this study 
are difficult to understand. Additionally, in this study, physicians from several ‘‘other hospital’’ 
specialties indicated that sedation was provided for reasons other than refractory symptoms.23 
Another study by Seale and colleagues reported on the same cohort as in the aforementioned study 
and found no difference regarding the use of continuous palliative sedation among physicians from 
different specialties.20
32 Continuous palliative sedation
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Strengths and limitations of this study
To the best of our knowledge, this is the first systematic review of published factors associated with 
the administration of continuous palliative sedation. However, several issues limit the interpretation 
of the findings in this review. First, several of the studies did not use determinants of palliative 
sedation as a primary outcome; rather, the studies considered such factors during a secondary 
analysis of the data. Accordingly, our methodological assessment according to Hawker’s method 
evaluated the aims, methods, analysis, results, and implications of research questions that were not 
directed toward the purpose of our review. Second, all of the reviewed studies were retrospective 
and primarily used questionnaires with response rates varying between 42% and 75%, which carry 
their own associated limitations because of recall bias and nonresponder bias. Moreover, in this type 
of study, it is only possible to examine associations; cause-and-effect relationships cannot be studied.  
effect relationships cannot be studied. Third, several of the
findings were based on the answers of patients’ proxies or
based on information from ge eral practitioners who pro-
vided information about patients who died in the hospital,
thus making the findings susceptible to under- or overesti-
mation bias. Fourth, all included studies focused on contin-
uous deep palliative sedation, whereas the objective of this
study was to identify the determinants of the administration
of continuous palliative sedation in general, which potentially
limits extrapolation from the studies. Additionally, the study
designs varied with respect to population, setting, and at-
tending physician, all of which make comparisons difficult
and limit the generalizability of the results. Fifth, in several
studies, multivariate calculations of an odds ratio or relative
risk were lacking, and descriptions of the statistical methods
were inadequate, e.g., information on the factors used in the
multivariate models was absent. In addition, none of the
multivariate models included factors such as the patient’s
symptom severity. Moreover, comparing one determinant
across several studies can be problematic because of differ-
ences in the underlying multivariate models and the number
and types of factors used in the analyses. Furthermore, the
results of different studies regarding the same determinant
are not always consistent. Finally, there is wide variation in
terminology for independent variables. Terms such as ‘‘de-
terminant’’ or ‘‘predictor’’ are often used in the literature, even
in cases in which a causal relationship is not present. In such
cases, terms such as ‘‘association’’ or ‘‘correlation’’ would be
more appropriate.
Conclusions
Although th literature suggests that there are several de-
terminants of the administration of continuous palliative se-
dation, this review uncovered important gaps in our current
understanding of these determinants and even questioned
whether the identified factors are actually determinants or
would be better labeled as factors associated with the ad-
ministration of continuous palliative sedation. This gap in our
current understanding of the mechanisms leading to contin-
uous palliative sedation limits our ability to offer proactive
care to patients requiring palliative measures. In particular,
determinants that can be acted upon early in the clinical pal-
liative care trajectory are more relevant from a clinical per-
spective, e.g., factors such as medication, symptoms, and
symptom severity. In such cases, appropriately applied
394 abstracts remained after exclusion of studies
681 records
identified in
PubMed
892 records
identified in
EMBASE
16 records
identified in
CINAHL
1088 records remained after duplicates were removed
13 articles met the criteria
for inclusion
28 full-text articles
assessed for eligibility in
cases of lack of consensus
Consensus meeting
Consensus meeting
Eight studies were
reviewed
13 full-text articles
assessed to verify
multivariate statistical
analyses and fair-to-good
or good methodological
quality
9 full-text articles assessed
to verify multivariate
statistical analyses and
fair-to-good or good
methodological quality
FIG.1. Flow diagram of the studies that were assessed and included.
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Third, several of the findings were based on the answers of patients’ proxies or based on information 
from general practitioners who provided information about patients who died in the hospital, 
thus making the findings susceptible to under- or overestimation bias. Fourth, all included studies 
focused on continuous deep palliative sedation, whereas the objective of this study was to identify 
the determinants of the administration of continuous palliative sedation in general, which potentially
limits extrapolation from the studies. Additionally, the study designs varied with respect to 
population, setting, and attending physician, all of which make comparisons difficult and limit the 
generalizability of the results. Fifth, in several studies, multivariate calculations of an odds ratio 
or relative risk were lacking, and descriptions of the statistical methods were inadequate, e.g., 
information on the factors used in the multivariate models was absent. In addition, none of the 
multivariate models included factors such as the patient’s symptom severity. Moreover, comparing 
one determinant across several studies can be problematic because of differences in the underlying 
multivariate models and the number and types of factors used in the analyses. Furthermore, the 
results of different studies regarding the same determinant are not always consistent. Finally, there is 
wide variation in terminology for independent variables. Terms such as ‘‘determinant’’ or ‘‘predictor’’ 
are often used in the literature, even in cases in which a causal relationship is not present. In such 
cases, terms such as ‘‘association’’ or ‘‘correlation’’ would be more appropriate.
Conclusions
Although the literature suggests that there are several determinants of the administration of 
continuous palliative sedation, this review uncovered important gaps in our current understanding 
of these determinants and even questioned whether the identified factors are actually determinants 
or would be better labeled as factors associated with the administration of continuous palliative 
sedation. This gap in our current understanding of the mechanisms leading to continuous palliative 
sedation limits our ability to offer proactive care to patients requiring palliative measures. In particular, 
determinants that can be acted upon early in the clinical palliative care trajectory are more relevant 
from a clinical perspective, e.g., factors such as medication, symptoms, and symptom severity. In 
such cases, appropriately applied interventions can alter the course of symptoms and the patient’s 
eventual need for palliative sedation. However, knowledge of determinants of the administration of 
continuous palliative sedation does not exclude the need for qualified personnel. Physicians must 
be competent in the assessment of symptoms and the symptoms’ correct treatment prior to starting 
continuous palliative sedation and in the administration and evaluation of continuous palliative 
sedation.
Future research regarding determinants of the use of palliative sedation should be performed using a 
prospective multicenter study design and a research protocol that includes clear and timely baseline 
measurements during the patient’s trajectory, e.g., at admission to a hospital. Such studies should 
use a multivariate analysis after clearly defining continuous palliative sedation and should focus on 
clinically relevant determinants.
34 Continuous palliative sedation
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Chapter 3
Patient-related determinants of the administration of continuous 
palliative sedation in hospices and palliative care units: a prospective, 
multicenter, observational study.
van Deijck RH, Hasselaar JG, Verhagen SC, Vissers KC, Koopmans RT.
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Abstract
Context. 
Knowledge of determinants that are associated with the administration of continuous palliative sedation (CPS) 
helps physicians identify patients who are at risk of developing refractory symptoms, thereby enabling proactive 
care planning. 
Objectives. 
This study aims to explore which patient-related factors at admission are associated with receiving CPS later 
in the terminal phase of life.
Methods. 
A prospective multicenter observational study was performed in six Dutch hospices and three nursing home-
based palliative care units. The association between patient-related variables at admission (age, gender, 
diagnosis, use of opioids or psycholeptics, number of medications, Karnofsky Performance Status scale score, 
Edmonton Symptom Assessment System distress score, and Glasgow Coma Scale score) and the administration 
of CPS at the end of life was analyzed.
Results. 
A total of 467 patients died during the study period, of whom 130 received CPS. In univariate analysis, 
statistically	 significant	differences	were	noted	between	 the	 sedated	 and	nonsedated	patients	with	 respect	 to	
younger age (P = 0.009), malignancy as a diagnosis (P = 0.05), higher Karnofsky Performance Status score  
(P = 0.03), the use of opioids (P < 0.001), the use of psycholeptics (P = 0.003), and higher Edmonton Symptom 
Assessment System distress score (P = 0.05). Multivariate logistic regression analysis showed that only the use 
of	opioids	at	admission	(odds	ratio	1.90;	95%	confidence	interval	1.18-3.05)	was	significantly	associated	with	
the administration of CPS. 
Conclusion. 
Physicians should be aware that patients who use opioids at admission have an increased risk for the 
administration of CPS at the end of life. In this group of patients, a comprehensive personalized care plan 
starting at admission is mandatory to try to prevent the development of refractory symptoms. Further research 
is recommended, to identify other determinants of the administration of CPS and to investigate which early 
interventions	will	be	effective	to	prevent	the	need	for	CPS	in	patients	at	high	risk.
39Determinants, practice and outcome
1
2
3
4
5
6
7
INTRODUCTION
Patients with a terminal illness can experience severe symptoms during the last phase of their lives.
For some patients, these symptoms become unbearable and refractory, and palliative sedation 
becomes a last-resort treatment option.1,2 Although there is still a lack of consensus on a definition, 
palliative sedation has been defined as ‘‘the deliberate lowering of a patient’s level of consciousness in 
the last stages of life’’ and refers to brief, intermittent, or continuous sedation.3 Continuous palliative 
sedation (CPS) aims to reduce proportionally the consciousness of the patient until the moment of 
death.3 Although CPS can be administered as a medical intervention at the end of the continuum of 
palliative care, it must be seen as a last-resort intervention.4,5 CPS not only takes away a patient’s 
suffering, deep CPS also takes away any potential positive and meaningful experiences a patient 
might have.1,6-9 Besides, research shows that relatives, nurses, and physicians sometimes experience 
the administration of CPS as a burden.10,11 
In palliative care, the early identification, assessment, and treatment of physical, psychosocial, and 
spiritual problems are important in maintaining quality of life.12 However, little is known about the 
early identification of patients at high risk for CPS.13 Hence, to improve the practice of palliative 
care and CPS in particular, it is useful to identify patient-related determinants early in the palliative 
trajectory, associated with the administration of CPS at the end of life. The identification of these 
determinants could improve advanced care planning and quality of life for high-risk complex 
patients in a terminal phase. It may help physicians to inform these patients early in the palliative 
trajectory about the possibility of the administration of CPS in case refractory symptoms occur in 
the last two weeks of life. In addition, the identification of these determinants helps physicians to 
become timely aware of and respond to an increased risk of the development of a complexity of 
symptoms in palliative patients leading to refractory suffering. Early effective interventions in these 
patients could possibly prevent or decrease the need for CPS. 
Therefore, the objective of this study was to identify patient-related determinants of the administration 
of CPS at admission to a hospice or nursing home-based palliative care unit (PCU). Based on our 
previously reported review and clinical relevance, we hypothesize that age, gender, diagnosis, use of 
opioids or psycholeptics, number of medications, functional status, symptom distress, and level of 
consciousness on admission could be associated with the administration of CPS.13
Determinants: prospective study
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Methods
Setting and Patient Population
This study involved a prospective observational multicenter study in six hospices and three nursing
home PCUs in The Netherlands. Patient admission to these settings is based on an estimated life 
expectancy of less than three months, according to the referring physician. Inclusion criteria for the 
study were any new admission during study episode, written informed consent, and an age of 18 
years or older.
Data Collection and Follow-Up
Data were collected between the first of March 2011 and the first of March 2013 and included a 
follow-up period of three months. Data collection ended when the patient died, was discharged, or 
at the end of the study period.
Measures/Assessments
The patient’s functional status was evaluated using the Karnofsky Performance Status (KPS) scale.14 
The Dutch-translated version of the KPS is a descriptive ordinal scale that rates the patient’s functional 
status in 10-point intervals ranging from normal functioning (100) to dead (0).15 The validity and 
reliability of the KPS have been shown in patients admitted to a hospice and in cancer patients.16,17
The level of consciousness of the patient was evaluated using the Glasgow Coma Scale (GCS).18 The 
GCS has three subscales: eyes, movement, and verbal reactions. The score ranges from 15 (normal 
consciousness) to 3 (deep comatose). The GCS has good psychometric properties, and its wide use 
supports the application of the GCS in this study.19-23 
To assess symptom severity, the Edmonton Symptom Assessment System (ESAS) was used.24 This 
scale consists of nine 100-mm visual analogue scales assessing pain, activity, nausea, depression, 
anxiety, drowsiness, appetite, sensation of well-being, and shortness of breath.24 Higher scores reflect 
greater symptom severity. The symptom distress score is calculated by summing the nine individual 
symptom scores. The assessment is completed by the patient. In case of a decision-incompetent 
patient, a family member or nurse completed the ESAS. In this study, a validated Dutch version 
was used.25 Although more psychometric research has been advised, the ESAS has been widely 
adopted in palliative care programs for clinical and research purposes and is a well-recognized and 
commonly used standard assessment tool for pain and symptom assessment.26
The study protocol required completion of the assessments within five days after admission, to 
prevent contamination of the patient-related factors with clinical interventions from the attending 
physicians and nurses. Nurses registered the date of admission, gender and age of the patient, KPS, 
medication use, and GCS on admission. In addition, nurses instructed patients for completing the 
ESAS. The attending physician recorded the patient’s diagnosis using the International Statistical 
Classification of Diseases and Related Health Problems 10th Edition.27 Diagnosis was defined as 
‘‘disease(s) which influenced the health status of the patient at admission.’’ Furthermore, in case the 
patient died, the physician registered the date of death and whether CPS was administered. Palliative 
sedation was defined according to the Dutch national guideline, and CPS was defined as ‘‘palliative 
sedation administered until death.’’3 This definition excluded situations in which medication 
was administered in normal doses to relieve insomnia and/or anxiety, where sedation was an 
unintended side effect of medication or where palliative sedation was only administered temporarily.  
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The attending physician determined the indication for CPS and the doses, combinations, and duration 
of the drugs administered. Furthermore, the research protocol did not formalize the discussion with 
the patient or their representative concerning advanced care planning and CPS. The physician was 
free in the way he discussed these items, but to get acceptance of the study, obviously, CPS and the 
possible reasons to start this intervention were discussed at admission.
Training
The first author (R. H. P. D. v. D.) provided a halfday training session for the participating nurses and 
physicians separately. The nurses practiced the assessments using vignettes. Instruction was given 
on the case report forms and the period of time to complete the assessments. The definitions in the 
study protocol were explained to the physicians, and patient cases were used to clarify the criteria 
for CPS.
Ethical Considerations
The study followed guidelines for good clinical practice and was conducted after approval of the 
research ethics committee of the Radboud University Medical Centre (ref 2010/407). Patients or their 
representatives (in cases of a decision-incompetent patient) were invited to participate via oral and 
written information. For patients who did not participate, only anonymous demographic data were 
collected for the purpose of nonresponder analysis.
Statistical Analysis
The primary outcome was the administration of CPS. Patients who died were categorized into two 
groups; those who did and those who did not receive CPS. Patients who were discharged or who 
were still alive after the follow-up period were excluded from further analyses. When one or two 
symptoms were missing from the ESAS, the symptom distress score was calculated via the imputation 
of the mean score of the known symptoms per patient, so-called ipsative mean imputation.28 When 
the ESAS was completed later than five days after admission or when there were more than two 
missing symptoms, the ESAS symptom distress score was considered missing.
Medication was categorized as opioids (Anatomical Therapeutic Chemical classification N02A); 
psycholeptics (Anatomical Therapeutic Chemical classification N05); and the total number of drugs 
with the exclusion of ophthalmic, cutaneous, and rescue medications. 
We compared patients who were sedated and who were not on characteristics at admission using 
independent sampled t-tests and Pearson’s chi-square tests. To assess the independent relationship of 
the characteristics at admission and the administration of CPS (yes/no), we used a multiple logistic 
regression model. To take into account the clustering of patients in hospices and PCUs, the location 
was included in the model. 
To handle missing data, we used multiple imputation creating five imputed data sets. All patient 
characteristics including location were included in the imputation procedure. We combined the 
results of the multiple logistic regression models across the five data sets. As a sensitivity analysis, 
the outcome of the multivariate model without using multiple imputation was also assessed. 
The probability of being sedated was calculated in odds ratios (ORs) with 95% CIs. P-values were 
two-sided, and an alpha <0.05 was considered statistically significant. Statistical analyses were 
performed using SPSS, version 20.0.0 (SPSS, Inc., Chicago, IL).
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Results
Patients
During the study period, of 803 patients admitted to the participating hospices or PCUs, 503 patients 
gave written informed consent. The included patients (n = 503) did not differ from the excluded 
patients (n = 300) with regard to gender, age, KPS score (P = 0.20, P = 0.12, P = 0.34, respectively, data 
not shown) or one of the diagnoses. At the end of the study, four included patients remained alive 
and 32 included patients had been discharged. A total of 467 patients died and were included for 
further analysis; 130 of these patients (27.8%) received CPS (Fig. 1). This percentage, with a range of 
13.5%-48.1%, was associated with location (Pearson’s chi-square 33.802, df = 8, P < 0.001). The mean 
duration from admission until death for the 467 patients was 33.5 days (SD 42.7) with a median 
duration of 19 days (range 0-305). No significant differences between nonsedated (mean 33.1 days 
[SD 43.3]) and sedated patients (mean 34.8 days [SD 41.2]) were observed (P = 0.70).
Population and Univariate Analysis
At admission, more than half of the study popula-
tion consisted of patients aged 76 years and older, hav-
ing cancer, with a KPS score of 40 or less, and a GCS
score of 13 or more. The distribution of men and
women was similar. Half of the patients (50.2%)
used one or more opioids, and 42.2% of the patients
used psycholeptics. The mean number of drugs used
was 5.7 (Table 1).
Statistically significant differences were noted be-
tween the sedated and nonsedated patients with
respect to younger age, malignancy as a diagnosis,
higher KPS score, the use of opioids, or the use of psy-
choleptics (Table 1).
For the ESAS, for two patients more than two symp-
toms were missing, the ESAS was not completed by 53
patients and 71 patients completed the ESAS later
than five days after admission. In univariate analysis,
the mean ESAS distress score at admission was signifi-
cantly higher in the sedated group than in the nonse-
dated group (Table 1).
Multivariate Analysis
Multivariate logistic regression analysis showed that
the use of opioids at admission was significant associ-
ated with the administration of CPS (OR 1.90; 95%
CI 1.18e3.05; P ¼ 0.008; Table 2). Sensitivity analysis,
using a model without multiple imputation, also iden-
tified the use of opioids at admission (OR 1.98; 95%
CI 1.13e3.46; P ¼ 0.017; data not shown).
Discussion
To our knowledge, this is the first study to prospec-
tively investigate the association between patient-
related characteristics at admission and the eventual
administration of CPS. We found that only the use
of opioids at admission in hospices and nursing
home PCUs was independently positively associated
with the administration of CPS. No statistically signifi-
cant independent association was found for gender,
age, use of psycholeptics, diagnosis of malignancy,
KPS score, GCS score, ESAS symptom distress score,
or number of medications on admission.
Results in Relation to Other Studies and Potential
Mechanisms
The positive independent association between CPS
and the use of opioids at admission could indicate
that specific symptoms treated with opioids (such as
pain or dyspnea) were more difficult to control in
these patients in the palliative trajectory.29 Caraceni
et al.30 reported that palliative sedation was more
frequently indicated in patients with recurrent
Fig. 1. Flowchart of patients throughout the study.
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Population and Univariate Analysis
At admission, more than half of the study population consisted of patients aged 76 years and older, 
having cancer, with a KPS score of 40 or less, and a GCS score of 13 or more. The distribution of men 
and women was similar. Half of the patients (50.2%) used one or more opioids, and 42.2% of the 
patients used psycholeptics. The mean number of drugs used was 5.7 (Table 1).
Statistically significant differences were noted between the sedated and nonsedated patients with 
respect to younger age, malignancy as a diagnosis, higher KPS score, the use of opioids, or the use of 
psycholeptics (Table 1).
For the ESAS, for two patients more than two symptoms were missing, the ESAS was not completed 
by 53 patients and 71 patients completed the ESAS later than five days after admission. In univariate 
analysis, the mean ESAS distress score at admission was significantly higher in the sedated group 
than in the nonsedated group (Table 1).
dyspnea in the last seven days of life (OR 4.2; 95% CI
1.9e9.2). Therefore, dyspnea and pain could be the
underlying determinants for CPS rather than the
use of opioids as such. Additionally, a direct causal
relationship between opioid use and CPS could be
present because of opioid-induced delirium, which
in turn may result in the need for CPS.30e32 Interven-
tions such as opioid rotation and regular screening
for and treatment of delirium could reduce the even-
tually need for CPS in such cases. Patients with opioid
use at admission should be informed about the
possible side effects of this medication, the need of
regular evaluation, and the possible interventions
when side effects occur, with CPS as a last-resort inter-
vention. In The Netherlands, the vast majority of the
general public accepts the use of palliative sedation
at the end of life, although the term palliative seda-
tion is not well known among the general public.33
The finding that many people do not know the
term palliative sedation emphasizes the importance
to clearly inform patients and relatives about palliative
sedation and to verify their beliefs on and expecta-
tions of palliative sedation. Information should
include that palliative sedation is a last-resort interven-
tion for refractory suffering, that the life expectancy
of a patient may not exceed 2 weeks at the moment
CPS is started and that CPS has to be distinguished
from euthanasia.3
Previous retrospective studies did no focus on an
association between the use of psycholeptics and the
administration of CPS.13 In this study, the use of psy-
choleptics at admission showed a marginally signifi-
cant association with the administration of CPS.
Psycholeptics, for example, haloperidol, are usually
prescribed for the management of delirium in pallia-
tive care.34 Agitated delirium tends to worsen over
time and often becomes refractory in the terminal
phase leading to palliative sedation.35 For this reason,
we assume that the association between the use of psy-
choleptics at admission and CPS could be a surrogate
of an underlying delirium.
When approaching the terminal phase of life, symp-
toms may exacerbate other symptoms or evolve into a
cascade of symptoms; this may lead to a situation in
which the patient eventually experiences unbearable
and refractory suffering, and an indication for CPS
Table 1
Patient-Related Characteristics at Admission to a Hospice or a Palliative Care Unit for Patients Who Were Sedated During
Admission and Those Who Were Not
Variable
Population
(n ¼ 467)
Sedated
(n ¼ 130)
Not Sedated
(n ¼ 337) P-value
Age, number (%) 0.009a
<55 yrs 23 (4.9) 12 (9.2) 11 (3.3)
55e75 yrs 188 (40.3) 57 (43.8) 131 (38.9)
>75 yrs 256 (54.8) 61 (46.9) 195 (57.9)
Gender, number (%) 0.78a
Male 224 (48.0) 61 (46.9) 163 (48.4)
Female 243 (52.0) 69 (53.1) 174 (51.6)
Malignant neoplasms, number (%) 0.05a
No malignant neoplasms 76 (16.3) 14 (10.8) 62 (18.4)
Malignant neoplasms 391 (83.7) 116 (89.2) 275 (81.6)
Glasgow Coma Scale (GCS), number (%) 0.09a
Score 3e6 18 (4.1) 2 (1.6) 16 (5.1)
Score 7e12 45 (10.2) 9 (7.2) 36 (11.4)
Score 13e15 378 (85.7) 114 (91.2) 264 (83.5)
Karnofsky score, number (%) 0.03a
Score 0e40 368 (79.0) 101 (77.7) 267 (79.5)
Score 50e70 93 (20.0) 25 (19.2) 68 (20.2)
Score 80e100 5 (1.1) 4 (3.1) 1 (0.3)
Opioid use, number (%) <0.001a
No opioid use 231 (49.8) 46 (35.4) 185 (55.4)
Opioid use 233 (50.2) 84 (64.6) 149 (44.6)
Psycholeptics use, number (%) 0.003a
No psycholeptics use 268 (57.8) 61 (46.9) 207 (62.0)
Psycholeptics use 196 (42.2) 69 (53.1) 127 (38.0)
Number of medications, mean (SD) 5.7 (3.5) 6.1 (3.2) 5.5 (3.6) 0.06b
ESAS distress score 9, mean (SD) 37.5 (15.4) 40.1 (16.2) 36.4 (15.0) 0.05b
ESAS ¼ Edmonton Symptom Assessment System.
Data were missing for the Karnofsky score in one patient, on opioids, psycholeptics, and number of medications for three patients.
For ESAS, 126 patients were excluded in univariate analysis: six symptoms were missing for one patient, eight symptoms for one patient, and all symptoms for 53
patients. Seventy-one patients completed the scale later than five days after admission. Ipsative mean imputation was used in 20 patients: one symptom was missing
for 19 patients, two symptoms for one patient. There was no significant difference in the distribution of missing data between the sedated and nonsedated groups.
Data on GCS were missing for 26 patients.
Values in bold are significant.
aChi-square test.
bStudent t-test.
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Multivariate Analysis
Multivariate logistic regression analysis showed that the use of opioids at admission was significant 
associated with the administration of CPS (OR 1.90; 95% CI 1.18-3.05; P = 0.008; Table 2). Sensitivity 
analysis, using a model without multiple imputation, also identified the use of opioids at admission 
(OR 1.98; 95% CI 1.13-3.46; P = 0.017; data not shown).
Discussion
To our knowledge, this is the first study to prospectively investigate the association between patient-
related characteristics at admission and the eventual administration of CPS. We found that only 
the use of opioids at admission in hospices and nursing home PCUs was independently positively 
associated with the administration of CPS. No statistically significant independent association was 
found for gender, age, use of psycholeptics, diagnosis of malignancy, KPS score, GCS score, ESAS 
symptom distress score, or number of medications on admission.
Results in Relation to Other Studies and Potential Mechanisms
The positive independent association between CPS and the use of opioids at admission could indicate
that specific symptoms treated with opioids (such as pain or dyspnea) were more difficult to control 
in these patients in the palliative trajectory.29 Caraceni et al.30 reported that palliative sedation was 
more frequently indicated in patients with recurrent dyspnea in the last seven days of life (OR 4.2; 
95% CI 1.9-9.2). Therefore, dyspnea and pain could be the underlying determinants for CPS rather 
than the use of opioids as such. Additionally, a direct causal relationship between opioid use and 
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arises.3 Therefore, our hypothesis was that a higher
symptom distress score at admission would be a risk
factor. However, the results of this study did not sup-
port this hypothesis. It is possible that specific symp-
toms such as pain or agitation, rather than the
aggregated score, could have influenced the chance
of CPS. The sample size of our population, although
considerable for palliative care research, did not allow
for a subanalysi of individual symptoms or clusters,
that is, the use of opioids and the symptoms pain
and dyspnea.
In contrast to previous retrospective studies, the
multivariate analysis in our prospective study did not
confirm an association between male or younger age
patients and the administration of CPS.30,36e39 Howev-
er, our study population differed from the retrospec-
tive studies by including only a small number of
young adults and being restricted to a hospice and
nursing home PCU setting.30,36e39
Literature reports an association between the pres-
ence of cancer and the administration of CPS.37e39
None of these retrospective studies included symp-
toms or symptom distress scores in their multivariate
model.37e39 In the univariate analysis, our study
demonstrated significant differences between the
sedated and nonsedated patients regarding the diag-
nosis of malignancy; however, the multivariate analysis
did not confirm this association.
Although we focused on patient-related factors, this
study showed also that location is associated with the
administration of CPS. The umbrella term location
makes it difficult to identify the specific underlying
factors of this term. A review on determinants of
CPS from the literature showed that the following
nonepatient-related factors were associated with the
administration of CPS: very or extremely nonreligious
physicians, physicians working in ‘‘other hospital’’ spe-
cialties, physicians in favor of assisted death, and
Dutch-speaking community setting in Belgium.13 Be-
sides, other characteristics of health care providers
and characteristics of location, that is, what is allowed
in a location based on the religious affiliation, could
also be an explanatory factor that results in differences
in the administration of CPS between locations.
Furthermore, the ‘‘how’’ of determining intolerability
of suffering and refractoriness is not established in
guidelines.40 This can result in subjectivity in deter-
mining the refractoriness of symptoms and therefore
in variation of the eventually administration of CPS.
Our study was not intended to find location-
dependent variables, but our results underline the
need to perform such a study in the future.
Strengths and Limitations
A strength of this study was its prospective multi-
center design, the clear operational definition of
CPS and the use of validated, clinically relevant assess-
ments at a well-defined time point. Additionally, the
large number of sedated patients made it possible to
look at the independent relationship of multiple char-
acteristics at admission and the administration of CPS
in the terminal phase of life.41
Nevertheless, some limitations of this study warrant
attention. First, an important limitation of this study is
the number of protocol violations and missing compo-
nents of some patients’ ESAS, which influenced the
power of the study and therefore its validity. However,
multivariate models with and without multiple imputa-
tion were used to control for understating uncertainty.
These models showed a similar association between
the administration of CPS at the end and the use of
opioids at admission.
Second, assessm nts were performed at admission
to identify patients who were at risk of developing re-
fractory symptoms at the end of the palliative trajec-
tory. However, we could not determine whether the
associations found in this study were time sensitive
or not.
Third, 503 of 803 patients (62.6%) participated in
our study. Although the 503 patients were a represen-
tative sample regarding gender, age, KPS, and diag-
nosis of the total population, nonresponder bias
cannot be excluded.
Fourth, the reported variability in the administra-
tion of CPS in our study could reflect a different un-
derstanding of CPS among the participating
physicians and nurses. However, we did all efforts to
Table 2
A Multiple Logistic Regression: Determinants of
Continuous Palliative Sedation, Measured at Admission
to a Hospice or a Palliative Care Unit (n ¼ 467)
Determinant
Direction
(Reference)
Odds
Ratio 95% CI P-value
Gender Male (female) 0.97 0.62e1.52 0.91
Malignant
neoplasms
Present
(not present)
1.42 0.68e2.93 0.35
Opioid use Present
(not present)
1.90 1.18e3.05 0.008
Psycholeptics
use
Present
(not present)
1.57 1.00e2.49a 0.05
Age Olderb 0.98 0.96e1.00a 0.12
Karnofsky score Higherb 1.06 0.86e1.29 0.59
Glasgow Coma
Scale
Higherb 1.10 0.96e1.27 0.16
Number of
medications
Higherb 1.02 0.95e1.09 0.60
ESAS Higherb 1.01 0.99e1.03 0.24
ESAS ¼ Edmonton Symptom Assessment System.
Nagelkerke R square 0.19.
Values in bold are significant.
aFor psycholpetics, the CI to three decimal places was 0.996 to 2.489, with a
P-value of 0.052. For age, the CI to three decimal places was 0.964 to 1.004,
with a P-value of 0.115.
bContinuous variable.
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CPS could be present because of opioid-induced delirium, which in turn may result in the need for 
CPS.30-32 Interventions such as opioid rotation and regular screening for and treatment of delirium 
could reduce the eventually need for CPS in such cases. Patients with opioid use at admission should 
be informed about the possible side effects of this medication, the need of regular evaluation, and 
the possible interventions when side effects occur, with CPS as a last-resort intervention. In The 
Netherlands, the vast majority of the general public accepts the use of palliative sedation at the end of 
life, although the term palliative sedation is not well known among the general public.33 The finding 
that many people do not know the term palliative sedation emphasizes the importance to clearly 
inform patients and relatives about palliative sedation and to verify their beliefs on and expectations 
of palliative sedation. Information should include that palliative sedation is a last-resort intervention 
for refractory suffering, that the life expectancy of a patient may not exceed 2 weeks at the moment 
CPS is started and that CPS has to be distinguished from euthanasia.3
Previous retrospective studies did not focus on an association between the use of psycholeptics and 
the administration of CPS.13 In this study, the use of psycholeptics at admission showed a marginally 
significant association with the administration of CPS. Psycholeptics, for example, haloperidol, are 
usually prescribed for the management of delirium in palliative care.34 Agitated delirium tends to 
worsen over time and often becomes refractory in the terminal phase leading to palliative sedation.35 
For this reason, we assume that the association between the use of psycholeptics at admission and 
CPS could be a surrogate of an underlying delirium. 
When approaching the terminal phase of life, symptoms may exacerbate other symptoms or evolve 
into a cascade of symptoms; this may lead to a situation in which the patient eventually experiences 
unbearable and refractory suffering, and an indication for CPS arises.3 Therefore, our hypothesis 
was that a higher symptom distress score at admission would be a risk factor. However, the results 
of this study did not support this hypothesis. It is possible that specific symptoms such as pain or 
agitation, rather than the aggregated score, could have influenced the chance of CPS. The sample size 
of our population, although considerable for palliative care research, did not allow for a subanalysis 
of individual symptoms or clusters, that is, the use of opioids and the symptoms pain and dyspnea.
In contrast to previous retrospective studies, the multivariate analysis in our prospective study did not 
confirm an association between male or younger age patients and the administration of CPS.30,36-39 
However, our study population differed from the retrospective studies by including only a small 
number of young adults and being restricted to a hospice and nursing home PCU setting.30,36-39 
Literature reports an association between the presence of cancer and the administration of CPS.37-39
None of these retrospective studies included symptoms or symptom distress scores in their 
multivariate model.37-39 In the univariate analysis, our study demonstrated significant differences 
between the sedated and nonsedated patients regarding the diagnosis of malignancy; however, the 
multivariate analysis did not confirm this association. 
Although we focused on patient-related factors, this study showed also that location is associated 
with the administration of CPS. The umbrella term location makes it difficult to identify the specific 
underlying factors of this term. A review on determinants of CPS from the literature showed that 
the following non-patient-related factors were associated with the administration of CPS: very or 
extremely nonreligious physicians, physicians working in ‘‘other hospital’’ specialties, physicians 
in favor of assisted death, and Dutch-speaking community setting in Belgium.13 Besides, other 
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characteristics of health care providers and characteristics of location, that is, what is allowed 
in a location based on the religious affiliation, could also be an explanatory factor that results in 
differences in the administration of CPS between locations. Furthermore, the ‘‘how’’ of determining 
intolerability of suffering and refractoriness is not established in guidelines.40 This can result in 
subjectivity in determining the refractoriness of symptoms and therefore in variation of the eventually 
administration of CPS. Our study was not intended to find location-dependent variables, but our 
results underline the need to perform such a study in the future. 
Strengths and Limitations
A strength of this study was its prospective multicenter design, the clear operational definition of CPS 
and the use of validated, clinically relevant assessments at a well-defined time point. Additionally, 
the large number of sedated patients made it possible to look at the independent relationship of 
multiple characteristics at admission and the administration of CPS in the terminal phase of life.41
Nevertheless, some limitations of this study warrant attention. First, an important limitation of this 
study is the number of protocol violations and missing components of some patients’ ESAS, which 
influenced the power of the study and therefore its validity. However, multivariate models with 
and without multiple imputation were used to control for understating uncertainty. These models 
showed a similar association between the administration of CPS at the end and the use of opioids at 
admission. 
Second, assessments were performed at admission to identify patients who were at risk of developing 
refractory symptoms at the end of the palliative trajectory. However, we could not determine whether 
the associations found in this study were time sensitive or not. 
Third, 503 of 803 patients (62.6%) participated in our study. Although the 503 patients were a 
representative sample regarding gender, age, KPS, and diagnosis of the total population, nonresponder 
bias cannot be excluded.
Fourth, the reported variability in the administration of CPS in our study could reflect a different 
understanding of CPS among the participating physicians and nurses. However, we did all efforts 
to minimize this, by providing a training where the definitions in the study protocol were explained 
and patients’ cases were used to clarify the criteria for CPS. Furthermore, previous reported research 
on palliative sedation showed that almost all physicians reported that they knew about the Dutch 
national guideline and mostly rated their level of level of knowledge about the contents of the 
guideline as good to excellent.42
Finally, this study was performed in hospices and nursing home PCUs in The Netherlands. Most 
patients were aged 76 years and older with a low Karnofsky index, reflecting a relatively low 
functional status. The findings in this study may not be generalizable to other populations, care 
settings, and countries.
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Conclusion
This study showed that the use of opioids at admission to a hospice or PCU was independently 
positively associated with the chance of the administration of CPS. In patients with this characteristic, 
physicians should be aware of the higher risk of developing refractory symptoms leading to CPS in 
the terminal phase of life, and a comprehensive care plan, including end-of-life interventions that 
meet the patient’s goals, values, needs, and preferences, should be developed early in the palliative 
trajectory. Besides, physicians should inform these patients early in the palliative trajectory about the 
possibility of the administration of CPS in case refractory symptoms occur in the last two weeks of 
life. This study was not performed to unravel the specific underlying symptoms or mechanism that 
increases the chance of patients with opioid usage to develop refractory symptoms in the end stage 
of life. Further studies will be necessary to find such mechanisms. Furthermore, such research should 
find other determinants of the administration of CPS, involving different settings and populations, 
and finally examine if interventions based on such knowledge will be effective to prevent the 
development of refractory symptoms in the terminal stage of life of these high-risk patients, and 
eventually the need for CPS.
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The practice of continuous palliative sedation in elderly patients: 
a nationwide explorative study among Dutch nursing home physicians.
van Deijck RH, Krijnsen PJ, Hasselaar JG, Verhagen SC, Vissers KC, Koopmans RT.
J Am Geriatr Soc 2010;58(9):1671-8
52 Continuous palliative sedation
Chapter 4
Abstract
Objectives: 
To study the practice of continuous palliative sedation (CPS) by Dutch nursing home physicians in 2007.
Design: 
A structured retrospective questionnaire.
Setting: 
Nationwide nursing home physician study in the Netherlands.
Participants: 
One	thousand	two	hundred	fifty-four	nursing	home	physicians	received	a	questionnaire	concerning	their	last	
case of CPS in 2007; 54% (n = 675) responded. 
Measurements: 
Characteristics of CPS and requests for euthanasia were measured.
Results: 
Three hundred sixteen patients were described. The majority had cancer or dementia. The most-reported 
refractory symptoms were pain (52%), anxiety (44%), exhaustion (44%), dyspnea (40%), delirium (24%), 
loss of dignity (18%), and existential distress (16%). In 98% of cases, CPS was aimed at symptom relief.  
Of patients with cancer, 17% had previously requested euthanasia. The mean starting dose of midazolam was 
31 mg every 24 hours (range 0–240 mg/24 h), and the mean end dose was 48 mg every 24 hours (range 0–480 
mg/24 h).
Conclusion: 
In addition to physical symptoms, anxiety, exhaustion, loss of dignity, and existential distress are often 
mentioned as refractory symptoms in the decision to start CPS by nursing home physicians. Furthermore, 
close	 to	 one	 in	 five	 patients	with	 cancer	 had	made	 a	 previous	 request	 for	 euthanasia.	 The	 dosage	 range	 of	
midazolam	 in	 this	 study	 fits	 the	 recommendations	 of	 the	Dutch	 national	 guideline	 on	 palliative	 sedation,	
although international studies show smaller dosage ranges. Finally, prospective research about the acceptability 
and assessment of nonphysical symptoms as indications for CPS is recommended.
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INTRODUCTION
Since the 1990s, there has been a growing interest in palliative care in the Netherlands. Although 
historically administered in people with cancer, palliative care is increasingly administered to patients 
without cancer too. Despite improvements in palliative care, some symptoms remain hard to treat or 
relieve. If one or more symptoms in a patient who is dying cause unbearable suffering, and conventional 
modes of treatment are not effective or fast acting enough (so-called refractory symptoms), an indication 
arises to administer palliative sedation.
The third national Dutch study on end-of-life decisions was the first to report on the practice of what was 
then referred to as terminal sedation in the Netherlands.1 In response to this study, the Dutch government 
stressed the need for a national guideline on palliative sedation.2 In 2005, the Royal Dutch Medical 
Association (RDMA) issued a national guideline on palliative sedation.3,4 Despite this guideline, the 
practice of palliative sedation remained a controversial subject. Furthermore, a Dutch study found that 
continuous deep sedation was being used increasingly more often, whereas the use of euthanasia was 
decreasing.5 This suggested that palliative sedation was possibly being administered as an alternative to 
euthanasia. 
Although the RDMA guideline gives a comprehensive framework for clinical decision-making, the 
recommendations are mainly expert-based. The methodological, practical, and ethical challenges 
involved limit research on palliative sedation. In particular, research on palliative sedation in a population 
of frail and elderly patients has proved to be problematic for nursing home physicians. The available 
studies indicate that the refractory symptoms are mostly anxiety, pain, and dyspnea. The drugs most 
often administered are benzodiazepines, and in most cases the duration of continuous deep sedation 
is 7 days or less, no life-shortening effect is reported, and artificial hydration is withheld.5–13 In 2005, it 
was estimated that nursing home physicians used continuous deep sedation in conjunction with end-
of-life decisions in 5.9% of all deaths.7 However, all but one of these studies originated from before the 
introduction of the RDMA guideline, and data were obtained mostly from limited samples. Furthermore, 
these studies often neglected to consider the practices of nursing home physicians (characterized by a 
large percentage of elderly patients without cancer) separately from other care settings such as hospitals 
and home care (with mainly patients with cancer).14 Nursing home physicians find it difficult to define 
patients as terminally ill or to predict their life expectancy, and the pattern of symptom prevalence is 
different from that of patients with cancer.14 It was therefore hypothesized that in patients with cancer, the 
refractory symptoms for continuous palliative sedation (CPS) would differ from those of patients without 
cancer. Moreover, the difficulty of predicting life expectancy of people without cancer could complicate 
the administration of CPS, because a precondition for its use within the RDMA guideline is that death 
will ensue within 1 to 2 weeks. More insights into this specific group of patients shall contribute to the 
further development of guidelines on palliative sedation and could provide more targeted palliative care. 
There is an international demand for more research on monitoring national trends and patterns in end-of-
life care, such as (continuous) palliative sedation, including the administration of artificial nutrition and 
hydration, the drugs and dosages administered, and the interval between the administration of sedating 
drugs and death.15,16
Practice of CPS 
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The practice of CPS by Dutch nursing home physicians was therefore investigated in a nationwide study. 
Special attention was paid to differences in the administration of CPS to the subgroups of patients with 
cancer and dementia.
METHODS
Respondents
All registered members of the Dutch Association of Nursing Home Physicians were eligible for the study 
(n = 1,441). Because of a parallel ongoing study on palliative sedation in the Amsterdam and Rotterdam 
regions, 187 of the 292 members in this region were excluded. A structured retrospective questionnaire 
was sent to the remaining 1,254 nursing home physicians in February 2008. A return envelope was sent 
with the questionnaire, and full confidentiality was assured. After 3 weeks, all physicians received a 
reminder to return the questionnaire so as to maximize the response rate. Data collection ended in May 
2008.
Questionnaire
The questionnaire was a revised version of a previously reported questionnaire.9 The original 
questionnaire was adapted to nursing home patients and piloted by 20 nursing home physicians, which 
resulted is some minor modifications. In the questionnaire, palliative sedation and refractory symptoms 
were defined according to the RDMA national guideline.3 Palliative sedation was defined as ‘‘deliberately 
lowering a patient’s level of consciousness in the final stage of life,’’ and a symptom was considered 
refractory if ‘‘none of the conventional modes of treatment were effective or fast-acting enough, and/or 
if these modes of treatment were accompanied by unacceptable side-effects.’’ It was clearly stated in the 
questionnaire that the study explicitly focused on CPS, defined as ‘‘sedation continued until death.’’ 
The questionnaire consisted of 38 closed-ended questions and six open questions and was divided into 
two parts. The first part included questions about the respondent’s age, sex, years of clinical experience 
with end-of-life care (<5, 5–15, ≥16), whether they had at some time administered CPS (yes/no), and 
whether they were aware of the RDMA guideline on palliative sedation (yes/no). In addition, their 
knowledge of the contents of the guideline was assessed on a 5-point scale (poor to excellent). Each 
respondent was also asked about the number of patients who died in 2007 (0, 1–5, 6–10, 11–20, 21–50, >50) 
and the exact number of occasions on which CPS was administered in 2007. The second part addressed 
the practice of CPS in the most-recent case in 2007, with an explicit request to retrieve the information 
from the patient’s medical file. This part included questions about the patient’s age, sex, and primary 
disease (dementia, cancer, cardiovascular disease, pulmonary disease, nervous system disease, other 
diagnosis). When respondents filled in more than one primary diagnosis, it was registered as ‘‘multiple.’’ 
In the questionnaire, no distinction was made between informed consent (yes/no) from the patient or the 
patient’s legal representative. The indicating symptoms for CPS were pain, dyspnea, delirium, anxiety, 
vomiting, nausea, exhaustion, existential distress, loss of dignity, and other (more than one answer 
possible). The aim of CPS was defined as symptom relief, life shortening, or other (more than one answer 
possible). The respondents were asked whether a previous request for euthanasia had been reported. The 
physician judged the life expectancy before the start of CPS (1–4, 5–7, 8–14 , ≥15 days), and the duration 
of the CPS was defined in the exact number of days. In addition, whether the respondent expected a life-
shortening effect of CPS (yes/no), whether CPS provided symptom relief according to the respondents 
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(4-point scale: no, hardly, partially, completely), and what the level of consciousness of the patient was 
at the time adequate symptom relief was attained from CPS (6-point scale: alert and orientated, drowsy, 
eyes closed follow directives, eyes closed responding to physical stimuli, eyes closed not responding to 
physical stimuli, disturbed brainstem function) was asked about. Respondents were also asked what the 
patient’s intake was before the start of CPS (0, 1–500, 501–1,500, ≥1,501 mL) and whether they withheld, 
withdrew, started, or continued artificial hydration and feeding. To determine which medication was 
used to facilitate the start and continuation of CPS, the respondents were asked to fill in a maximum of 
three drugs, in order of rank, stating the starting and end dose (mg/24 h) and the route of administration.
Analysis
Descriptive analysis was performed using proportions for categorical variables and means ± standard 
deviations for continuous variables, using SPSS version 14.0.2 (SPSS, Inc,. Chicago, IL). The goodness-
of-fit test was used to determine the representativeness of the registered nursing home physicians in the 
study of the total population of registered nursing home physicians. The duration of CPS was categorized, 
in categories similar to those used in the question to assess life expectancy before the start of CPS, for the 
analyses. To study the differences in the administration of CPS to patients with cancer and dementia, 
Pearson chi-square and Fisher exact tests were used. All P-values were two sided, and an alpha of .05 was 
considered to indicate statistical significance.
RESULTS
Respondents
Six hundred seventy-five of the 1,254 physicians returned the questionnaire (54% response rate) (Figure 
1). In 2007, 28 respondents were not actively practicing and were excluded from the analysis, resulting in a 
study population of 647 respondents. For sex (P = .10; goodness-of-fit test) and age (P = .87; goodness of fit 
test), the respondents were representative of the total population of registered nursing home physicians. 
The majority of the respondents were women (65%). Mean age was 45 (range 25–65). Eighty percent of the 
nursing home physicians had more than 5 years of experience with palliative care, and 72% had at some 
time administered CPS. Almost all of them knew about the RDMA guideline on palliative sedation (98%). 
Fifty-two percent rated their level of knowledge about the contents of the guideline as good to excellent, 
and 12% rated their knowledge as moderate to poor (Table 1).
Forty-nine percent (n = 316) of the respondents indicated that they had used CPS in 2007; 307 of these 
provided information about the exact number of occasions on which CPS was administered in 2007 (9 
missing); 60% (n = 185) administered CPS once or twice, and 22% (n = 69) administered CPS three to 
five times. One nursing home physician indicated that she had administered CPS to 30 patients in 2007. 
According to the data, a maximum of 15% of all patients who died in 2007 in the Netherlands and were 
treated by nursing home physicians received CPS.
Patients
Three hundred sixteen cases were described, mostly women (57%) of high age. The majority of the 
patients had cancer or dementia (Table 2). In all but one case, patient informed consent was obtained from 
the patient or the relative who was the patient’s legal representative.
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Characteristics of CPS
Eighty-two percent of patients were treated with CPS for two or more refractory symptoms, mostly pain, 
anxiety, exhaustion, or dyspnea (Table 3). If there was only one refractory symptom (n = 55), it was usually 
dyspnea (n = 16), pain (n = 12), or exhaustion (n = 10). In one case, existential distress was reported as 
the only refractory symptom. In 98% of cases, symptom relief was the aim of CPS. In 2% of cases, the co-
intention was life shortening, whereas 1% (n = 2) had shortening of life as the sole intention. In 12% of 
cases, a previous request for euthanasia had been reported. In 94% of the patients, life expectancy was 7 
days or less, and the duration of CPS was 7 days or less in 97% of the cases. The mean duration of the CPS 
was 2.8 days (median 2.0, range 0–21 days). Twenty-six percent of all physicians estimated that CPS had 
shortened life. According to the respondents, CPS provided complete symptom relief in 89% of the cases. 
At the time adequate symptom relief by CPS was attained, 47% of the patients had a level of consciousness 
varying from alert to responding to physical stimuli. Fifty-one percent of the patients were not responsive 
to physical stimuli, and 2% had a very deep level of unconsciousness, with disturbed brainstem function.
Hydration and Nutrition
Eighty-two percent of the patients had an intake of no more than 500 mL the day before CPS started, and 
17% had no intake (Table 4). Three patients who received artificial hydration and nutrition had an intake 
of more than 1,500 mL a day. In 98% of cases, no artificial hydration was administered during CPS. In the 
group of patients who received artificial hydration before the start of CPS (n = 20), administration was 
discontinued in 15 and continued in five. Artificial hydration was started in one patient.
continuous variables, using SPSS version 14.0.2 (SPSS, Inc,.
Chicago, IL). The goodness-of-fit test was used to determine
the representativeness of the registered nursing home physi-
cians in the study of the total population of registered nursing
home physicians. The duration of CPS was categorized, in
categories similar to those used in the question to assess life
expectancy before the start of CPS, for the analyses. To study
the differences in the administration of CPS to patients with
cancer and dementia, Pearson chi-square and Fisher exact
tests were used. All P-values were two sided, and an alpha of
.05 was considered to indicate statistical significance.
RESULTS
Respondents
Six hundred seventy-five of the 1,254 physicians returned
the questionnaire (54% response rate) (Figure 1). In 2007,
28 respondents were not actively practicing and were ex-
cluded from the analysis, resulting in a study population of
647 respondents. For sex (P5.10; goodness-of-fit test) and
age (P5.87; goodness of fit test), the respondents were
representative of the total population of registered nursing
home physicians.
The majority of the respondents were women (65%).
Mean age was 45 (range 25–65). Eighty percent of the
nursing home physicians had more than 5 years of expe-
rience with palliative care, and 72% had at some time ad-
ministered CPS. Almost all of them knew about the RDMA
guideline on palliative sedation (98%). Fifty-two percent
rated their level of knowledge about the contents of the
guideline as good to excellent, and 12% rated their knowl-
edge as moderate to poor (Table 1).
Forty-nine percent (n5 316) of the respondents indi-
cated that they had used CPS in 2007; 307 of these provided
information about the exact number of occasions on which
CPS was administered in 2007 (9 missing); 60% (n5185)
administered CPS once or twice, and 22% (n5 69) admin-
istered CPS three to five times. One nursing home physician
indicated that she had administered CPS to 30 patients in
2007. According to the data, a maximum of 15% of all
patients who died in 2007 in the Netherlands and were
treated by nursing home physicians received CPS.
Patients
Three hundred sixteen cases were described, mostly women
(57%) of high age. The majority of the patients had cancer
or dementia (Table 2). In all but one case, patient informed
consent was obtained from the patient or the relative who
was the patient’s legal representative.
Characteristics of CPS
Eighty-two percent of patients were treated with CPS for
two or more refractory symptoms, mostly pain, anxiety,
exhaustion, or dyspnea (Table 3). If there was only one
refractory symptom (n555), it was usually dyspnea
(n516), pain (n512), or exhaustion (n5 10). In one case,
existential distress was reported as the only refractory
symptom.
In 98% of cases, symptom relief was the aim of CPS. In
2% of cases, the co-intention was life shortening, whereas
1% (n52) had shortening of life as the sole intention. In
12% of cases, a previous request for euthanasia had been
reported.
In 94% of the patients, life expectancy was 7 days or
less, and the duration of CPS was 7 days or less in 97% of
1,441 registered members
Dutch Association of
Nursing Home Physicians
1,254 physicians eligible for
inclusion in study 
187 physicians Amsterdam
and Rotterdam region
excluded
675 physicians responded to
the questionnaire
(response rate 54%)
647 physicians included
316 physicians indicated
they had used continuous
palliative sedation in 2007
28 physicians excluded
(not actively practicing)
Figure 1. Flowchart of physicians throughout the study.
Table 1. Characteristics of Nursing Home Physicians
(N5 647)
Characteristic n (%)
Age
25–39 189 (29)
40–54 339 (52)
55–65 118 (18)
Sex
Female 419 (65)
Male 228 (35)
Experience, years
o5 129 (20)
5–15 269 (42)
415 247 (38)
Ever administered CPS
No 184 (29)
Yes 461 (72)
Aware of guideline on palliative sedation
No 12 (2)
Yes 634 (98)
Knowledge of contents of guideline
Good to excellent 334 (52)
Reasonable 236 (37)
Moderate to poor 74 (12)
Data were missing for one physician on age and awareness of guideline on
palliative sedation, for two physicians on experience and ever administered
continuous palliative sedation (CPS), and for three physicians on knowledge
of contents of guideline.
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28 respondents were not actively practicing and were ex-
cluded from the analysis, resulting in a study population of
647 respondents. For sex (P5.10; goodness-of-fit test) and
age (P5.87; goodness of fit test), the respondents were
representative of the total population of registered nursing
home physicians.
The majority of the respondents were women (65%).
Mean age was 45 (range 25–65). Eighty percent of the
nursing home physicians had more than 5 years of expe-
rience with palliative care, and 72% had at some time ad-
ministered CPS. Almost all of them knew about the RDMA
guideline on palliative sedation (98%). Fifty-two percent
rated their level of knowledge about the contents of the
guideline as good to excellent, and 12% rated their knowl-
edge as moderate to poor (Table 1).
Forty-nine percent (n5 316) of the respondents indi-
cated that they had used CPS in 2007; 307 of these provided
information about the exact number of occasions on which
CPS was administered in 2007 (9 missing); 60% (n5185)
administered CPS once or twice, and 22% (n5 69) admin-
istered CPS three to five times. One nursing home physician
indicated that she had administered CPS to 30 patients in
2007. According to the data, a maximum of 15% of all
patients who died in 2007 in the Netherlands and were
treated by nursing home physicians received CPS.
Patients
Three hundred si teen cases were de cribed, mostly women
(57%) of high age. The majority of the patients had cancer
or dementia (Table 2). In all but one case, patient informed
consent was obtained from the patient or the relative who
was the patient’s legal representative.
Characteristics of CPS
Eighty-two percent of patients were treated with CPS for
two or more refractory symptoms, mostly pain, anxiety,
exhaustion, or d spnea (Table 3). If there was only one
refractory symptom (n555), it was usually dyspnea
(n516), pain (n512), or exhaustion (n5 10). In one case,
existential distress was reported as the only refractory
symptom.
In 98% of cases, symptom relief was the aim of CPS. In
2% of cases, the co-intention was life shortening, whereas
1% (n52) had shortening of life as the sole intention. In
12% of cases, a previous request for euthanasia had been
reported.
In 94% of the patients, life expectancy was 7 days or
less, and the duration of CPS was 7 days or less in 97% of
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Dutch Association of
Nursing Home Physicians
1,254 physicians eligible for
inclusion in study 
187 physicians Amsterdam
and Rotterdam region
excluded
675 physicians responded to
the questionnaire
(response rate 54%)
647 physicians included
316 physicians indicated
they had used continuous
palliative sedation in 2007
28 physicians excluded
(not actively practicing)
Figure 1. Flowchart of physicians throughout the study.
Table 1. Characteristics of ursing Home Physicians
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Characteristic n (%)
Age
25–39 189 (29)
40–54 339 (52)
55–65 118 (18)
S x
Female 419 (65)
Male 228 (35)
Experienc , years
o5 129 (20)
5–15 269 (42)
415 247 (38)
Ever administered CPS
No 184 (29)
Yes 461 (72)
Aware of guideline on palliative sedation
No 12 (2)
Yes 634 (98)
Knowledge of contents of guideline
Good to excellent 334 (52)
Reasonable 236 (37)
Moderate to poor 74 (12)
Data were missing for one physician on age and awareness of guideline on
palliative sedation, for two physicians on experience and ever administered
continuous palliative sedation (CPS), and for three physicians on knowledge
of contents of guideline.
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Practice of CPS
the cases. The mean duration of the CPS was 2.8 days (me-
dian 2.0, range 0–21 days). Twenty-six percent of all phy-
sicians estimated that CPS had shortened life.
According to the respondents, CPS provided complete
symptom relief in 89% of the cases. At the time adequate
symptom relief by CPS was attained, 47% of the patients
had a level of consciousness varying from alert to respond-
ing to physical stimuli. Fifty-one percent of the patients
were not responsive to physical stimuli, and 2% had a very
deep level of unconsciousness, with disturbed brainstem
function.
Hydration and Nutrition
Eighty-two percent of the patients had an intake of no more
than 500mL the day before CPS started, and 17% had no
intake (Table 4). Three patients who received artificial hy-
dration and nutrition had an intake of more than 1,500mL
a day.
In 98% of cases, no artificial hydration was adminis-
tered during CPS. In the group of patients who received
artificial hydration before the start of CPS (n5 20), admin-
istration was discontinued in 15 and continued in five. Ar-
tificial hydration was started in one patient.
Drugs
To facilitate the start and continuation of CPS, 91% of the
patients were administered midazolam, 64% received mor-
phine, and 18% were prescribed haloperidol (Table 5).
In 65% of cases, a combination of a benzodiazepine
(midazolam, diazepam, clorazepate dipotassium, clonaze-
pam) and an opioid (morphine, fentanyl) was prescribed,
30% were administered a benzodiazepine without an
opioid, and 3% were prescribed an opioid without a
benzodiazepine.
With the exception of two patients, midazolam was
administered subcutaneously. The mean starting dose of
midazolam was 31mg every 24 hours (median 30mg/24 h),
the mean end dose was 48mg every 24 hours (median
Table 2. Characteristics of Patients (N5 316)
Characteristic n (%)
Age
o41 1 (1)
41–60 32 (10)
61–80 142 (45)
480 138 (44)
Sex
Female 179 (57)
Male 134 (43)
Primary diagnosis
Cancer 118 (38)
Dementia 63 (20)
Nervous system disease 39 (13)
Cardiovascular disease 32 (10)
Pulmonary disease 23 (7)
Multiple 23 (7)
Other 15 (5)
Data were missing for three patients on age, sex, and primary diagnosis.
Table 3. Characteristics of Continuous Palliative Seda-
tion (CPS) (N5 316 Patients)
Characteristic n (%)
Refractory symptom
Pain 164 (52)
Anxiety 139 (44)
Exhaustion 137 (44)
Dyspnea 124 (40)
Delirium 74 (24)
Loss of dignity 58 (18)
Existential distressw 50 (16)
Number of symptoms
1 55 (18)
2 102 (32)
3 85 (27)
4 48 (15)
�5 24 (8)
Intentionz
Symptom relief 309 (98)
Life shortening 7 (2)
Request for euthanasia
Yes 38 (12)
No 276 (88)
Life expectancy, days
1–4 217 (69)
5–7 78 (25)
8–14 15 (5)
�14 4 (1)
Duration of CPS, days
1–4 266 (85)
5–7 36 (12)
8–14 8 (3)
�14 2 (1)
CPS shortened life
Yes 79 (26)
No 229 (74)
Effect of CPS
Complete symptom relief 276 (89)
Partially symptom relief 34 (11)
Hardly any or no symptom relief 0 (0)
Level of consciousness at adequate symptom relief
Alert and orientated 1 (0,3)
Drowsy 13 (4)
Eyes closed, following directives 10 (3)
Eyes closed, responding to physical stimuli 120 (39)
Eyes closed, not responding to physical stimuli 156 (51)
Disturbed brainstem function 7 (2)
More than one refractory symptom possible; seven most frequently refrac-
tory symptoms shown.
wMeasured using a dichotomous question. Existential distress is characterized
according to the Royal Dutch Medical Association guideline as patients close
to death with a range of severe physical complaints, where there is the feeling
that one’s existence is empty or meaningless and the distress cannot be al-
leviated by communication or spiritual support.
zMore than one intention possible.
Data were missing for two patients on refractory symptom, request for eu-
thanasia, and life expectancy; for four patients on duration of CPS; for six
patients on effect CPS; for eight patients on expected shortened life; and for
nine patients on level of consciousness at adequate symptom relief.
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30mg/24 h). The dose range of midazolam at the start of
sedation was 0 to 240mg every 24 hours, and the dose
range at the time of death was 0 to 480mg every 24 hours.
Two patients received a benzodiazepine other than mid-
azolam at the start of sedation, which was changed to mid-
azolam later on. In four patients, the administration of
midazolam was ceased 24 hours or more before death. For
morphine, which was given subcutaneously in all cases, the
mean starting dose was 47mg every 24 hours (median
30mg/24 h), and the mean end dose was 65mg every 24
hours (median 60mg/24 h).
Primary Disease
Comparing the administration of CPS to patients with can-
cer and dementia, there were only statistically significant
differences between a previous request for euthanasia (can-
cer 17%, dementia 0%; Po.001, Fisher exact test), a life
expectancy of 4 days or less before the start of the CPS
(cancer 64%, dementia 78%; P5.03, Pearson chi-square
test), and an absence of intake before the start of the CPS
(cancer 11%, dementia 33%; P5.001, Pearson chi-square
test). No statistically significant differences were found be-
tween patients with cancer or dementia in distribution of
re ractory symptoms, level of consciousness at the time ad-
equate symptom f was attained, or duration and effect
of CPS (data not shown).
DISCUSSION
To the authors’ knowledge, this is the first nationwide
Dutch study to provide insight into the practice of CPS by
nursing home physicians in a population of frail older
adult with a high percent ge of patients suffering from
terminal cancer and ementia. The vast majority of Dutch
nur ing home physicians have experience with administer-
ing CPS at some time. In 2007, most patients were elderly
women and had two or more refractory symptoms. The
most frequent of these were pain, anxiety, exhaustion, and
dyspnea. In almost all cases, symptom relief was the aim,
and in 12% of cases, a previous request for euthanasia had
been repor d. Life expecta cy and uration of the CPS
were 7 days or less n almos patients. In general, nursing
home physicians judged CPS to be effective in relieving re-
fractory symptoms. More than half of the patients were
unresponsive to physical stimuli at the time adequate symp-
tom relief was attained and must be qualified as being in
deep and continuous sedation. For 82% of patients, intake
was less than 500mL before the start of CPS, and in most
cases artificial hydration was withheld during CPS. Mid-
azolam was the most frequently used drug. The adminis-
tration of CPS to patients with cancer and dementia differed
significantly with respect to the following factors: previ-
ously made request for euth asia, life expectancy of 4 days
or less, and absence of intake before the start of CPS.
Care should be taken when comparing the figures of
this study with the results of previous international studies.
First, this study did not include temporary or intermittent
palliative sedation, and the questionnaire used the term
‘‘continuous palliative sedation.’’ Most studies performed
over the past decade have focused on continuous deep se-
dation,5–9,11–13,17–30 which covers just 53% of the cases in
the current study. Second, the Netherlands is the only
country where nursing home medicine exists as an inde-
pendent medical specialism with its own specific training
program.31 In other countries, general practitioners or
other physicians take care of these patients. Within these
constraints, some of the results of the current study will be
compared here with those of previous studies.
The distribution of symptoms considered refractory in
this study is in line with previous studies,7–9,11–13 although
the current study found a higher frequency of loss of dignity
Table 4. Nutri ion and Hydra ion (N5 316 Patients)
Nutrition and Hydration n (%)
Intake before the start of CPS, mL
0 53 (17)
1–500 201 (65)
501–1,500 52 (17)
41,500 3 (1)
Artificial hydration
Discontinued 15 (5)
Continued 5 (2)
Started 1 (0,3)
Not started 293 (93)
Artificial feeding
Discontinued 12 (4)
Continued 6 (2)
Started 1 (0,3)
Not started 293 (94)
Data were missing for two patients on artificial hydration, four patients on
artificial feeding, and six patients on intake before the start of continuous
palliative sedation (CPS).
Table 5. Six Most-Frequently Used Drugs to Facilitate the Start and Continuation of Continuous Palliative Sedation
Drug n (%)
mg/24/h, Mean  Standard Deviation (Range)
Administration (%)Start Dose End Dose
Midazolam 289 (91) 30.6  26.1 (0–240) 47.7  56.8 (0–480) Subcutaneous (99)
Morphine 201 (64) 47.5  49.7 (0–600) 65.5  64.7 (5–600) Subcutaneous (100)
Haloperidol 57 (18) 6.3  5.6 (1–30) 6.0  6.6 (0–30) Subcutaneous (93)
Levomepromazine 22 (7) 35.3  36.8 (0–150) 50.8  32.3 (8–150) Subcutaneous (100)
Fentanyl 17 (5) 1.48  0.98 (0.29–3.60) 1.58  0.95 (0.29–3.60) Transdermal (100)
Diazepam 13 (4) 25.4  13.9 (10–60) 24.0  20.1 (0–60) Rectal (83)
Data were missing for nine patients.
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Drugs
To facilitate the start and continuation of CPS, 91% of the patients were administered midazolam, 64% 
received morphine, and 18% were prescribed haloperidol (Table 5). In 65% of cases, a combination of a 
benzodiazepine (midazolam, diazepam, clorazepate dipotassium, clonazepam) and an opioid (morphine, 
fentanyl) was prescribed, 30% were administered a benzodiazepine without an opioid, and 3% were 
prescribed an opioid without a benzodiazepine. With the exception of two patients, midazolam was 
administered subcutaneously. The mean starting dose of midazolam was 31 mg every 24 hours (median 
30 mg/24 h), the mean end dose was 48 mg every 24 hours (median 30 mg/24 h). The dose range of 
midazolam at the start of sedation was 0 to 240 mg every 24 hours, and the dose range at the time of 
death was 0 to 480 mg every 24 hours. Two patients received a benzodiazepine other than midazolam at 
the start of sedation, which was changed to midazolam later on. In four patients, the administration of 
midazolam was ceased 24 hours or more before death. For morphine, which was given subcutaneously in 
all cases, the mean starting dose was 47 mg every 24 hours (median 30 mg/24 h), and the mean end dose 
was 65 mg every 24 hours (median 60 mg/24 h).
Primary Disease
Comparing the administration of CPS to patients with cancer and dementia, there were only statistically 
significant differences between a previous request for euthanasia (cancer 17%, dementia 0%; P < .001, 
Fisher exact test), a life expectancy of 4 days or less before the start of the CPS (cancer 64%, dementia 
78%; P = .03, Pearson chi-square test), and an absence of intake before the start of the CPS (cancer 11%, 
dementia 33%; P = .001, Pearson chi-square test). No statistically significant differences were found 
between patients with cancer or dementia in distribution of refractory symptoms, level of consciousness 
at the time adequate symptom relief was attained, or duration and effect of CPS (data not shown).
DISCUSSION
To the authors’ knowledge, this is the first nationwide Dutch study to provide insight into the practice of 
CPS by nursing home physicians in a population of frail older adults with a high percentage of patients 
suffering from terminal cancer and dementia. The vast majority of Dutch nursing home physicians have 
experience with administering CPS at some time. In 2007, most patients were elderly women and had two 
or more refractory symptoms. The most frequent of these were pain, anxiety, exhaustion, and dyspnea. 
In almost all cases, symptom relief was the aim, and in 12% of cases, a previous request for euthanasia 
had been reported. Life expectancy and duration of the CPS were 7 days or less in almost all patients. 
In general, nursing home physicians judged CPS to be effective in relieving refractory symptoms.  
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country where nursing home medicine exists as an inde-
pendent medical specialism with its own specific training
program.31 In other countries, general practitioners or
other physicians take care of these patients. Within these
constraints, some of the results of the current study will be
compared here with those of previous studies.
The distribution of symptoms considered refractory in
this study is in line with previous studies,7–9,11–13 although
the current study found a higher frequency of loss of dignity
Table 4. Nutrition and Hydration (N5 316 Patients)
Nutrition and Hydration n (%)
Intake before the start of CPS, mL
0 53 (17)
1–500 201 (65)
501–1,500 52 (17)
41,500 3 (1)
Artificial hydration
Discontinued 15 (5)
Continued 5 (2)
Started 1 (0,3)
Not started 293 (93)
Artificial feeding
Discontinued 12 (4)
Continued 6 (2)
Started 1 (0,3)
Not started 293 (94)
Data were missing for two patients on artificial hydration, four patients on
artificial feeding, and six patients on intake before the start of continuous
palliative sedation (CPS).
Table 5. Six Most-Frequently Used Drugs to Facilitate the Start and Continuation of Continuous Palliative Sedation
Drug n (%)
mg/24/h, Mean  Standard Deviation (Range)
Administration (%)Start Dose End Dose
Midazolam 289 (91) 30.6  26.1 (0–240) 47.7  56.8 (0–480) Subcutaneous (99)
Morphine 201 (64) 47.5  49.7 (0–600) 65.5  64.7 (5–600) Subcutaneous (100)
Haloperidol 57 (18) 6.3  5.6 (1–30) 6.0  6.6 (0–30) Subcutaneous (93)
Levomepromazine 22 (7) 35.3  36.8 (0–150) 50.8  32.3 (8–150) Subcutaneous (100)
Fentanyl 17 (5) 1.48  0.98 (0.29–3.60) 1.58  0.95 (0.29–3.60) Transdermal (100)
Diazepam 13 (4) 25.4  13.9 (10–60) 24.0  20.1 (0–60) Rectal (83)
Data were missing for nine patients.
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More than half of the patients were unresponsive to physical stimuli at the time adequate symptom relief 
was attained and must be qualified as being in deep and continuous sedation. For 82% of patients, intake 
was less than 500 mL before the start of CPS, and in most cases artificial hydration was withheld during 
CPS. Midazolam was the most frequently used drug. The administration of CPS to patients with cancer 
and dementia differed significantly with respect to the following factors: previously made request for 
euthanasia, life expectancy of 4 days or less, and absence of intake before the start of CPS.
Care should be taken when comparing the figures of this study with the results of previous international 
studies. First, this study did not include temporary or intermittent palliative sedation, and the 
questionnaire used the term ‘‘continuous palliative sedation.’’ Most studies performed over the past 
decade have focused on continuous deep sedation, 5–9,11–13,17–30 which covers just 53% of the cases in 
the current study. Second, the Netherlands is the only country where nursing home medicine exists as 
an independent medical specialism with its own specific training program.31 In other countries, general 
practitioners or other physicians take care of these patients. Within these constraints, some of the results 
of the current study will be compared here with those of previous studies. 
The distribution of symptoms considered refractory in this study is in line with previous studies,7–9,11–13 
although the current study found a higher frequency of loss of dignity (18% vs 6.5%) and exhaustion 
(44% vs 13%) and a lower frequency of anxiety (44% vs 65.2%).9 The RDMA guideline explicitly mentions 
exhaustion as a contributor to refractory suffering because its presence may exacerbate suffering, and it is 
a determining factor of the patient’s endurance. This may lead to the conclusion that palliative sedation 
is the only reasonable option left.3 Furthermore, little is known about the pathogenesis of exhaustion, so 
conventional modes of treatment may be less successful than treatments for other symptoms at the end 
of life.32
The presence of loss of dignity and existential distress is consistent with previous research, although 
some authors have questioned whether viewing existential suffering as a symptom or a medical state 
is justified,33 but given the involvement of physicians with dying patients, existential distress cannot 
be separated from the domain of medicine and can therefore be a part of the indication for palliative 
sedation. The RDMA guideline does not define this state but instead describes or characterizes it in the 
text: ‘‘In such cases, this existential suffering cannot be alleviated by communication or spiritual support. 
These patients have often been through a great deal of distress, are often extremely ill and weak, close 
to death, and have a range of physical complaints, some of them often severe. The patient’s body has 
reached its end, literally and figuratively, and everything that needed saying has been said and there is 
the feeling that one’s existence is empty or meaningless (existential suffering).’’3
In a retrospective study, it is not possible to determine the precise reason for the patient’s existential 
suffering. Despite the vagueness of the term, existential suffering often proves to be an important reason 
for discussing end-of-life decisions. A prospective study to determine exactly what happens in these cases 
would be worthwhile. 
In 2004, it was reported that 59% of all nursing home physicians performed continuous deep palliative 
sedation with the (co)intention of hastening death.11 The current study found a considerably lower 
percentage (2%). In 12% of all cases, and 17% of patients with cancer, a previous request for euthanasia 
had been reported. These percentages are higher than found in previous research in nursing home 
populations, with percentages of 6.5% and 9% found.7,9 This might indicate that CPS is used as an 
alternative to euthanasia in some cases. Why a euthanasia request was not granted in such cases needs to 
be investigated. 
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Whether artificial nutrition and hydration should be forgone in CPS is a subject of ongoing debate. 
In other European countries, continuous deep sedation in nursing homes and residential homes is 
frequently administered with artificial nutrition and hydration.23 The current study shows that nursing 
home physicians in the Netherlands mostly do not administer artificial fluids. The minimal intake before 
sedation in the vast majority of the study population could be a contributing factor in this decision by 
nursing home physicians. It could be argued that artificial hydration is medically futile, hampers the 
natural dying process, and may result in additional suffering, whereas withholding artificial hydration 
will not influence survival. 
The general consensus is that midazolam is the drug of choice for inducing CPS because of its fast onset 
of action, the ease of titration, and the option of rapid reversibility. Morphine is not considered to be a 
suitable drug for inducing CPS.3,4,16 The current study revealed a higher frequency of a benzodiazepines 
being used to induce and maintain CPS than previous nursing home physician studies (95% vs 75–89%) 
and found a lower frequency of an opioid without a benzodiazepine being used for this purpose (3% vs 
10–26%).7,11,12 This shift is probably because of the publication of the RDMA guideline, as well as media 
attention to the issue and the ongoing debate among physicians. Despite these changes in practice, it 
was found that nursing home physicians increased the mean dose of morphine during CPS. Morphine 
is usually continued as a symptom-directed treatment, but benzodiazepines are administrated to induce 
sedation.13,34 The reason of the increase of the morphine dosages is unclear.
Almost all other studies show smaller dose ranges, with a lower maximum dose of midazolam than in 
the current study,18,19,24,35–44 although the mean dose of midazolam used in the current study was lower 
than or similar to that in most other studies.18,19,24,35–37,39–41,43,45,46 Furthermore, only nine patients 
received an end dose of midazolam greater than 120 mg every 24 hours, and the dose range was consistent 
with the recommendations of the RDMA guideline. Moreover, continuous deep palliative sedation was 
administered in only 53% of cases, suggesting that the doses used were proportional to patients’ needs, 
although little is known about the pharmacokinetics of midazolam in a frail, elderly population. Further 
research is needed to support the medication recommendations of the RDMA guideline.
Despite the specific pathophysiology and symptomatology of each primary underlying disease, no 
statistically significant differences were found between the distribution of refractory symptoms in patients 
with cancer and dementia. In addition, no statistically significant differences were found in outcomes of 
CPS, such as symptom relief and duration.
There was a statistically shorter life expectancy in terminally ill patients with dementia than in patients 
with cancer before the start of CPS. The fact that more patients with dementia had no intake before the 
start of CPS might have helped the physician to determine that death would ensue within 1 or 2 weeks. In 
addition, it suggests that whether nutrition or hydration will be withheld during CPS is discussed more 
frequently for patients with cancer than for those with dementia.
This is the first nationwide study of the practice of CPS by Dutch nursing home physicians. Nevertheless, 
these findings should be interpreted within the constraints of a questionnaire study. First, there were 
limitations with respect to the study population. Although the respondents were representative regarding 
sex and age of the total population of registered nursing home physicians, a portion of nursing home 
physicians in the Amsterdam and Rotterdam regions were excluded, and the response rate was only 54%.
Possible differences between respondents and nonrespondents, as well as the excluded physicians 
in the Amsterdam and Rotterdam regions, with respect to the practice of CPS cannot be excluded.  
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Second, although clear definitions of palliative sedation and refractory symptoms in the questionnaire 
were used, items such as loss of dignity and existential distress were not defined. Also primary disease 
was not defined using, for example, the International Classification of Diseases. Third, refractoriness 
of suffering was not determined by investigating the etiology of each type of suffering, what types of 
treatment had been attempted before sedation, and how symptoms were recognized, especially in patients 
with dementia. Fourth, respondents may have had difficulty recalling patient characteristics, although 
recall bias was probably limited because of the instruction to use data extracted from the medical file. 
This study shows that, in addition to physical symptoms, nursing home physicians often mention anxiety, 
exhaustion, loss of dignity, and existential distress as refractory symptoms in the decision to start CPS. 
Furthermore, close to one in five patients with cancer had made a previous request for euthanasia. The 
dosage range of midazolam in this study fits the recommendations of the Dutch national guideline on 
palliative sedation, although international studies show smaller dosage ranges. Further prospective 
research about the acceptability and assessment of nonphysical symptoms as indications for CPS and the 
optimal medication scheme for CPS in frail elderly patients is recommended. Finally, adequate palliative 
care with careful assessment of potential reversible factors and nonsedating alternatives should be the 
keystone of treatment before starting palliative sedation.
Practice of CPS
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The practice of continuous palliative sedation in long-term care 
for	frail	patients	with	existential	suffering.
van Deijck RH, Hasselaar JG, Krijnsen PJ, Gloudemans AJ, Verhagen SC, Vissers KC, 
Koopmans RT.
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Abstract
Some	 guidelines	 and	 recommendations	 identify	 existential	 suffering	 as	 a	 potential	 refractory	 symptom	 for	
which continuous palliative sedation (CPS) can be administered under certain conditions. However, there has 
been	little	research	on	the	characteristics	of	patients	with	existential	suffering	treated	with	CPS	and	the	degree	
to	which	the	preconditions	are	fulfilled.	The	aim	of	this	study	was	to	provide	insight	into	this	specific	indication	
for CPS. Questionnaires were sent to nursing home physicians in the Netherlands, who described 314 patients. 
Existential	suffering	was	a	refractory	symptom	in	83	of	the	patients.	For	most	of	the	patients	with	refractory	
existential	suffering,	other	refractory	symptoms	were	also	reported,	and	life	expectancy	was	seven	days	or	less;
informed consent for initiating CPS had been obtained in all cases. Consultation and intermittent sedation before 
the start of CPS were far less frequently reported than one would expect based on the guidelines. Multivariate 
analysis showed that being male, having previously requested euthanasia, having a nervous system disease, or 
having	an	other	diagnosis	were	positively	correlated	with	the	administration	of	CPS	for	existential	suffering.	
We conclude that more attention should be paid to the suggested preconditions and to the presence of existential 
suffering	in	male	patients	or	patients	with	a	nervous	system	disease.
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INTRODUCTION
When patients with a terminal disease experience refractory symptoms — that is, symptoms that do 
not respond to conventional therapies, despite intensive efforts, or that cannot be controlled without 
causing intolerable side effects1 — an indication arises for palliative sedation. Palliative sedation has been 
defined as “the deliberate lowering of a patient’s level of consciousness in the last stage of life”,1 and it is 
considered an ethically acceptable therapy for patients with refractory symptoms.1-4 The term “palliative 
sedation” encompasses two distinct types of intervention: brief or intermittent sedation, and continuous 
palliative sedation (CPS) administered until death.1 Although both represent stages in the ongoing process 
of providing proportional sedation for refractory symptoms, the distinction is made to emphasize the fact 
that CPS is only to be administered to patients who are near death.1 There is sometimes a lack of clarity 
regarding the difference between CPS and euthanasia, and it has been suggested that some physicians 
view CPS as a way of avoiding euthanasia.1 However, both the European Association for Palliative Care 
Ethics Task Force5 and the Royal Dutch Medical Association1 have clearly stated that CPS is a medical 
intervention and is totally different from euthanasia in its aim, procedure, and result.
The most common indications for administering palliative sedation are delirium, dyspnea, and pain. 
Palliative sedation is also sometimes used to treat existential suffering.6,7 Definitions of existential 
suffering at the end of life include: loss of a sense of personal meaning; loss of a sense of life’s purpose; 
fear of death; feelings of despair, anguish, and hopelessness; perception of being a burden to others; loss 
of dignity; sense of helplessness; and sense of betrayal.8 In the palliative care community, there is still a 
lack of consensus on a definition of existential suffering. Furthermore, although existential suffering is 
considered to be a condition that medical practitioners must address,9 there is no general consensus on 
whether palliative sedation is an appropriate intervention for it.10 Existential suffering may occur long 
before the terminal phase.2,11 It tends not to be progressive in the sense that suffering caused by physical 
symptoms is (it often fluctuates), and psychological adaptation and coping are common.2,11 Also, it is 
difficult for practitioners to determine whether a patient’s existential suffering is refractory2,11,12 and 
to distinguish it from treatable psychiatric conditions such as depression.12 This may cause them to 
administer CPS in cases where other, more conventional therapies would be more appropriate. Although 
interventions for existential suffering are not well established,2,11,12 the American Medical Association 
(AMA) contends that existential suffering is better addressed through interventions other than palliative 
sedation.13 Despite the AMA’s position on this issue, some guidelines and recommendations identify 
existential suffering as a potential refractory symptom that can be treated with CPS under specific 
conditions. These preconditions include: an expert in psychosocial problems and meaning-of-life issues 
has been consulted;1-4,14-16 intermittent sedation is initiated before CPS is attempted;2,16 the patient has 
a life expectancy of a maximum of one to two weeks;1,14,15 informed consent has been obtained;14 and 
existential suffering is not the patient’s sole refractory symptom.1 
Most patient-based studies focus on the frequency of existential suffering as an indication for CPS,17-32 
but little insight has been achieved into the characteristics of patients with existential suffering treated 
with CPS and the degree to which the preconditions have been fulfilled. A few studies have focused on 
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the use of palliative sedation for existential suffering. Morita investigated the use of palliative sedation to 
relieve psychoexistential suffering in 90 terminally ill cancer patients in palliative care units in Japan.33 
The condition of these patients was generally poor, and their suffering was refractory, despite the fact that 
they were receiving intermittent sedation and specialized psychiatric, psychological, and/or religious 
counselling. CPS was administered to them on the basis of informed consent. In another study, by Morita 
et al., data of previous studies was reanalyzed in order to clarify the physical conditions of 20 terminally 
ill cancer patients with existential suffering who received sedation in a palliative care unit.34 Most of 
these patients were in extremely poor physical condition just before sedation: 95 percent had a Palliative 
Performance Scale score under 40, could take nourishment orally only by mouthfuls or less, and had 
a predicted survival time of three weeks or less. One patient received sedation for existential suffering 
alone. Anquinet et al. interviewed 35 physicians involved in caring for cancer patients with psychological 
and existential suffering who had been continuously sedated until they died.35 The physicians reported 
that they had attempted an array of pharmacological and psychological interventions, which were 
ultimately ineffective or inappropriate, to relieve the patients’ suffering before applying CPS. Reported 
preconditions for administering sedation were the presence of refractory physical symptoms, a short life 
expectancy, and the patient’s explicit request for sedation.
Furthermore, little is known about which patient characteristics are correlated with the administration of 
CPS for existential suffering. Knowledge of such characteristics could help physicians and other healthcare 
professionals to identify patients at risk of developing refractory existential suffering and thereby facilitate 
early referral to a psychotherapist, social worker, or spiritual counsellor, possibly precluding the need for 
CPS. 
The aim of this study was therefore to provide greater insight into the characteristics of patients with 
existential suffering who are treated with CPS and the degree to which the preconditions for administering 
CPS are fulfilled.
METHODS
Study Design and Data Collection
A structured retrospective questionnaire was sent to 1,254 nursing home physicians in February 2008.36 
All registered members of the Dutch Association of Elderly Care Physicians were eligible for the study 
(n=1,441), except 187 of the 292 members in the Amsterdam and Rotterdam regions — they were excluded 
due to their involvement in a parallel, ongoing study on palliative sedation that was being conducted in 
these regions. Only anonymous data were collected. A reminder to return the questionnaire was sent after 
three weeks. Data collection ended in May 2008.
Questionnaire
In the questionnaire, CPS was defined as “the deliberate lowering of a patient’s level of consciousness 
in the last stage of life, continued until the time of death.” The questionnaire consisted of 38 closed-
ended questions and six open-ended questions and was divided into two parts. The first part contained 
13 questions about the characteristics of the respondent — for example, age, sex, and years of clinical 
experience with end-of-life care. The second part contained questions about the respondent’s most 
recent case involving CPS within the previous 12 months and an explicit request to retrieve information 
from patients’ medical files; this part also included questions about the patient’s age, sex, and primary 
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diagnosis (dementia, cancer, cardiovascular disease, pulmonary disease, nervous system disease, or other 
diagnosis). When respondents listed more than one primary diagnosis, it was registered as “multiple.” 
Respondents were asked whether a previous request for euthanasia had been reported, whether they had 
considered intermittent sedation before commencing CPS, and whether they had discussed alternative 
strategies with another professional (a physician, nurse, palliative care consultant, spiritual counsellor, 
other, or nobody) before deciding to start CPS. In the questionnaire, no distinction was made between 
informed consent given by the patient or by the patient’s legal representative. The indicating symptoms 
for CPS were pain, dyspnea, delirium, anxiety, vomiting, nausea, exhaustion, existential suffering, loss of 
dignity, and other (it was possible to provide more than one answer). Respondents were asked to explain 
their purpose in initiating CPS by selecting one or more of these options: symptom relief, life shortening, 
or other. They were also requested to record patients’ life expectancy before the start of CPS (1 to 4 days, 
5 to 7 days, 8 to 14 days, and 15 days or more); CPS duration was to be expressed as an exact number of 
days. In addition, respondents were asked whether CPS delivered symptom relief (on a 4-point scale: no, 
hardly, partially, or completely), and what the patient’s level of consciousness was at the time adequate 
symptom relief was achieved (on a 6-point scale: alert and oriented; drowsy; eyes closed, following 
directives; eyes closed, responding to physical stimuli; eyes closed, not responding to physical stimuli; 
or disturbed brainstem function). Then they were asked to describe the patient’s intake before the start 
of CPS (0, 1 to 500, 501 to 1,500, ≥1,501 mL) and to note whether they had withheld, withdrawn, started, 
or continued artificial hydration and feeding. Finally, respondents were asked to list a maximum of three 
drugs they used for CPS, and to state the starting and end dose (mg/24 h) and route of administration.
pectancy, and the patient’s explicit request for
sedation. 
Furthermore, little is known about which
patient characteristics are correlated with the
administration of CPS for existential suffering.
Knowledge of such characteristics could help
physicians and other healthcare professionals to
identify patients at risk of developing refractory
existential suffering and thereby facilitate early
referral to a psychotherapist, social worker, or
spiritual counsellor, possibly precluding the need
for CPS. 
The aim of this study was therefore to provide
greater insight into the characteristics of patients
with existential suffering who are treated with
CPS and the degree to which the preconditions for
administering CPS are fulfilled. 
METHODS
Study Design and Data Collection
A structured retrospective questionnaire was sent
to 1,254 nursing home physicians in February
2008 (36). All registered members of the Dutch
Association of Elderly Care Physicians were eligi-
ble for the study (n=1,441), except 187 of the 292
members in the Amsterdam and Rotterdam
regions — they were excluded due to their
involvement in a parallel, ongoing study on pal-
liative sedation that was being conducted in these
regions. Only anonymous data were collected.
A reminder to return the questionnaire was sent
after three weeks. Data collection ended in May
2008.  
Questionnaire
In the questionnaire, CPS was deﬁned as “the
deliberate lowering of a patient’s level of con-
sciousness in the last stage of life, continued until
the time of death.” The questionnaire consisted of
38 closed-ended questions and six open-ended
questions and was divided into two parts. The
ﬁrst part contained 13 questions about the charac-
teristics of the respondent — for example, age,
sex, and years of clinical experience with end-of-
life care. The second part contained questions
about the respondent’s most recent case involving
CPS within the previous 12 months and an
explicit request to retrieve information from
patients’ medical ﬁles; this part also included
questions about the patient’s age, sex, and
primary diagnosis (dementia, cancer, cardiovascu-
lar disease, pulmonary disease, nervous system
disease, or other diagnosis). When respondents
listed more than one primary diagnosis, it was
registered as “multiple.” Respondents were asked
whether a previous request for euthanasia had
been reported, whether they had considered inter-
mittent sedation before commencing CPS, and
whether they had discussed alternative strategies
with another professional (a physician, nurse, pal-
liative care consultant, spiritual counsellor, other,
or nobody) before deciding to start CPS. In the
questionnaire, no distinction was made between
informed consent given by the patient or by the
patient’s legal representative. The indicating
symptoms for CPS were ain, dyspnea, delirium,
anxiety, vomiting, nausea, exhaustion, existential
suffering, loss of dignity, and other (it was possi-
ble to provide more than one answer). Respon-
dents were asked to explain their purpose in initi-
ating CPS by selecting one or more of these
options: symptom relief, life shortening, or other.
They were also requested to record patients’ life
expectancy before the start of CPS (1 to 4 days, 5
to 7 days, 8 to 14 days, and 15 days or more); CPS
duration was to be expressed as an exact number
of days. In additi n, respondents were asked
whether CPS delivered symptom relief (on a 4-
point scale: no, hardly, partially, or completely),
and what the patient’s level of consciousness was
at the time adequate symptom relief was achieved
(on a 6-point scale: alert and oriented; drowsy;
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Figure 1 / Flowchart of Physicians throughout 
the Study
1,441 registered members
of the Dutch Association 
of Elderly Care Physicians
187 physicians from the
Amsterdam and Rotterdam
regions excluded
28 physicians excluded 
(not actively practising)
2 physicians excluded
(did not provide information
about the type of refractory
symptoms)
1,254 physicians were
eligible for inclusion 
in the study
675 physicians responded
to the questionnaire
(response rate: 53.8%)
316 physicians indicated
they had used continuous
palliative sedation in 2007
314 physicians provided
information about the type
of refractory symptoms
231 physicians reported a
case without the indication
of existential suffering
83 physicians reported a
case with the indication of
existential suffering 
647 physicians included 
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Analysis
This study involved a subanalysis of a previously published study,36 and focused on refractory existential 
suffering. For this study, patients with existential suffering were defined as those for whom the respondent 
had filled in the tick box for existential suffering and/or loss of dignity as a refractory symptom. 
A descriptive analysis was performed using proportions for categorical variables and means and standard 
deviations for continuous variables. Patient age was categorized as: younger than 51, 51 to 80, and 81 years 
and older. The duration of CPS was categorized as: 1 to 4, 5 to 7, 8 to 14, and more than 14 days. To analyze 
the correlation between characteristics of patients with existential suffering and the administration of 
CPS, gender, age, dementia, cancer, cardiovascular disease, pulmonary disease, nervous system disease, 
other diagnoses, multiple diagnoses, and previous requests for euthanasia were analyzed as independent 
variables using Pearson’s chi-squared test. Using the aforementioned independent variables, multiple 
logistic regression models were constructed to analyze the probability of patients with existential suffering 
being sedated. Data are reported with odds ratios (OR) and 95 percent confidence intervals (95 percent 
CI). All p-values were tested as two-sided, and an alpha value of .05 was considered to indicate statistical 
significance. Statistical analyses were performed using the SPSS 20.0 (IBM Corp., 2011). 
RESULTS
A total of 675 physicians returned the questionnaire (a 53.8 percent response rate). We excluded 331 
respondents because they had not administered CPS in the past year, and 28 because they were not actively 
practising. Of the remaining 316 respondents, we excluded 2 because they did not provide information 
about the type of refractory symptoms they had encountered among their patients. The final sample 
consisted of data describing the cases of 314 patients receiving CPS. Of these, 83 patients (26.4 percent) 
who had received CPS for existential suffering were identified. In this group, 1 patient (1.2 percent) 
receiving CPS had existential suffering as a sole refractory symptom. For 73 patients (88.0 percent), 
existential suffering coexisted with one to four other refractory symptoms; 9 patients (10.8 percent) had 
five to seven other refractory symptoms. Among those patients who did not report existential suffering 
(n=231), 54 (23.4 percent) had one refractory symptom and 177 (76.6 percent) had two to five refractory 
symptoms. 
Characteristics before the Administration of CPS 
The day before the patients with existential suffering had commenced CPS, 80.5 percent of them had 
received oral intake or artificial hydration of 500 mL or less. Intermittent sedation was considered in 
40.2 percent of cases. In 4.8 percent of cases, the attending physician consulted a spiritual counsellor, and 
in 8.4 percent of cases, a palliative care consultant was called upon. For all patients receiving CPS for 
existential suffering, informed consent was obtained for the administration of CPS. Life shortening was 
the physician’s rationale for CPS in 6.0 percent of cases. For 90.4 percent of the patients, life expectancy at 
the start of CPS was seven days or less (Table 1). 
Characteristics during the Administration of CPS 
For all but three patients with refractory existential suffering, no artificial hydration was administered 
during CPS. At the time adequate symptom relief was obtained, 60.7 percent of the patients were not 
responsive to physical stimuli. The mean end dose of midazolam, the most frequently used drug for CPS, 
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was 46.1 mg every 24 hours. For 96.4 percent of the patients, the duration of CPS was seven days or less. 
According to the respondents, CPS provided complete symp tom relief in 92.5 percent of cases (Table 2). 
Correlation between Patient Characteristics and CPS 
Univariate analysis revealed that patients sedated for existential suffering were more likely to be male 
(p=0.01) and to have been diagnosed with nervous system disease (p<0.01) or other condition (for example, 
cachexia, anxiety, aspiration pneumonia, renal failure, ileus, or fracture) (p=0.04); they were also more 
likely to have requested euthanasia (p<0.01) (Table 3). 
Multivariate logistic regression analysis showed that the nature of the underlying disease was significantly 
correlated with the administration of CPS for existential suffering (p<0.01). Having a nervous system 
disease (OR: 3.64; 95 percent CI: 1.64-8.06) (p<0.01) or an “other diagnosis” (OR: 4.61; 95 percent CI: 
1.34-15.81) (p=0.02) were positively correlated with the administration of CPS for existential suffering as  
compared to having cancer. Moreover, multivariate analysis showed that certain patient characteristics 
were correlated with the administration of CPS for existential suffering: being male (OR: 1.91; 95 percent CI: 
1.11-3.28) (p=0.02); and having requested euthanasia (OR: 2.93; 95 percent CI: 1.37-6.26) (p=0.01) (Table 4). 
 
patients receiving CPS for existential suffering,
informed cons nt w s obtained for the adminis-
tration of CPS. Life shortening was the physician’s
rationale for CPS in 6.0 percent of cases. For 90.4
percent of the patients, life expectancy at the start
of CPS was seven days or less (Table 1). 
Characteristics during 
the Administration of CPS
For all but three patients with refractory existen-
tial suffering, no artiﬁcial hydration was adminis-
tered during CPS. At the time adequate symptom
relief was obtained, 60.7 percent of the patients
were not responsive to physical stimuli. The mean
end dose of midazolam, the most frequently used
drug for CPS, was 46.1 mg every 24 hours. For
96.4 percent of the patients, the duration of CPS
was seven days or less. According to the respon-
dents, CPS provided complete symp tom relief in
92.5 percent of cases (Table 2).
Correlation between Patient Characteristics 
and CPS
Univariate analysis revealed that patients sedated
for existential suffering were more likely to be
male (p=0.01) and to have been diagnosed with
nervous system disease (p<0.01) or other condi-
tion (for example, cachexia, anxiety, aspiration
pneumonia, renal failure, ileus, or fracture)
(p=0.04); they were also more likely to have
requested euthanasia (p<0.01) (Table 3). 
Multivariate logistic regression analysis
showed that the nature of the underlying disease
was significantly correlated with the administra-
tion of CPS for existential suffering (p<0.01).
Having a nervous system disease (OR: 3.64;
95 percent CI: 1.64-8.06) (p<0.01) or an “other
diagnosis” (OR: 4.61; 95 percent CI: 1.34-15.81)
(p=0.02) were positively correlated with the
administration of CPS for existential suffering as
compared to having cancer. Moreover, multivari-
ate analysis showed that certain patient character-
istics were correlated with the administration of
CPS for existential suffering: being male (OR: 1.91;
95 percent CI: 1.11-3.28) (p=0.02); and having
requested euthanasia (OR: 2.93; 95 percent CI:
1.37-6.26) (p=0.01) (Table 4).
DISCUSSION
This study provides insight into the practice of
administering CPS to treat existential suffering. In
almost all of the patients reported on in the study,
existential suffering coexisted with refractory
physical symptoms, and life expectancy was
seven days or less. In all cases, informed consent
for the administration of CPS had been obtained
from either the patient or the patient’s legal repre-
sentative. Intermittent sedation and consultation
before commencing CPS were less frequently
reported. Having a nervous system disease or
“other diagnosis” was positively correlated with
receiving CPS for existential suffering compared
to having cancer. Moreover, the multivariate
analysis showed that being male or having
requested euthanasia were positively correlated
with receiving CPS for existential suffering.
Some guidelines and recommendations de -
scribe specific preconditions for offering CPS
for existential suffering (1-4, 14-16). The results of
this study related to the presence of physical
symptoms in patients with existential suffering,
informed consent, and limited life expectancy are
generally in line with these preconditions. How -
ever, the use of intermittent sedation and consul-
tation with a palliative care consultant or spiritual
counsellor before starting CPS were far less fre-
quently reported than one would expect, given
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Table 2 / Characteristics during the Administration
of Continuous Palliative Sedation (CPS)
for Patients with Existential Suffering
(n=83)a
Indication
of existential
suffering
Characteristic No. (%)
Artificial hydrationb
Discontinued 2 (2.4)
Continued 3 (3.7)
Started 0 (0)
Not started 77 (93.9)
Level of consciousness at adequate 
symptom relief b
Alert and oriented 0 (0)
Drowsy 3 (3.8)
Eyes closed, following directives 4 (5.1)
Eyes closed, responding to physical stimuli 24 (30.4) 
Eyes closed, not responding to physical 
stimuli 46 (58.2)
Disturbed brainstem function 2 (2.5)
Duration of CPS, daysb
1-4 76 (91.6)
5-7 4 (4.8)
8-14 3 (3.6)
>14 0 (0)
Effect of CPSb
Complete symptom relief 74 (92.5)
Partial symptom relief 6 (7.5) 
Hardly any or no symptom relief 0 (0)
Midazolam initial dose, mg/24 hc 28.6 (18.6)d
Midazolam final dose, mg/24 hc 46.1 (60.8)d
a Data were missing for one patient on “Artificial hydration”; 
for three patients on “Effect of CPS”; for four patients on 
“Level of consciousness at adequate symptom relief”; 
for eight patients on “Midazolam initial dose”; 
and for 12 patients on “Midazolam final dose.”
b Data are given as a number (percentage).
c Data are given in mean (standard deviation). 
d Administration routes were subcutaneous, except for one, 
which was intramuscular.
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eyes closed, following directives; eyes closed,
responding to physical stimuli; eyes closed, not
responding to physical stimuli; or disturbed brain-
stem function). Then they were asked to describe
the patient’s intake before the start of CPS (0, 1 to
500, 501 to 1,500, ≥1,501 mL) and to note whether
they had withheld, withdrawn, started, or contin-
ued artiﬁcial hydration and feeding. Finally,
respondents were asked to list a maximum of
three drugs they used for CPS, and to state the
starting and end dose (mg/24 h) and route of
administration. 
Analysis
This study involved a subanalysis of a previously
published study (36), and focused on refractory
existential suffering. For this study, patients with
existential suffering were deﬁned as those for
whom the respondent had ﬁlled in the tick box for
existential suffering and/or loss of dignity as a
refractory symptom. 
A descriptive analysis was performed using
proportions for categorical variables and means
and standard deviations for continuous variables.
Patient age was categorized as: younger than 51,
51 to 80, and 81 years and older. The duration of
CPS was categorized as: 1 to 4, 5 to 7, 8 to 14, and
more than 14 days. To analyze the correlation
between characteristics of patients with existential
suffering and the administration of CPS, gender,
age, dementia, cancer, cardiovascular disease, pul-
monary disease, nervous system disease, other
diagnoses, multiple diagnoses, and previous
requests for euthanasia were analyzed as inde-
pendent variables using Pearson’s chi-squared
test. Using the aforementioned independent vari-
ables, multiple logistic regression models were
constructed to analyze the probability of patients
with existential suffering being sedated. Data are
reported with odds ratios (OR) and 95 percent
confidence intervals (95 percent CI). All p-values
were tested as two-sided, and an alpha value of
.05 was considered to indicate statistical signifi-
cance. Statistical analyses were performed using
the SPSS 20.0 (IBM Corp., 2011). 
RESULTS
A total of 675 physicians returned the question-
naire (a 53.8 percent response rate). We excluded
331 respondents because they had not adminis-
tered CPS in the past year, and 28 because they
were not actively practising. Of the remaining 316
respondents, we excluded 2 because they did not
provide information about the type of refractory
symptoms they had encountered among their
patients. The ﬁnal sample consisted of data
describing the cases of 314 patients receiving CPS.
Of these, 83 patients (26.4 percent) who had
received CPS for existential suffering were identi-
ﬁed. In this group, 1 patient (1.2 percent) receivi g
CPS had existential suffering as a sole refractory
symptom. For 73 patients (88.0 percent), existen-
tial suffering coexisted with one to four other
refractory symptoms; 9 patients (10.8 percent) had
ﬁve to seven other refractory symptoms. Among
those patients who did not report existential suf-
fering (n=231), 54 (23.4 percent) had one refractory
symptom and 177 (76.6 percent) had two to ﬁve
refractory symptoms. 
Characteristics before 
the Administration of CPS
The day before the patients with existential suffer-
ing had commenced CPS, 80.5 percent of them
had received oral intake or artiﬁcial hydration of
500 mL or less. Intermittent sedation was consid-
ered in 40.2 percent of cases. In 4.8 percent of
cases, the atten ing physician consul ed a spiri-
tual counsellor, and in 8.4 percent of cases, a pal-
liative care consultant was called upon. For all
Table 1 / Characteristics before the Administration
of Continuous Palliative Sedation (CPS)
for Patients with Existential Suffering
(n=83)a
Indication
of existential
suffering
Characteristic No. (%)
Intake before the start of CPS, mL
0 11 (13.4)
1-500 55 (67.1)
501-1,500 15 (18.3)
>1,500 1 (1.2)
Intermittent sedation considered
No 49 (59.8)
Yes 33 (40.2)
Informed consent
No 0 (0)
Yes 81 (100)
Consultation with palliative care consultant
No 76 (91.6)
Yes 7 (8.4)
Consultation with spiritual counsellor
No 79 (95.2)
Yes 4 (4.8)
Intention of the physicianb
Symptom relief 80 (96.4)
Life shortening 5 (6.0)
Life expectancy, days
1-4 53 (63.9)
5-7 22 (26.5)
8-14 5 (6.0)
>14 3 (3.6)
a Data were missing for one patient on “Intake before the start 
of CPS” and “Intermittent sedation considered”; for two patients 
on “Informed consent.” 
b More than one intention was possible.
74 Continuous palliative sedation
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Table 3 / Patient Characteristics with and without Existential Suffering as a Reported Indication 
for Continuous Palliative Sedation 
With indication of Without indication of
existential suffering (n=83) existential suffering (n=231)
Characteristica No. (%) No. (%) p-valueb
Age 
<51 years 3 (3.6) 9 (3.9) 0.58
51-80 years 47 (56.6) 114 (50.0)
>80 years 33 (39.8) 105 (46.1)
Gender 
Male 45 (54.2) 87 (38.2) 0.01
Female 38 (45.8) 141 (61.8)
Dementia 
No dementia 71 (86.6) 177 (77.3) 0.07
Dementia 11 (13.4) 52 (22.7)
Cancer
No cancer 54 (65.9) 140 (61.1) 0.45
Cancer 28 (34.1) 89 (38.9)
Cardiovascular disease
No cardiovascular disease 76 (92.7) 203 (88.6) 0.30
Cardiovascular disease 6 (7.3) 26 (11.4)
Pulmonary disease 
No pulmonary disease 77 (93.9) 211 (92.1) 0.60
Pulmonary disease 5 (6.1) 18 (7.9)
Nervous system disease 
No nervous system disease 62 (75.6) 210 (91.7) <0.01
Nervous system disease 20 (24.4) 19 (8.3)
Other diagnosis
No other diagnosis 75 (91.5) 222 (96.9) 0.04
Other diagnosis 7 (8.5) 7 (3.1)
Multiple diagnoses
No multiple diagnoses 77 (93.9) 211 (92.1) 0.60
Multiple diagnoses 5 (6.1) 18 (7.9)
Previous request for euthanasia
No previous request 64 (78.0) 210 (91.3) <0.01
Previous request 18 (22.0) 20 (8.7)
a Data were missing for three patients on “Age,” “Gender,” “Dementia,” “Cancer,” “Cardiovascular disease,” “Pulmonary disease,” 
“Nervous system disease,” “Other diagnosis,” and “multiple diagnoses”; for ”two patients on “Previous request for euthanasia.”  
b Pearson’s chi-squared test; significant p-values are shown in boldface.
Table 4 / A Multiple Logistic Regression: Patient Characteristics Correlated with the Administration 
of Continuous Palliative Sedation for Existential Suffering (n=307)
Determinant Direction (reference) ORa 95% CIb p-valuec
Gender Male (female) 1.91 1.11 – 3.28 0.02
Age <51 years (>80 years) 0.66 0.14 – 3.06 0.59
Age 51-80 years (>80 years) 1.24 0.69 – 2.25 0.48
Dementia Present (cancer) 0.89 0.38 – 2.08 0.79
Cardiovascular disease Present (cancer) 0.82 0.29 – 2.31 0.71
Pulmonary disease Present (cancer) 0.94 0.31 – 2.91 0.92
Nervous system disease Present (cancer) 3.64 1.64 – 8.06 <0.01
Other diagnosis Present (cancer) 4.61 1.34 – 15.81 0.02
Multiple diagnoses Present (cancer) 0.88 0.28 – 2.75 0.83
Previous request Present (not present) 2.93 1.37 – 6.26 0.01for euthanasia
a Odds ratio.
b Confidence interval.
c Significant p-values are shown in boldface.
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DISCUSSION
This study provides insight into the practice of administering CPS to treat existential suffering. In almost all 
of the patients reported on in the study, existential suffering coexisted with refractory physical symptoms, 
and life expectancy was seven days or less. In all cases, informed consent for the administration of CPS 
had been obtained from either the patient or the patient’s legal representative. Intermittent sedation and 
consultation before commencing CPS were less frequently reported. Having a nervous system disease 
or “other diagnosis” was positively correlated with receiving CPS for existential suffering compared 
to having cancer. Moreover, the multivariate analysis showed that being male or having requested 
euthanasia were positively correlated with receiving CPS for existential suffering. 
Some guidelines and recommendations describe specific preconditions for offering CPS for existential 
suffering.1-4,14-16 The results of this study related to the presence of physical symptoms in patients 
with existential suffering, informed consent, and limited life expectancy are generally in line with these 
preconditions. However, the use of intermittent sedation and consultation with a palliative care consultant 
or spiritual counsellor before starting CPS were far less frequently reported than one would expect, given 
the guidelines. Applying intermittent sedation before administering CPS would allow patients a time 
out and give healthcare providers a chance to reassess, possibly preventing a vicious cycle of existential 
suffering.11 Although physicians are generally aware of the importance of recognizing and treating 
existential suffering at the end of life, this is not always included in advance care planning and training 
programs. Routine consultation with experts in the fields of psychology, psychiatry, or spirituality/
religion is therefore recommended in such cases.37 In the Netherlands, the Comprehensive Cancer Centre 
has established a national network of consultation teams specializing in palliative care services. 
Our multivariate analysis showed that some patient characteristics were positively correlated with the 
administration of CPS for existential suffering. In our questionnaire, we didn’t ask the respondents to 
specify the category nervous system disease in terms of precise diagnosis. This category could include 
rapidly progressive diseases of the nervous system, like amyotrophic lateral sclerosis. With such diseases, 
the fear that symptoms experienced today will be worse tomorrow can induce hopelessness and existential 
distress.38 In focusing intently on treating the physical symptoms of the disease, physicians might fail to 
attend to existential suffering. Regarding the questionnaire category “other diagnosis,” the diversity of the 
diagnoses reported by respondents and the limited number of cases involved makes it more difficult to 
identify a clear correlation with the administration of CPS for existential suffering. A possible explanation 
for male gender being positively correlated with initiation of CPS is that psychosocial and spiritual care 
has a more emotional orientation and is thus, perhaps, a less appropriate and effective approach to take 
with male patients.39 The positive correlation of a euthanasia request with the decision to commence 
CPS may suggest that such a request places the patient with existential suffering on a slippery slope 
toward CPS —physicians could be opting to apply CPS even in cases were euthanasia would be more 
appropriate. However, careful interpretation is warranted. We did not ask physicians why a previous 
request for euthanasia was not granted. There could be plausible reasons for denying such a request. 
For example, it might not have been possible to arrange a consultation with an independent physician 
because the patient was dying very quickly; thus, one of the legal criteria allowing for euthanasia could 
not be met. Furthermore, some of our findings — such as the dose of midazolam administered and level 
of consciousness at adequate symptom relief — point to a proportional use of CPS and do not reflect an 
intention on the part of the physician to hasten death. Other findings, however, could indicate the presence 
Existential sufferering
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of an intention to hasten death, as some respondents reported a co-intention of life shortening. Also, no 
artificial hydration was administered for some patients during CPS, despite their intake of more than 500 
mL before the start of CPS. Although suspending artificial nutrition and hydration during administration 
of CPS conforms to the Dutch guideline,1 such patients are likely to die sooner as a result of dehydration, 
and an intention of life shortening could therefore be present. 
LIMITATIONS
Several limitations of this study warrant attention. First, there is no clear, accepted operational definition 
of “existential suffering,” which has given rise to the risk of physicians making inconsistent diagnoses; 
this could have biased the validity of our results. Also, we merged the refractory symptoms of existential 
suffering and loss of dignity, as loss of dignity is mentioned in the literature as part of existential suffering;8 
however, we did not include exhaustion, which, besides being a physical pathogenesis, can also have 
an existential aspect. Second, in almost all patients, refractory existential suffering coexisted with other 
refractory physical symptoms. In this study, we could not determine what impact existential suffering 
had on the decision to administer CPS, whether this suffering was truly refractory, or whether treatment 
of it really could have reduced the need for CPS. However, other research has shown that among patients 
starting CPS, a refractory state can be the result of multiple symptoms.26,29,40-42 In such cases, the 
initiation of CPS tends to arise from a clinical situation in which physical and nonphysical symptoms 
interact to create a refractory state.1,40 Timely interventions could stop this cascade of symptoms and 
prevent a refractory state from developing. Third, although our respondents were representative of the 
gender and age of the total registered nursing home physician population,36 the response rate was 53.8 
percent; nonresponse bias may therefore have influenced our results. Also, a portion of the nursing home 
physicians in the Amsterdam and Rotterdam regions were excluded from participation, and, due to the 
design of the study, recall bias could be present. Fourth, this is an explorative study, which decreases 
model robustness. Finally, since existential suffering can be influenced by cultural factors, the findings of 
this study might not be generalizable to other countries or ethnic groups.  
CONCLUSION AND RECOMMENDATIONS
Although an awareness of and respect for the needs of patients with existential suffering is an essential 
part of medical care, the use of CPS for existential suffering should be approached with caution, and 
such treatment should be offered in compliance with the preconditions laid out in the relevant guidelines 
and recommendations. Preconditions such as consultation with an expert in psychosocial problems and 
meaning-of-life issues, and administration of intermittent sedation before the start of CPS, deserve more 
attention. Furthermore, this study shows that greater attention needs to be paid to the existential suffering 
experienced by patients, especially male patients and those with a nervous system disease. Appropriate 
interventions for these patients could alter the course of their symptoms, and consequently their need for 
CPS. Among patients receiving CPS, refractory existential suffering nearly always occurs in conjunction 
with refractory physical symptoms. Further research is therefore needed to determine how existential 
suffering affects or is affected by other symptoms patients may be experiencing, and prospective research 
should be undertaken to clarify the impact of existential suffering on the decision to administer CPS. Such 
research could also illuminate the reasons behind decisions not to grant requests for euthanasia. Finally, 
we need to develop a consistent definition of existential suffering in the literature, as the lack of consensus 
on such a definition further hinders discussion and research efforts. 
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Chapter 6
Level of discomfort decreases after the administration of continuous palliative 
sedation: a prospective multicenter study in hospices and palliative care units.
van Deijck RH, Hasselaar JG, Verhagen SC, Vissers KC, Koopmans RT.
J Pain Symptom Manage 2016;52(3):361-9 
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Abstract
Context. 
A gold standard or validated tool for monitoring the level of discomfort during continuous palliative sedation 
(CPS)	is	lacking.	Therefore,	little	is	known	about	the	course	of	discomfort	in	sedated	patients,	the	efficacy	of	
CPS, and the determinants of discomfort during CPS.
Objectives. 
To identify the course of discomfort in patients receiving CPS.
Methods. 
A prospective observational multicenter study in nine hospices and palliative care units was performed. The 
Discomfort Scale-Dementia of Alzheimer Type (DS-DAT) was independently assessed for monitoring of 
patient discomfort during CPS. The DS-DAT scores range from 0 (no observed discomfort) to a maximum of 
27 (high level of observed discomfort). Using a mixed model, the mean group score of discomfort between four 
predefined	time	frames	of	CPS	was	compared,	correcting	for	confounding	patient	characteristics.
Results. 
A total of 130 patients were sedated, and the DS-DAT was completed in 106 patients at least once. The median 
duration of the sedation in these 106 patients was 25.5 hours (range 2-161). The mean score of the DS-DAT 
in	the	phase	before	sedation	was	12.16	(95%	CI	9.83-14.50)	and	decreased	significantly	to	8.06	(95%	CI	5.53-
10.58)	in	the	titration	phase	of	sedation.	The	mean	score	of	the	DS-DAT	in	the	final	phase	of	sedation	was	7.42	
(95% CI 4.90-9.94).
Conclusion. 
This study shows that CPS is associated with a decrease in the level of discomfort within an acceptable time 
frame, although in some sedated patients higher levels of discomfort in the last hours of life occurred. Although 
the DS-DAT seems to be of value for monitoring the level of discomfort during CPS, the results of this study 
should be interpreted within the constraints of the limitations, and further research on the psychometric 
properties of this tool is needed before the DSDAT can be used in clinical practice.
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INTRODUCTION
When all options to treat severe burdensome symptoms in terminally ill patients have been exhausted 
or treatments are associated with unacceptable side effects, the use of palliative sedation (PS) can 
be considered.1-4 PS is the intentional lowering of consciousness of a patient in the last phase of life.1 
The objective of PS is to alleviate discomfort caused by refractory symptoms.1-4 The gold standard for 
detecting distress is patient self-report.5 However, patients who are sedated cannot be consulted as 
PS produces an impaired capacity to communicate, which places them at a higher risk of unrelieved 
discomfort.3,4,6 Therefore, we have to rely on subjective assessments of professionals or on observer rating 
scales in sedated patients. Such assessments focus on signs of discomfort rather than signs of comfort, 
and, therefore, a decrease of discomfort can be interpreted as an increase of comfort. 
Although there is no evidence that monitoring PS with observer scales results in better symptom 
control, it seems plausible that the use of an observational assessment instrument helps to ensure that 
the patient becomes comfortable while sedated, prevents unnecessary dose escalation, and improves 
communication between professionals and the patients’ families.7,8 Several authors emphasize the need 
for clinical research on the efficacy in terms of a patient’s comfort and control of refractory symptoms 
during palliative sedation.8-12 However, a review of PS guidelines shows that only five of nine guidelines 
recommend specific assessment methods to monitor palliative sedation, and these are mostly focused on 
the level of consciousness rather than on discomfort.9 One of the scales recommended by the European 
Association for Palliative Care is the Richmond Agitation-Sedation Scale.2 The Richmond Agitation-
Sedation Scale is used to standardize the sedation level in response to sedatives and hypnotics and is a 
numerical scale ranging from +4 to -5 (+4 for combative state and -5 for unarousable state with no response 
to voice or physical stimuli).13 Only a score of -5 on this scale corresponds with absent awareness and 
a state in which a patient shows no signs of discomfort, presuming that the patient does not experience 
suffering. However, palliative sedation should be applied proportionately; that is, for consciousness to 
be lowered to the extent that is necessary and sufficient to relieve symptoms to the degree desired.1,3,4 
Only under exceptional circumstances is immediate titration to an unarousable state with no response to 
voice or physical stimuli required, for example, in case of terminal restlessness or in a catastrophic event 
such as massive bleeding or asphyxia caused by airway obstruction. Therefore, the aim of monitoring the 
level of consciousness with this scale is not to score discomfort but to alert the physician if the sedation 
is too deep. The Critical-Care Pain Observation Tool, another scale recommended by the European 
Association for Palliative Care to help assess pain and distress in patients with a lowered consciousness, 
was developed to monitor a specific symptom instead of discomfort in patients admitted to an intensive 
care unit, and requires the application of physical stimuli.2 Furthermore, according to a systematic review, 
only a minority of patient-based studies on palliative sedation reported the use of observational scales, 
and most of these scales were used to monitor only the depth of sedation and not the quality.8 The few 
scales used in these studies to monitor on a symptom level were based on the evaluation by the attending 
nurse or physician using a Likert or visual analog scale. Therefore, little is known about the course of 
discomfort in sedated patients, the efficacy of PS, and the determinants of discomfort during PS. For 
the latter, such determinants could help physicians identify patients who are at risk of higher levels of 
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discomfort during sedation. In these patients, intensive monitoring and evaluation of the administration 
of continuous palliative sedation (CPS) could help to achieve more comfort in sedated patients, especially 
in the last hours of their lives. To the best of our knowledge, only the prospective study of Morita and 
colleagues reported on this topic and found no significant differences in patient age, sex, performance 
status, icterus, target symptoms for sedation, and sedative medications between the patients with 
adequate and inadequate symptom relief.14 
In the absence of a gold standard or a validated scale, the Discomfort Scale-Dementia of Alzheimer Type 
(DS-DAT) may be a good observer scale for monitoring the level of discomfort in sedated patients. The 
DS-DAT was developed for determining discomfort in patients with advanced dementia of Alzheimer 
type.15 These patients have lost their cognitive capacity and verbal communication ability and are 
dependent on nursing staff to assess and treat their discomfort, which is similar to patients undergoing 
PS. In addition, the face validity of this scale for monitoring discomfort in sedated patients appears to be 
good, as the items of the scale correspond to the current clinical assessment and the recommendations of 
some guidelines of measuring discomfort by facial expressions and body movements.3,16 Moreover, the 
DSDAT focuses on discomfort instead of individual symptoms like other instruments used in research 
on PS, appears to be more objective compared to Likert scales, does not require applying (pain) stimuli, 
and can be carried out by physicians as well as nurses.7,8 The main objective of this study was to identify 
the course of discomfort using the DS-DAT in patients receiving CPS, who were admitted to a hospice 
or nursing home-based palliative care unit (PCU). A secondary goal of this study was to identify patient-
related determinants of discomfort in last hours of life of sedated patients.
Methods
Setting, Patient Population, Data Collection, Follow-Up, and Inclusion Criteria 
This study involved a prospective observational multicenter study performed between March 2011 and 
December 2012 in six hospices and three nursing home PCUs in The Netherlands with a follow-up period 
of three months. Patient admission to these settings was based on an estimated life expectancy of less than 
three months according to the referring physician. In case of a new admission during the study period, the 
attending physician invited the patient or their representative (in cases of a decision-incompetent patient) 
to participate via oral and written communication. The data collection ended when the patient died, was 
discharged, or at the end of the follow-up period. For analysis, inclusion criteria were written informed 
consent and the use of CPS. 
Measures/Assessments 
The attending physician recorded the patient’s diagnosis using a tick box based on the International 
Classification of Diseases and Related Health Problems 10th Edition.17 As soon as an indication for CPS 
occurred according to the attending team, the physician recorded: patient’s intake the day before the start 
of CPS (no intake; only sips of fluid and no food; small amounts of fluid [less than 1 L] and none or minimal 
amount of food; normal fluid intake [more than 1 L] and skips meals; normal fluid and food intake), the 
refractory symptom for CPS (pain, dyspnea, delirium [according to the Diagnostic and Statistical Manual 
of Mental Disorders, fourth edition, revised], vomiting, nausea, anxiety, exhaustion, existential suffering, 
and other [more than one answer possible]), whether they withheld, withdrew, started, or continued 
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artificial hydration, and the date and time of the start and end of CPS.18 After the patient died, the effect 
of CPS on symptom relief according to the physician was recorded (four-point scale: no, hardly, partially, 
completely). 
CPS was defined as ‘‘PS administered until death.’’ This definition excluded situations in which 
medication was administered in normal doses to relieve insomnia and/or anxiety, where sedation was an 
unintended side effect of medication or where PS was only administered temporarily. During a half-day 
training session for the participating physicians, the definitions in the study protocol were explained to 
the physicians, and patient cases were used to clarify the criteria for CPS. Because of the observational 
study design, the protocol did not formulate under what conditions the decision-making process should 
take place, and the attending physician determined the indication for CPS.
To prevent bias, independent monitoring of the level of discomfort was carried out by nurses not involved 
in the daily care of the patient. The independent nurse was informed by the attending team immediately 
when sedation was indicated. The DS-DAT was assessed by the independent nurses just before the start 
of CPS and twice daily thereafter. The DS-DAT is a relatively complex scale, especially scoring of intensity, 
duration, and the number of items.19 Therefore, before the start of the study, all independent nurses (n = 
58) were instructed and practiced how to use the scale during a training session, in which an instructional 
Digital Versatile Disc was shown. They also were instructed not to share information with and receive 
Level of discomfort
all assessments between 15 minutes and eight hours af-
ter the start of CPS were included. The time frame
‘‘final phase of sedation’’ is referring to assessments
performed in the period between eight hours preced-
ing death and the moment of death. The remaining
assessments were included in the ‘‘in between phase.’’
A mixed model was used to analyze the repeated as-
sessments of the DS-DAT and to calculate the mean
group score of the DS-DAT for the different time
frames, with 95% CIs. The group means were
controlled for the following covariates: age; gender;
the diagnosis of malignant neoplasms; chronic lower
respiratory diseases; and symptoms of pain, dyspnea,
delirium, anxiety, exhaustion, and existential distress.
Assessments of DS-DATwere excluded when the ‘‘titra-
tion phase of sedation’’ and the ‘‘final phase of seda-
tion’’ coincided. This overlap in time frames could
occur in case of a short survival after the administra-
tion of CPS.
For analyzing the association between patients’
characteristics and the level of discomfort close to
death, the assessments of the DS-DAT in the ‘‘final
phase of sedation’’ were used. If multiple assessments
per patient were present in this phase, the assessment
closest to the moment of death was used.
Descriptive analysis was performed using propor-
tions for categorical variables and means  standard
deviations for continuous variables. For analyzing the
association between patients’ characteristics, re-
corded by the attending team, and the level of
discomfort as dependent continuous variable, re-
corded by the independent nurse, Student t-test
was used for dichotomous independent variables,
analysis of variance for categorical independent vari-
ables and the Pearson correlation for continuous in-
dependent variables. For analyzing the differences in
the mean scores of the DS-DAT for the different
time frames, a t-test was used. All P-values were
two-sided, and an alpha of 0.05 was considered statis-
tically significant. Statistical analyses were performed
using SPSS version 20.0 (IBM/SPSS, Inc., Armonk,
NY).
Item 
A. Noisy breathing
Negative sounding noise on inspiration or expiration; breathing looks strenuous, labored, or wearing; respirations sound 
loud, harsh, or gasping; difficulty breathing or trying hard at attempting to achieve a good gas exchange; episodic bursts 
or rapid breaths or hyperventilation.
B. Negative vocalization
Noise or speech with a negative or disapproving quality; hushed low sounds such as constant muttering with guttural 
tone; monotone, subdued, or varying pitched noise with a definite unpleasant sound, faster rate than a conversation or 
drawn out as in moan or groan; repeating the same words with a mournful tone; expressing hurt or pain.
C. Content facial expression
Pleasant calm looking face; tranquil, at ease, or serene; relaxed facial expression with a slack unclenched jaw; overall 
look is one of peace.
D. Sad facial expression
Troubled looking face; looking hurt, worried, lost, or lonesome; distressed appearance; sunken, “hang dog” look with 
lackluster eyes; tears; crying.
E. Frightened facial expression
Scared, concerned looking face; looking bothered, fearful, or troubled; alarmed appearance with open eyes and pleading 
face.
F. Frown
Face looks strained; stern or scowling looks; displeased expression with a wrinkled brow and creases in the forehead;
corners of mouth turned down.
G. Relaxed body language
Easy openhanded position; look of being in a restful position and may be cuddled up or stretched out; muscles look of 
normal firmness and joints are without stress; look of idle, lazy of “laid back”; appearance of “just killing the day”; 
casual.
H. Tense body language
Extremities show tension; wringing hands, clenched fist, or knees pulled up tightly; look of being in a strained and 
inflexible position.
I. Fidgeting
Restless impatient motion; acts squirming of jittery; appearance of trying to get away from hurt area; forceful touching, 
tugging, or rubbing of body parts.
Fig. 1. Discomfort ScaleeDementia of Alzheimer Type (DS-DAT) items. Adapted from Hurley AC, Volicer BJ, Hanrahan PA,
Houde S, Volicer L. Assessment of discomfort in advanced Alzheimer patients. Res Nurs Health 1992; 15:369e377.
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information from the clinical staff during the study to prevent contamination. The DS-DAT consists of 
nine four-point items, and the summed scores range from 0 (no observed discomfort) to a maximum of 
27 (high level of observed discomfort). The items are noisy breathing, negative vocalization, sad facial 
expression, frightened facial expression, frown, tense body language, fidgeting, content facial expression, 
and relaxed body language (Fig. 1). Scores are based on frequency, intensity, and duration of the observed 
behavior over five minutes and range from 0 (not observed) to 3 (present in high intensity and for almost 
the entire rating period). To calculate the summed scores, the scores of the two ‘‘positive items’’ (content 
facial expression and relaxed body language) are reversed. Discomfort is defined by the developers of 
the scale as a negative emotional and/or physical state, subject to variation in magnitude in response to 
internal or environmental conditions.15 The validity and reliability of the (Dutch translation of the) DS-
DAT have been shown in several studies in Alzheimer patients, with reliability and validity coefficient 
alpha scores ranging from 0.67 to 0.98.15,20-24 
Ethical Considerations 
The study followed the guidelines for good clinical practice and was conducted after approval of the 
research ethics committee of the Radboud University Medical Centre (ref 2010/407). For patients who did 
not participate in this study, only anonymous demographic data were collected.
Statistical Analysis
All patients with at least one DS-DAT assessment were included in the analysis. We grouped the 
assessments of the DS-DAT into four time frames: ‘‘phase before sedation,’’ ‘‘titration phase of sedation,’’ 
‘‘in between phase,’’ and ‘‘final phase of sedation.’’ For the time frame ‘‘phase before sedation,’’ all 
assessments until 15 minutes after the start of CPS were included. For the time frame ‘‘titration phase of 
sedation,” all assessments between 15 minutes and eight hours after the start of CPS were included. The 
time frame ‘‘final phase of sedation’’ is referring to assessments performed in the period between eight 
hours preceding death and the moment of death. The remaining assessments were included in the ‘‘in 
between phase.’’ 
A mixed model was used to analyze the repeated assessments of the DS-DAT and to calculate the 
mean group score of the DS-DAT for the different time frames, with 95% CIs. The group means were 
controlled for the following covariates: age; gender; the diagnosis of malignant neoplasms; chronic lower 
respiratory diseases; and symptoms of pain, dyspnea, delirium, anxiety, exhaustion, and existential 
distress. Assessments of DS-DAT were excluded when the ‘‘titration phase of sedation’’ and the ‘‘final 
phase of sedation’’ coincided. This overlap in time frames could occur in case of a short survival after the 
administration of CPS. 
For analyzing the association between patients’ characteristics and the level of discomfort close to death, 
the assessments of the DS-DAT in the ‘‘final phase of sedation’’ were used. If multiple assessments per 
patient were present in this phase, the assessment closest to the moment of death was used. 
Descriptive analysis was performed using proportions for categorical variables and means  ± standard 
deviations for continuous variables. For analyzing the association between patients’ characteristics, 
recorded by the attending team, and the level of discomfort as dependent continuous variable, recorded 
by the independent nurse, Student t-test was used for dichotomous independent variables, analysis of 
variance for categorical independent variables and the Pearson correlation for continuous independent 
variables. For analyzing the differences in the mean scores of the DS-DAT for the different time frames, a 
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t-test was used. All P-values were two-sided, and an alpha of 0.05 was considered statistically significant. 
Statistical analyses were performed using SPSS version 20.0 (IBM/SPSS, Inc., Armonk, NY).
Results
During the study period, 503 of 803 admitted patients (62.6%) gave written informed consent. Patients 
with written informed consent did not differ from those without with regard to gender (P = 0.20), age (P = 
0.12), and diagnosis. A total of 467 patients died; 130 of these patients (27.8%) received CPS (Fig. 2). Most 
of the sedated patients were women of advanced age, and the majority of the patients had cancer (Table 1).  
For 106 sedated patients, the DS-DAT was completed at least one time, with a median of three and a 
range of 1-14 assessments per patient, resulting in a total of 352 DS-DAT assessments across all phases. 
The median duration of the sedation was 25.5 hours (range 2-161), with a mean duration of 34.2 hours (SD 
31.4). In 97.1% of cases, the physician withheld artificial hydration during CPS, and in 2.9% of cases, the 
physician continued artificial hydration (data not shown). 
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Results
During the study period, 503 of 803 admitted pa-
tients (62.6%) gave written informed consent. Patients
with written informed consent did not differ from
those without with regard to gender (P ¼ 0.20), age
(P ¼ 0.12), and diagnosis. A total of 467 patients
died; 130 of these patients (27.8%) receive CPS
(Fig. 2). Most of the sedated patients were women of
advanced age, and the majority of the patients had
cancer (Table 1).
For 106 sedated patien s, the DS-DAT was
completed at least one time, with a median of three
and a range of 1e14 assessments per patient, resulting
in a total of 352 DS-DAT assessments across all phases.
The median duration of the sedation was 25.5 hours
(range 2e161), with a mean duration of 34.2 hours
(SD 31.4). In 97.1% of cases, the physician withheld
artificial hydration during CPS, and in 2.9% of cases,
the physician continued artificial hydration (data not
shown).
Mean Score of Discomfort in Different Time Frames
For 16 assessments of the DS-DAT, ‘‘the titration
phase’’ and ‘‘the final phase’’ coincided, resulting in
a sample of 101 patients with a total of 336 DS-DAT
assessments. The adjusted mean score of the DS-
DAT in the phase before sedation was 12.16 (95%
CI 9.83e14.50), and this decreased significantly to
8.06 (95% CI 5.53e10.58) in the titration phase of
sedation and remained relatively stable until the
moment of death (Table 2). A significant reduction
in discomfort compared to the phase before sedation
was found for all three of the following phases of CPS
(P < 0.001).
Written informed consent (n = 503)
Sedated patients (n = 130)
Excluded from analysis (n = 24)
• DS-DAT was not registered 
Excluded from analysis (n = 373)
• Patients were discharged (n = 32) 
• Patients were alive after follow-up 
period (n = 4)
• Patients not sedated (n = 337)
Excluded (n = 300):
• No written informed consent
DS-DAT was registered (n = 106)
Univariate 
analysis was used 
to explore the 
association 
between patients’ 
characteristics 
and the level of 
discomfort in the 
last hours of life
(n = 58)
A mixed model 
was used to 
calculate the 
mean group score 
of the DS-DAT
(n = 101)
Excluded from analysis (n = 5)
• Patients with one measurement of the 
DS-DAT in which the titration phase 
and the final phase coincided
Assessed for eligibility (n = 803)
• patients admitted to six hospices and
three palliative care units
Fig. 2. Flowchart of patients throughout the study. DS-DAT ¼ Discomfort ScaleeDementia of Alzheimer Type.
Vol. - No. - - 2016 5Level of Discomfort After Administration of Continuous Palliative Sedation
88 Continuous palliative sedation
Chapter 6
Mean Score of Discomfort in Different Time Frames 
For 16 assessments of the DS-DAT, ‘‘the titration phase’’ and ‘‘the final phase’’ coincided, resulting in a 
sample of 101 patients with a total of 336 DS-DAT assessments. The adjusted mean score of the DS-DAT 
in the phase before sedation was 12.16 (95% CI 9.83-14.50), and this decreased significantly to 8.06 (95% 
CI 5.53-10.58) in the titration phase of sedation and remained relatively stable until the moment of death 
(Table 2). A significant reduction in discomfort compared to the phase before sedation was found for all 
three of the following phases of CPS (P < 0.001).
Association Between Patients’ Characteristics and the Level of Discomfort Close to Death
A total of 58 patients fulfilled the study criteria for the analysis between patients’ characteristics and the 
level of discomfort in the final phase of sedation (Fig. 2). The median time between the assessment of the 
DS-DAT in the final phase of sedation and the moment of death was 251 minutes (SD 125). The mean 
duration of CPS in these patients was 36.86 hours (SD 30.17), with no significant association between 
duration of CPS and the level of discomfort in the last eight hours of life (P = 0.427, data not shown). 
Gender, age, and the presence of malignant neoplasms were not significantly associated with the level of 
discomfort during sedation in the last eight hours of life (P = 0.911, P = 0.299, P = 0.737, respectively, data 
not shown). Patient intake of a small amount of fluid and none/minimal amount of food or more the day 
before the start of sedation (P = 0.045), the presence of the refractory symptom vomiting (P = 0.014), and 
the presence of multiple refractory symptoms (P = 0.049) were positively associated with a higher mean 
discomfort score during the last eight hours of life (Table 3). 
In cases in which, according to the physician’s opinion, CPS provided complete symptom relief (n = 46), 
the mean score of the DS-DAT was 4.61 (SD 3.41). In cases in which, according to the physician’s opinion, 
CPS provided no to partial symptom relief (n = 11), the mean score of the DS-DAT was significantly 
higher (7.09 [SD 3.56]; P = 0.026, data not shown).
Association Between Patients’ Characteristics and the
Level of Discomfort Close to Death
A total of 58 patients fulfilled the study criteria for
the analysis between patients’ characteristics and the
level of discomfort in the final phase of sedation
(Fig. 2). The median time between the assessment of
the DS-DAT in the final phase of sedation and the
moment of death was 251 minutes (SD 125). The
mean duration of CPS in these patients was
36.86 hours (SD 30.17), with no significant association
between duration of CPS and the level of discomfort
in the last eight hours of life (P ¼ 0.427, data not
shown).
Gender, age, and the presence of malignant neo-
plasms were not significantly associated with the level
of discomfort during sedation in the last eight hours
of life (P ¼ 0.911, P ¼ 0.299, P ¼ 0.737, respectively,
data not shown). Patient intake of a small amount of
fluid and none/minimal amount of food or more
the day before the start of sedation (P ¼ 0.045), the
presence of the refractory symptom vomiting
(P ¼ 0.014), and the presence of multiple refractory
symptoms (P ¼ 0.049) were positively associated with
a higher mean discomfort score during the last eight
hours of life (Table 3).
In cases in which, according to the physician’s
opinion, CPS provided complete symptom relief
(n ¼ 46), the mean score of the DS-DAT was 4.61
(SD 3.41). In cases in which, according to the physi-
cian’s opinion, CPS provided no to partial symptom
relief (n ¼ 11), the mean score of the DS-DAT was
significantly higher (7.09 [SD 3.56]; P ¼ 0.026, data
not shown).
Discussion
To the best of our knowledge, this is the first study
to prospectively investigate the level of discomfort
before and during the administration of CPS
measured independently by the DS-DAT. This study
showed that discomfort significantly decreases within
eight hours after the start of CPS and remains rela-
tively stable until the moment of death. Furthermore,
this study showed that an intake of at least a small
amount of fluid before sedation, the presence of the
refractory symptom vomiting and the presence of mul-
tiple refractory symptoms were positively associated
with a higher mean score of the DS-DAT during the
last eight hours of life.
Results in Relation to Other Studies and Potential
Mechanisms
Although CPS is increasingly considered to be an
ethically and legally acceptable therapy for a select
group of patients,1e4 evidence regarding the efficacy
of this intervention is scarce. This study showed that
the administration of CPS appears to be an effective
intervention for treating refractory symptoms. More-
over, even in the first eight hours after the start of
CPS during which the physician has to titrate the medi-
cation, the level of discomfort decreased significantly
and remained at a median score of lower than eight.
Although there is no cutoff point of theDS-DAT that re-
flects comfort in patients with CPS, a score of eight is
mentioned in the literature as the cutoff point for
high vs. not high discomfort in a population of
confused elderly patients or patients with demen-
tia.21,22 In our opinion, the DS-DAT is potentially a use-
ful scale for measuring comfort during CPS in
combination with the subjective assessment of the
physician and the nurse. Our finding that CPS provided
complete symptom relief according to the physician
was associated with a lower mean score of the indepen-
dently measured DS-DAT seems to support this.
Table 2
Mixed Model: Mean Score of the Discomfort
ScaleeDementia of Alzheimer Type (DS-DAT) in the
Different Time Frames
Phase Mean Score DS-DAT 95% CI
Phase before sedation 12.16 9.83e14.50
Titration phase of sedation 8.06 5.53e10.58
In between phase 7.82 5.48e10.16
Final phase of sedation 7.42 4.90e9.94
The group means were controlled in the mixed model for the following cova-
riates: age; gender; the diagnosis of malignant neoplasms; chronic lower res-
piratory diseases; and symptoms of pain, dyspnea, delirium, anxiety,
exhaustion, and existential distress. Age was evaluated at the following value:
71.70.
In ‘‘the phase before sedation,’’ 79 DS-DAT assessments were performed, 48
DS-DAT assessments were performed in ‘‘the titration phase,’’ 163 DS-DAT as-
sessments were performed in ‘‘the in between phase,’’ and 46 assessments in
‘‘the final phase.’’ For 16 assessments of the DS-DAT, ‘‘the titration phase’’ and
‘‘the final phase’’ coincided.
Table 1
Demographic Characteristics of Sedated Patients
(n ¼ 130)
Characteristic n (%)
Gender
Male 61 (46.9)
Female 69 (53.1)
Agea
<55 yrs 12 (9.2)
55e75 yrs 57 (43.8)
>75 yrs 61 (46.9)
Diagnosisb
Malignant neoplasms 116 (89.2)
Heart failure 12 (9.2)
Dementia 3 (2.3)
Chronic lower respiratory diseases 10 (7.7)
Cerebrovascular diseases 3 (2.3)
Parkinson disease 1 (0.8)
Diabetes mellitus 3 (2.3)
Other diagnoses 12 (9.2)
aMean age of 73.27 (SD 12.51).
bMore than one diagnosis possible.
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Association Between Patients’ Characteristics and the
Level of Discomfort Close to Death
A total of 58 patients fulfilled the study crit ria for
the analysis between patients’ characteristics and the
level of discomfort in the final phase of sedation
(Fig. 2). The media time between the assessment of
the DS-DAT in the final phase of sedation and the
moment of death was 251 minutes (SD 125). The
mean duration of CPS in these patients was
36.86 hours (SD 30.17), with no significant association
between duration of CPS and the level of discomfort
in the last eight hours of life (P ¼ 0.427, data not
shown).
Gender, age, and the presence of malignant neo-
plasms were not significantly associated with the level
of discomfort during sedation in the last eight hours
of life (P ¼ 0.911, P ¼ 0.299, P ¼ 0.737, respectively,
data not shown). Patient intake of a small amount of
fluid and none/minimal amount of food or more
the day before the start of sedation (P ¼ 0.045), the
presence of the refractory symptom vomiting
(P ¼ 0.014), and the presence of multiple refractory
symptoms (P ¼ 0.049) were positively associated with
a higher mean discomfort score during the last eight
hours of life (Table 3).
In cases in which, according to the physician’s
opinion, CPS provided complete symptom relief
(n ¼ 46), the mean score of the DS-DAT was 4.61
(SD 3.41). In cases in which, according to the physi-
cian’s opinion, CPS provided no to partial symptom
relief (n ¼ 11), the mean score of the DS-DAT was
significantly higher (7.09 [SD 3.56]; P ¼ 0.026, data
not shown).
Discussion
To the best of our knowledge, this is the first study
to prospectively investigate the level of discomfort
before and during the administration of CPS
measured independently by the DS-DAT. This study
showed that discomfort significantly decreases within
eight hours after the start of CPS and remains rela-
tively stable until the moment of death. Furthermore,
this study showed that an intake of at least a small
amount of fluid before sedation, the presence of the
refractory symptom vomiting and the presence of mul-
tiple refractory symptoms were positively associated
with a higher mean score of the DS-DAT during the
last eight hours of life.
Results in Relation to Other Studies and Potential
Mechanisms
Although CPS is increasingly considered to be an
ethically and legally acceptable therapy for a select
group of patients,1e4 evidence regarding the efficacy
of this intervention is scarce. This study showed that
the administration of CPS appears to be an effective
intervention for treating refractory symptoms. More-
over, even in the first eight hours after the start of
CPS during which the physician has to titrate the medi-
cation, the level of discomfort decreased significantly
and remained at a median score of lower than eight.
Although there is no cutoff point of theDS-DAT that re-
flects comfort in patients with CPS, a score of eight is
mentioned in the literature as the cutoff point for
high vs. not high discomfort in a population of
confused elderly patients or patients with demen-
tia.21,22 In our opinion, the DS-DAT is potentially a use-
ful scale for measuring comfort during CPS in
combination with the subjective assessment of the
physician and the nurse. Our finding that CPS provided
complete symptom relief according to the physician
was associated with a lower mean score of the indepen-
dently measured DS-DAT seems to support this.
Table 2
Mixed Model: Mean Score of the Discomfort
ScaleeDementia of Alzheimer Type (DS-DAT) in the
Different Time Frames
Phase Mean Score DS-DAT 95% CI
Phase before sedation 12.16 9.83e14.50
Titration phase of sedation 8.06 5.53e10.58
In between phase 7.82 5.48e10.16
Final phase of sedation 7.42 4.90e9.94
The group means were controlled in the mixed model for the following cova-
riates: age; ge der; the diagnosis of malignant neoplasms; c ronic lower res-
piratory diseases; and symptoms of pain, dyspnea, delirium, anxiety,
exhaustion, and existential distress. Age was evaluated at the following value:
71.70.
In ‘‘the phase before sedation,’’ 79 DS-DAT assessments were performed, 48
DS-DAT assessments were performed in ‘‘the titration phase,’’ 163 DS-DAT as-
sessments were performed in ‘‘the in between phase,’’ and 46 assessments in
‘‘the final phase.’’ For 16 assessments of the DS-DAT, ‘‘the titration phase’’ and
‘‘the final phase’’ coincided.
Table 1
Demographic Characteristics of Sedated Patients
(n ¼ 130)
Characteristic n (%)
Gender
Male 61 (46.9)
Female 69 (53.1)
Agea
<55 yrs 12 (9.2)
55 75 yrs 57 (43.8)
>75 yrs 61 (46.9)
Diagnosisb
Malignant neoplasms 116 (89.2)
Heart failure 12 (9.2)
Dementia 3 (2.3)
Chronic lower respiratory diseases 10 (7.7)
Cerebrovascular diseases 3 (2.3)
Parkinson disease 1 (0.8)
Diabetes mellitus 3 (2.3)
Other diagnoses 12 (9.2)
aMean age of 73.27 (SD 12.51).
bMore than one diagnosis possible.
6 Vol. - No. - - 2016van Deijck et al.
89Determinants, practice and outcome
1
2
3
4
5
6
7
Discussion
To the best of our knowledge, this is the first study to prospectively investigate the level of discomfort 
before and during the administration of CPS measured independently by the DS-DAT. This study showed 
that discomfort significantly decreases within eight hours after the start of CPS and remains relatively 
stable until the moment of death. Furthermore, this study showed that an intake of at least a small amount 
of fluid before sedation, the presence of the refractory symptom vomiting and the presence of multiple 
refractory symptoms were positively associated with a higher mean score of the DS-DAT during the last 
eight hours of life. 
Results in Relation to Other Studies and Potential Mechanisms
Although CPS is increasingly considered to be an ethically and legally acceptable therapy for a select 
group of patients,1-4 evidence regarding the efficacy of this intervention is scarce. This study showed 
that the administration of CPS appears to be an effective intervention for treating refractory symptoms. 
Moreover, even in the first eight hours after the start of CPS during which the physician has to titrate the 
medication, the level of discomfort decreased significantly and remained at a median score of lower than 
eight. Although there is no cutoff point of the DS-DAT that reflects comfort in patients with CPS, a score 
of eight is mentioned in the literature as the cutoff point for high vs. not high discomfort in a population 
of confused elderly patients or patients with dementia.21,22 In our opinion, the DS-DAT is potentially 
a useful scale for measuring comfort during CPS in combination with the subjective assessment of the 
physician and the nurse. Our finding that CPS provided complete symptom relief according to the 
physician was associated with a lower mean score of the independently measured DS-DAT seems to 
support this.
Level of discomfort
Regarding the association with a higher mean score of
theDS-DATin the lasthoursof life, thepresenceof ahigh-
er intake before the administration of CPS may result in
additional discomfor , which could be due t an increase
of ascites, peritumor and pulmonary edema, or salivary
and gastrointestinal secretions with more associated
symptoms.4,25 Our findi g that vomiting and multiple
symptomswereassociatedwithhigher levelsofdiscomfort
warrants further explanation. It is possible that vomiting
will not be diminished under sedation and new discom-
fort due to aspiration is induced, both resulting in a high-
er level of discomfort. For multiple symptoms, the
potential mechanism is unclear. Although CPS aims to
alleviate d scomfort, apparently e presence of more re-
fractory symptoms before the start of CPS makes it diffi-
cult to accomplish comfort during sedation. Existing
symptomsmay exacerbate other symptoms or may evolve
intoacascadeof symptoms,eventually leading toagreater
increase of discomfort compared to solitary symptoms.
Strengths and Limitations
The strength of this study is the independent moni-
toringof thecomfortof ahighly vulnerablepatientgroup:
sedated patients. Monitoring of patients was performed
in a carefully designed prospective multicenter study.
Nevertheless, some limitations warrant attention.
The most important limitation of this tudy is t e
use of a tool that is validated for monitoring the level
of discomfort in cognitively impaired (dementia) pa-
tients and not in co inuously s da ed p tients.
Research on measuring discomfort in Alzheimer pa-
tients has found that the DS-DAT has good psychomet-
ric properties. However, its validity and reliability has
not been shown in sedated patients, and we did not
test psychometric properties of the DS-DAT in this
population before this study. Notwithstanding this,
in our opinion, the DS-DAT has a good face validity.
Most items seem valid for determining discomfort in
sedated patients, except perhaps the item ‘‘noisy
breathing.’’ Here, it is possible that the observer
scored this item of the DS-DAT in cases in which a
‘‘death rattle’’ was present, whereas it is doubtful
whether sedated patients actually experience discom-
fort from this symptom.26 S cond, we categ riz d
the assessments of the DS-DAT into different time
frames, with a length of eight hours of the titration
Table 3
Association Between Patients’ Characteristics and Discomfort ScaleeDementia of Alzheimer Type (DS-DAT) Score During
the Final Phase of Sedation
Variable N (%) Mean Score (SD) DS-DAT P-Value
Patient’s intake the day before the start of CPSa
Small amount of fluid and none/minimal amount of food or more 14 (24.1) 6.64 (3.32) 0.045
Only sips of fluid and no food or less 44 (75.9) 4.61 (3.20)
Refractory symptomb
Pain present 24 (41.4) 5.42 (3.11) 0.55
Pain not present 34 (58.6) 4.88 (3.49)
Dyspnea present 20 (34.5) 5.10 (2.72) 1.00
Dyspnea not present 38 (65.5) 5.11 (3.62)
Delirium present 16 (27.6) 6.44 (4.07) 0.11
Delirium not present 42 (72.4) 4.60 (2.88)
Vomiting present 4 (6.9) 9.00 (3.65) 0.014
Vomiting not present 54 (93.1) 4.81 (3.14)
Nausea present 6 (10.3) 4.83 (2.64) 0.84
Nausea not present 52 (89.7) 5.13 (3.41)
Anxiety present 14 (24.1) 6.00 (3.70) 0.25
Anxiety not present 44 (75.9) 4.82 (3.18)
Exhaustion present 33 (56.9) 5.24 (3.43) 0.72
Exhaustion not present 25 (43.1) 4.92 (3.23)
Existential suffering present 14 (24.1) 5.43 (3.59) 0.68
Existential suffering not present 44 (75.9) 5.00 (3.26)
Other symptom present 11 (19.0) 5.55 (4.16) 0.63
Other symptom not present 47 (81.0) 5.00 (3.13)
Number of refractory symptoms
1 15 (25.9) 4.13 (3.14) 0.049c
2 17 (29.3) 4.18 (2.63)
3 14 (24.1) 6.29 (3.75)
4 9 (15.5) 5.44 (2.74)
5 3 (5.2) 8.67 (4.93)
CPS ¼ continuous palliative sedation; ANOVA ¼ analysis of variance.
Values in bold are significant.
In 54 patients, one assessment of the level of comfort was taken by the independent nurse during the last eight hours, and in four patients, there were two
observations.
aCategory ‘‘normal fluid and food intake’’: 0 patients, category ‘‘normal fluid intake and skips meals’’: 1 patient, category ‘‘small amount of fluid and none or
minimal amount of food’’: 13 patients, ‘‘only sips of fluid and no food’’: 35 patients, and category ‘‘no intake’’: 9 patients.
bMore than one indicating symptom for CPS possible.
cANOVA for factors with ordered levels.
Vol. - No. - - 2016 7Level of Discomfort After Administration of Continuous Palliative Sedation
90 Continuous palliative sedation
Chapter 6
Regarding the association with a higher mean score of the DS-DAT in the last hours of life, the presence 
of a higher intake before the administration of CPS may result in additional discomfort, which could be 
due to an increase of ascites, peritumor and pulmonary edema, or salivary and gastrointestinal secretions 
with more associated symptoms.4,25 Our finding that vomiting and multiple symptoms were associated 
with higher levels of discomfort warrants further explanation. It is possible that vomiting will not be 
diminished under sedation and new discomfort due to aspiration is induced, both resulting in a higher 
level of discomfort. For multiple symptoms, the potential mechanism is unclear. Although CPS aims to 
alleviate discomfort, apparently the presence of more refractory symptoms before the start of CPS makes 
it difficult to accomplish comfort during sedation. Existing symptoms may exacerbate other symptoms or 
may evolve into a cascade of symptoms, eventually leading to a greater increase of discomfort compared 
to solitary symptoms. 
Strengths and Limitations
The strength of this study is the independent monitoring of the comfort of a highly vulnerable patient 
group: sedated patients. Monitoring of patients was performed in a carefully designed prospective 
multicenter study. 
Nevertheless, some limitations warrant attention. The most important limitation of this study is the use of a 
tool that is validated for monitoring the level of discomfort in cognitively impaired (dementia) patients and 
not in continuously sedated patients. Research on measuring discomfort in Alzheimer patients has found 
that the DS-DAT has good psychometric properties. However, its validity and reliability has not been shown 
in sedated patients, and we did not test psychometric properties of the DS-DAT in this population before this 
study. Notwithstanding this, in our opinion, the DS-DAT has a good face validity. Most items seem valid for 
determining discomfort in sedated patients, except perhaps the item ‘‘noisy breathing.’’ Here, it is possible 
that the observer scored this item of the DS-DAT in cases in which a ‘‘death rattle’’ was present, whereas 
it is doubtful whether sedated patients actually experience discomfort from this symptom.26 Second, we 
categorized the assessments of the DS-DAT into different time frames, with a length of eight hours of the 
titration and final phases of sedation. Although this length of time is arbitrary, our assumption was that it is 
desirable to achieve comfort for the total duration of the administration of CPS and at least in the last hours of 
life. Focusing on these last hours of life, the attending physician was able to titrate the medication; therefore, 
comfort should have been achieved in most cases. In addition, for the time frame ‘‘phase before sedation,’’ 
all assessments until 15 minutes after the start of CPS were included. This time frame was based on the 
Tmax of midazolam after subcutaneous injection, the drug of choice for inducing CPS,1,27-31 which makes 
assessment of the maximum effect of midazolam only possible after 15 minutes. However, five assessments 
took place 15 minutes after the start of CPS, and we cannot rule out some effects on discomfort by the 
medication used to initiate CPS in these assessments. Third, in the different time frames of CPS, the patient 
population differed, partially due to variation in the duration of CPS in individual patients and partially 
due to an absence of the independent nurse in some cases. For the latter, a time delay between the decision 
for CPS and the arrival of the independent nurse occurred and, therefore, in some cases, the administration 
of CPS occurred before the assessment of the DS-DAT was possible. However, we addressed this limitation 
using a mixed model and correcting for multiple covariates. Fourth, the assessments of the DS-DAT during 
CPS took place only twice a day. We cannot rule out that scores of DS-DAT between the assessments of the 
independent nurse could differ then registered in our study, especially in case of the presence of delirium. 
Finally, this study was performed in hospices and nursing home PCUs in The Netherlands. The findings in 
this study may not be generalizable to other populations, care settings, and countries.
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Conclusion
This study showed that the administration of CPS is associated with a decrease in the level of discomfort 
and appears to be an effective intervention for refractory symptoms in the final days of a patient’s life. 
Furthermore, physicians should be aware that higher levels of discomfort in the last eight hours of life 
could be present in sedated patients who have an intake of a small amount of fluid of more before CPS, 
who have the refractory symptom vomiting and who have multiple refractory symptoms. The DS-DAT, 
an observer-based rating scale, is potentially a useful scale for measuring discomfort during CPS in 
combination with the subjective assessment of the physician and the nurse. However, the results of this 
study should be interpreted within the constraints of the given limitations, and before the DS-DAT can be 
used in clinical practice, further research on the reliability and validity of the DS-DAT is recommended. 
Such research should focus on the (face) validity of this tool, for example, using the Delphi method, and 
on its interrater and intrarater reliability. In addition, to obtain some concurrent validity, comparison 
between simultaneously assessments of the DS-DAT and subjective assessments of physicians and nurses 
should be performed.
Level of discomfort
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Introduction
Palliative sedation involves the deliberate lowering of a patient’s level of consciousness in the last stages 
of life. Palliative sedation can be administered if one or more symptoms (so-called refractory symptoms) 
in a dying patient causes unbearable suffering and conventional modes of treatment are not effective or 
fast-acting enough and/or if these modes of treatment are accompanied by unacceptable side-effects.1-4 
Palliative sedation refers to brief, intermittent or continuous palliative sedation (CPS).1 CPS must be 
considered as a last resort intervention. CPS not only takes away a patient’s suffering until the moment of 
death but also produces an impaired capacity to communicate, which takes away potential positive and 
meaningful experiences a patient might have.4-10 In addition, relatives, nurses and physicians sometimes 
experience the administration of CPS as a burden.11-17
The introduction of the Dutch national guideline on palliative sedation in 2005 gave a comprehensive 
framework for clinical decision-making. Moreover, there has been a remarkable increase in the number 
of empirical studies involving palliative sedation since 2000. However, there are still unanswered 
questions regarding the administration of CPS.1,18 Especially little is known about the determinants of 
the administration of CPS in general, the practice of CPS as performed by elderly care physicians and 
the outcome of this intervention in their patients. The main goal of the research described in this thesis 
was to provide more insight into these specific topics. In this final chapter, the main results of the studies 
presented in this thesis will be summarized. Also the methodological considerations and implications for 
clinical practice, health care policy and future research are provided.
Summary of findings
To answer the research questions formulated in the introduction of this thesis, we performed a systematic 
review of the literature, and designed a structured questionnaire and a prospective observational 
multicenter study. The questionnaire was sent to registered members of the Dutch Association of Elderly 
Care Physicians and Social Geriatricians. The prospective study was performed in six hospices and three 
nursing home-based palliative care units in the Netherlands. A summary of answers found is given below.
Which determinants of the administration of continuous palliative sedation are known in the published literature? 
In our systematic review, nine factors were found to be associated with the administration of CPS  
(chapter 2). Eight factors showed an increased probability for the administration of CPS: patients 
who were younger; patients who were male; patients with a cancer diagnosis; patients with feelings 
of hopelessness; patients dying in a hospital; and patients whose attending physicians were very or 
extremely nonreligious, working in ‘‘other hospital’’ specialties, or in favor of assisted death. The factor 
‘‘patients living in a Dutch-speaking community setting in Belgium’’ showed a decrease in the probability 
of receiving CPS.
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Are age, gender, diagnosis, use of opioids or psycholeptics, number of medications, functional status, symptom 
distress and level of consciousness at the time of admission to a hospice or nursing home-based palliative care unit 
associated with the administration of continuous palliative sedation at the end of life?
The results of our prospective study showed that only the use of opioids at admission was significantly 
independently associated with the administration of CPS (chapter 3). For the use of psycholeptics a 
marginally significant independent association was found. Although we focused on patient-related 
factors, this study showed also that residence was associated with the administration of CPS.
What is the practice of continuous palliative sedation by Dutch elderly care physicians? 
The respondents of our questionnaire described 316 cases of sedated patients (chapter 4). The majority 
of the patients were aged, women and had cancer or dementia. In all but one case, informed consent 
for the administration of CPS was obtained from the patient or the relative who was the patient’s 
legal representative. Eighty-two percent of patients were treated with CPS for two or more refractory 
symptoms, mostly pain, anxiety, exhaustion, dyspnea, delirium, loss of dignity, and existential distress. 
If there was only one refractory symptom, it was usually dyspnea, pain, or exhaustion. In 98% of cases, 
CPS was aimed at symptom relief. Of patients with cancer, 17% had previously requested euthanasia. 
Life expectancy and the duration of CPS were 7 days or less in almost all patients. According to the 
respondents, CPS provided complete symptom relief in 89% of the cases. More than half of the patients 
were unresponsive to physical stimuli at the time adequate symptom relief was attained and must be 
qualified as being under deep and continuous sedation. For 82% of patients, intake was less than 500 mL 
before the start of CPS, and in most cases artificial hydration was withheld during CPS. Midazolam was 
the most frequently used drug to facilitate the start and continuation of CPS. The mean starting dose of 
midazolam was 31 mg every 24 hours (range 0–240 mg/24 h), and the mean end dose was 48 mg every 
24 hours (range 0–480 mg/24 h). Twenty-six percent of all physicians estimated that the use of CPS had 
shortened patients’ life span.
Do	Dutch	elderly	care	physicians	fulfil	the	preconditions	for	administering	continuous	palliative	sedation	in	cases	in	
which	existential	suffering	is	present?
The results of our questionnaire showed that other refractory symptoms were also reported by elderly care 
physicians for most of the patients with refractory existential suffering and that life expectancy was seven 
days or less (chapter 5). Furthermore, informed consent for initiating CPS had been obtained in all cases. 
However, consultation and intermittent sedation before the start of CPS were far less frequently reported 
than one would expect based on the preconditions mentioned in guidelines and recommendations.
What is the course of discomfort in patients admitted to a hospice or nursing home-based palliative care unit receiving 
continuous palliative sedation?
In our prospective study, the Discomfort Scale–Dementia of Alzheimer Type (DS-DAT) was independently 
assessed for monitoring patient discomfort just before and during CPS (chapter 6). The results showed 
that discomfort, measured by the DS-DAT, significantly decreases within 8 hours after the start of CPS 
and remains relatively stable until the moment of death.
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Which characteristics of patients admitted to a hospice or nursing home-based palliative care unit determine  
(dis)comfort during the administration of continuous palliative sedation?
The results of our prospective study showed that the patient’s intake of a small amount of fluid or more 
just before CPS, the presence of vomiting or multiple symptoms were positively associated with a higher 
mean score on the DS-DAT during the last eight hours of life. Gender, age and the presence of malignant 
neoplasms and the refractory symptoms pain, dyspnea, delirium, nausea, anxiety, exhaustion, existential 
suffering and other symptoms were not significantly associated with the level of discomfort close to death 
during sedation (chapter 6).
Methodological considerations
The articles presented in this thesis focused on relatively unexplored topics related to the administration 
of CPS. The strengths of the studies in this thesis were a nationwide retrospective and a multicenter 
prospective design, the use of clear definitions of CPS and refractory symptom, and a large study 
population. Despite these strengths, the presented studies also had some important methodological 
considerations and limitations that should be taken into account when interpreting the results.
This thesis concerns the administration of CPS in general. Most patient-based studies performed over the 
past 15 years have focused on continuous deep sedation, which is a subtype of CPS.12,19-38 Therefore, 
care should be taken when comparing the results of the patient-based studies presented in this thesis with 
the results of previous international studies. In the Netherlands, there are two approaches to the depth 
of continuous sedation among physicians: starting with mild sedation and only increasing the depth if 
necessary, and deep sedation right from the start.39 The approach of deep sedation right from the start 
put the focus on the depth of the sedation instead of the presence or absence of discomfort. By taken 
this approach, waking during CPS is considered to be problematic, even in cases in which the patient is 
comfortable. In such cases, patient relatives could exert pressure on the physician for rapid dose escalation, 
creating more problems if the dose escalation does not have the desired effect. The Dutch national 
guideline and other guidelines on palliative sedation advise physicians to titrate sedatives, which means 
that the dose of sedative is adjusted to the level needed for proper relief of symptoms, and consciousness 
is reduced no more than necessary to adequately relieve suffering.1-3 A result of this recommendation is 
that immediate titration to an unarousable state with no response to voice or physical stimuli is required 
only under exceptional circumstances, e.g., in cases of terminal restlessness or in a catastrophic event 
such as massive bleeding or asphyxia caused by airway obstruction. Furthermore, patient-based research 
shows that deep sedation, i.e., no response to physical stimuli, is not always required.26,40-42 
In the retrospective and prospective study, clear definitions of palliative sedation, CPS and refractory 
symptom were used, and these definitions were in agreement with the Dutch national guideline on 
palliative sedation.1 However, specific items such as existential suffering and exhaustion were not 
properly defined. In the palliative care community, there is still a lack of consensus on a definition of 
existential suffering. Conceptions of existential suffering at the end of life may include (individually or in 
combination): loss of a sense of personal meaning; loss of a sense of life’s purpose; fear of death; feelings 
of despair, anguish, and hopelessness; perception of being a burden to others; sense of betrayal; sense of 
helplessness; and loss of dignity.43 In chapter 5, patients with existential suffering were defined as those 
patients for whom the respondent had filled in the tick box for existential suffering and/or loss of dignity 
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as a refractory symptom. However, we did not include exhaustion. Exhaustion can be caused not only 
by the physical deterioration due to terminal disease but also by the complex social interactions between 
patients and relatives, the struggle with loss of control, as well as by fear of the future.44 The lack of a 
clear definition of existential suffering in the retrospective study has given rise to the risk of physicians 
making inconsistent diagnoses; this inconsistency could have biased the validity of our results. It would 
be worthwhile to develop a consistent definition of existential suffering for the palliative care community 
because the lack of consensus on such a definition further hinders discussion and research efforts.
One of the objectives of this thesis was to observe the course of discomfort in patients receiving CPS. The 
gold standard for detecting distress is patient self-reporting.45 However, most patients who are sedated 
cannot be consulted as CPS produces an impaired capacity to communicate.3,4,7 Therefore, we have to 
rely on subjective assessments by professionals or on observer-based rating scales in sedated patients. 
Currently, there is no validated and generally accepted scale for monitoring discomfort in sedated 
patients. Due to the absence of a gold standard to monitor discomfort (and comfort) in sedated patients, 
validation of such a scale seems to be hard and raises several limitations. These limitations hamper the 
development of a scale that can be used in research and clinical practice. In the prospective study of 
this thesis, discomfort before and during the administration of CPS was assessed using the DS-DAT. In 
our opinion, the DS-DAT may be a good observer-based scale for monitoring the level of discomfort in 
sedated patients. Unfortunately, this scale is not yet validated for sedated patients and we did not perform 
such a study either. Nevertheless,  there are arguments to explain our choice of this scale. The DS-DAT 
was developed for determining discomfort in patients with advanced Alzheimer type dementia,46 and 
several studies in Alzheimer patients have shown that the DS-DAT has good psychometric properties.46-51 
Patients with advanced dementia have lost their cognitive capacity and verbal communication ability and 
are dependent on nursing staff to assess their discomfort, which is similar to patients undergoing CPS. 
Additionally, the face validity of this scale for monitoring discomfort in sedated patients appears to be 
good. The items of the scale correspond to the current clinical assessment and the recommendations of 
some guidelines for measuring discomfort by facial expressions and body movements.3,52 Moreover, the 
DS-DAT focuses on discomfort instead of individual symptoms such as other instruments used in research 
on PS or as recommended by guidelines (e.g., the Critical Care Pain Observation Tool).2 Additionally, the 
DS-DAT appears to be more objective compared with Likert scales, does not require applying (painful) 
stimuli, and can be carried out by physicians as well as nurses.53,54 Furthermore, the DS-DAT includes not 
only items related to discomfort but also items related to comfort (i.e., relaxed body language and content 
facial expression). In addition, the prospective study showed an association between the administration 
of CPS and a decrease in the level of discomfort afterward. Such an association demonstrates at least 
some content validity. Furthermore, the finding that CPS provided complete symptom relief according 
to the physician was associated with a lower mean score on the independently measured DS-DAT close 
to death indicates some concurrent validity, despite the fact that the assessments were not performed 
simultaneously. 
To prevent bias in the observational prospective study, i.e., to prevent changes in clinical management 
based on the outcome of the DS-DAT, independent monitoring of the level of discomfort was carried out 
by nurses not involved in the daily care of the patient. To limit the workload and make scheduling easier, 
these assessments were only scheduled just before the start of CPS and twice daily during the daytime 
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thereafter with fixed time windows. However, this design caused some (methodological) implications. 
First, we acknowledge that this design does not reflect clinical practice, and we cannot rule out that the 
discomfort of a patient in between the assessments by the independent nurse could differ from their 
observed DS-DAT scores, especially in case of the presence of delirium. Second, due to logistic problems 
related to the involvement of independent nurses, in some patients (some of) the assessments could not 
be performed. Third, the fixed time windows of the assessments caused differences in the time interval 
between the start of CPS and the first assessment using the DS-DAT after the start between patients. Due 
to missing data and differences in the time interval between the assessments, we could not compare the 
individual course of discomfort between patients receiving CPS. In order to calculate the mean group score 
of the DS-DAT, we categorized the assessments of the DS-DAT into different timeframes, with a length of 
eight hours for the titration and the final phase of sedation. Although this length of time was arbitrary, our 
assumption was that it is desirable to achieve comfort for the total duration of the administration of CPS 
and specially in the last hours of life. Focusing on these last hours of life, the attending physician was able 
to titrate the medication, and therefore comfort should have been achieved in most cases. In these different 
timeframes of CPS, the patient population differed, partially due to variation in the total duration of CPS 
in individual patients and partially due missing assessments. We addressed this difference using a mixed 
model and correcting for multiple covariates. 
In the prospective study a number of protocol violations of the assessment of the Edmonton Symptom 
Assessment System (ESAS), missing ESAS and missing components of some patients’ ESAS were present. 
All could influenced the power of the study and therefore its validity. Therefore, multivariate models 
with and without multiple imputation were used to control for understating uncertainty. These models 
showed a similar association. In studies in which research is combined with the daily care of patients, 
especially in a population of frail and highly vulnerable patients, protocol violations and missing data 
can be present. All residences were regularly visited during the study period to collect the data and to 
monitor the execution of the research protocol. During these visitations, nurses were asked for the reasons 
regarding the protocol violations and missing data. They often mentioned not only the work load with 
the daily care of patients as a reason but also the fear of burdening the patient, who already might be 
experiencing distress because of the admission and the presence of (non)physical symptoms. We did 
not ask the patients the reasons why they decided whether to take part in the study, but based on the 
information gathered from the physicians and nurses during the visitations, similar reasons were often 
present for patients who did not participate in the study. It seems that patients, although in a critical 
phase in life, are mostly willing to contribute to research. However, physicians and nurses have some 
reservations regarding burdening frail and vulnerable patients, and combining daily care and research is 
sometimes hard.   
The response rate to the questionnaire was 54%, and 63% of the patients participated in the prospective 
study. The respondents to the questionnaire were representative of the total population of registered 
elderly care physicians with respect to sex and age, and the participating patients in the prospective 
study were a representative sample of the total population with respect to sex, age, KPS and diagnosis. 
However, selection and non-responder bias cannot be excluded. 
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Finally, care should be taken when generalizing the results presented in this thesis. The designs of the studies 
in the literature review varied with respect to population, setting, country, and attending physician. The 
results of the retrospective and prospective studies presented in this thesis focused on CPS administered 
by elderly care physicians. The Netherlands is the only country where elderly care physicians exist as an 
independent medical specialty with its own specialist training program.55 Furthermore, the prospective 
study presented in this thesis was performed in hospices and nursing home palliative care units. Some 
of the results presented in this thesis seem to be applicable to the general practice of CPS regardless of 
country, setting or attending physician. However, cultural, legal, and organizational differences may exist 
that could potentially limit extrapolation.
Implications for clinical practice and health care policy
The results of the research described in this thesis give directions that are valuable for the care of patients in 
the palliative care trajectory and for optimizing the administration of CPS. These directions are discussed 
below, and summarized in table 1.
Monitor high-risk patients
Most of the reported determinants of the administration of CPS in this thesis were patient-related, e.g., 
patients who were younger, patients who were male, patients with a cancer diagnosis and patients who 
used opioids. From a clinical perspective, the use of opioids, the use of psycholeptics and patients with 
feelings of hopelessness are the most interesting of the patient-related determinants. These determinants 
can be acted upon early in the clinical palliative care trajectory. Appropriately applied interventions can 
alter the course of symptoms and thereby possibly limiting the patient’s eventual future need for palliative 
sedation. For the use of opioids, it is not clear whether the association is a direct causal relationship due to 
side effects or an indirect relationship due to symptoms of dyspnea and pain. For the use of psycholeptics, 
we assume that this association could be a surrogate of an underlying delirium. The mechanism in patients 
with feelings of hopelessness is unclear; it could be a determining factor of the patient’s endurance, and its 
presence may exacerbate suffering due to other symptoms. Although monitoring patients in the palliative 
care trajectory should be standard, in these high-risk patients extra screening for signs of opioid toxicity, 
the presence and intensity of delirium, pain, dyspnea and feelings of hopelessness should take place 
on a daily or at least weekly basis. Physicians and nurses must be competent in the assessment of the 
aforementioned symptoms, the correct treatment of such symptoms and the treatment of medication side 
effects prior to starting CPS. In the Netherlands, the Netherlands Comprehensive Cancer Organisation 
(IKNL) has established a national network of teams specialized in palliative care services that can be 
consulted to support and advise professional caregivers. Addiotionally, the attending physician can 
consult experts in the field of psychology or spirituality. If, despite such intensive assessments and 
consultations, symptoms evolve to a refractory state, palliative sedation should be considered. 
Inform high-risk patients early in the palliative trajectory and motivate advance care  
planning
Advance care planning and information on the indication and preconditions for CPS early in the palliative 
trajectory are necessary in all high-risk patients, especially if two or more determinants are present. The 
importance of developing advance care plans in the palliative phase has been emphasized; however, 
many patients and their caregivers still do not discuss possible end-of-life scenarios in the final phases of 
life.56 For patients who are sedated, more than half are not or only shortly before the start of CPS become 
involved in decision making.26 In acute situations there is often insufficient time to make well-informed, 
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balanced decisions concerning CPS.12 When patients and their relatives are suddenly confronted with 
discussions regarding CPS, death, loss of consciousness, and saying goodbye, high levels of stress can 
be experienced.15,57,58 Especially in cases of a patient who is not competent to make decisions, relatives 
sometimes feel the burden of responsibility for the decision to use sedation.58 Furthermore, the term 
palliative sedation is not well known among the general public in the Netherlands, and there is a variety 
of interpretations of the term.59 These factors emphasize the importance of clearly informing patients 
and relatives about palliative sedation and of verifying their beliefs about and expectations of palliative 
sedation, because the beliefs and expectations of patient and relatives may differ from professional 
opinions and guidelines.13 The moment at which advance care planning and the sharing of information 
on the indication and the preconditions for CPS in high-risk patients should take place can be debated. 
For high-risk patients admitted to a hospice or a PCU, such discussions could take place shortly after 
admission. Admission to these settings in the Netherlands is based on an estimated life expectancy of less 
than three months. At home or on admission to a hospital, the determination of the prognosis of a high-
risk patient can be more challenging. The general practitioner or medical specialist could use the surprise 
question, i.e., would you be surprised if this patient died within the next three to six months?   
Fulfil the preconditions for CPS for patients with existential suffering
Existential suffering is considered to be a condition that medical practitioners must address.1,60 However, 
there is no general consensus on whether palliative sedation is an appropriate intervention for this type of 
suffering.61 Existential suffering has different aspects from physical suffering. Existential suffering may 
occur long before the terminal phase, often tends to fluctuate, and psychological adaptation and coping are 
common.2,62 Additionally, it can be difficult for practitioners to determine whether a patient’s existential 
suffering is refractory, or to distinguish it from psychiatric conditions such as depression.2,62,63 Although 
interventions for existential suffering are not well established and may not be suitable for all patients,2,62-64 
these findings may cause physicians to administer CPS in cases where other, more conventional therapies 
would be more appropriate. Furthermore, existential suffering such as demoralization and hopelessness 
is linked to terminally ill patients’ desire for death.65,66 Such a desire can result in a request for euthanasia, 
but should not be resolved by the administration of CPS. Despite the lack of a general consensus on 
whether palliative sedation is an appropriate intervention for existential suffering, the results presented in 
this thesis and in other studies show that existential suffering often proves to be a reason for administering 
CPS.22,23,26,41,42,67 In these studies, existential suffering almost always coexists with refractory physical 
symptoms. Physicians suspect that the presence of certain physical symptoms is related to and may 
increase existential suffering and vice versa, accumulating into a ‘refractory state’.64,68,69 In addition, 
several guidelines and recommendations, including the Dutch national guideline on palliative sedation, 
identify existential suffering as a potential refractory symptom that can be treated with CPS under 
specific conditions (see table 1).1-4,70-72 However, the results presented in this thesis show that the use 
of intermittent sedation and consultation with a palliative care consultant or spiritual counsellor before 
starting CPS were far less frequently reported than one would expect given the recommendations of 
the guidelines. These preconditions deserve more attention in clinical practice. Applying intermittent 
sedation before administering CPS would allow patients a time out and give healthcare providers a 
chance to reassess, possibly preventing a vicious cycle of existential suffering.62 Although physicians 
are generally aware of the importance of recognizing and treating existential suffering at the end of life, 
this is not always included in advance care planning and training programs. Routine consultation with 
experts in the fields of psychology, psychiatry, or spirituality and religion is therefore recommended in 
such cases.73 
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Be aware of personal values in end-of-life care decision making
The prospective study on determinants in hospices and palliative care units in this thesis showed 
that residence is associated with the administration of CPS (chapter 3). Another study reported 
substantial clustering of the use of palliative sedation within physician practices.74 In the review 
on determinants in this thesis, the place of death, i.e., the hospital, was found to be associated 
with the administration of CPS (chapter 2). Different standards of care, policies towards end-of-
life interventions and complexity of clinical conditions in patients compared to other settings are 
mentioned as possible underlying factors for the umbrella term residence. 
However, physician-related factors could also contribute to this type of clustering. The review showed 
that there was an increased probability of the administration of CPS in patients whose attending 
physicians were very or extremely nonreligious or were in favor of assisted death. Furthermore, 
the ‘how’ of determining the intolerability of suffering and refractoriness by physicians is not 
established in guidelines.75 This omission can result in subjectivity in determining the refractoriness 
of symptoms and therefore to variation in the frequency of CPS.2 Although this thesis could not 
identify the specific underlying factors of the umbrella term residence, physician and nursing staff 
should be aware that their own values may enter into the end-of-life care decision making.76
Inform patients and relatives of the effectiveness of CPS before starting and monitor  
patients during CPS
The results presented in this thesis showed that the administration of CPS is associated with a decrease 
in the level of discomfort within an acceptable timeframe. However, physicians and nurses should 
also be aware that higher levels of discomfort in the last eight hours of life could be present in some 
sedated patients. Therefore, physicians should not only communicate with patients and their relatives 
that CPS is in general a fast-acting and effective intervention, but also that CPS is not a one-size-fits-all 
intervention and that monitoring of patients’ discomfort during sedation is essential. Currently, there 
is no validated and generally accepted scale for monitoring discomfort in sedated patients. Despite this 
absence, it is important to communicate prior to the start of CPS which signs of discomfort are looked 
for during sedation. Adequate communication regarding the roles and responsibilities of physicians, 
nurses and relatives during CPS is an essential part of that process.77,78 Consequently, all actors are 
aware when drug dosage adjustments should be made. By explicitly communicating beforehand 
which signs of discomfort are monitored and when drug dosage adjustments are required, the fear of 
family members for possible suffering of their sedated beloved one will decrease.12,15 For example, 
clear instructions on the clinical symptoms of Cheyne-Stokes respiration, death rattle and cyanosis can 
prevent different interpretations and increase the common sense of dying.79 Adequate communication 
before the start of CPS on signs of discomfort and drug dosage adjustments may also prevent family 
members from becoming impatient or even considering it unacceptable for the dying process to take 
so long, in turn putting pressure on the doctor to speed up the dying process.79 In clinical practice, 
the individual items of the DS-DAT, e.g., facial expression, body language, fidgeting and negative 
vocalization, can be used as parameters for measuring discomfort in sedated patients. 
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Discuss the administration of artificial hydration during CPS 
Palliative sedation, when appropriately indicated and correctly used, does not seem to have any 
detrimental effect on patient survival.5,80 However, one in four physicians estimated that CPS has 
shortened patients’ life span (chapter 4). An explanation for this finding could be that physicians 
commonly have difficulty in estimating life expectancy and are often inclined to overestimate it.81,82 
Another explanation could be that there is actually a life-shortening effect of CPS. In our retrospective 
study 18% of patients had an intake of more than 500 mL the day before CPS started, and artificial 
hydration was continued or started in only 2.3% of the patients. In these patients, CPS without 
artificial hydration can have a life-shortening effect. It could be argued that artificial hydration is 
medically futile, hampers the natural dying process, and may result in additional suffering. The 
Dutch national guideline on palliative sedation also does not recommend artificial hydration during 
sedation in general, however, in patients who have considerable oral intake before the start of 
continuous sedation, physicians should explicitly discuss the issue of artificial hydration before the 
start of continuous sedation, or physicians should offer intermittent sedation.1 When communicating 
with these patients one should discuss whether the application of artificial hydration during 
palliative sedation will improve the comfort of the sedated patient or not, and whether a possible 
life-shortening effect of CPS is acceptable if artificial hydration is not given.
Complement the Dutch national guideline on palliative sedation
The Dutch national guideline on palliative sedation recommends timely open communication 
between physicians and their patients about the realistic intentions, possibilities and limitations at 
the end of life.1 However, in this guideline more attention should be given to the timely identification, 
communication and monitoring of patients at high-risk for CPS. 
Furthermore, the Dutch national guideline emphasizes that agreements must be made regarding 
the observation points and times during CPS and about the factors that may lead to a review of 
the medication, but the guideline fails to describe how these efforts should be carried out.1 The 
Dutch national guideline should be more explicit on which signs of discomfort during CPS must be 
looked for, including the individual items of the DS-DAT. Improving the recommendations should 
induce better symptom control and more stable unambiguous application of palliative sedation.77 
Additionally, the Dutch national guideline should include intermittent sedation as a precondition 
for the use of CPS for treating refractory existential suffering. This type of sedation is less far-
reaching than the administration of CPS, and its use may prevent the eventual need for CPS for this 
type of suffering.
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Table 1. Directions for clinical practice and health care policy
Monitor high-risk patients
In patients who use opioids or psycholeptics and in patients with feelings of hopelessness, extra screening for signs of 
opioid toxicity, the presence and intensity of delirium, pain, dyspnea and feelings of hopelessness should take place.
Inform high-risk patientsa early in the palliative trajectory and motivate advance care planning
Inform high-risk patients about the indication and preconditions for CPS early in the palliative trajectory: communicate 
that	CPS	is	a	last	resort	intervention	for	refractory	suffering,	that	the	life	expectancy	of	a	patient	may	not	exceed	2	
weeks at the moment CPS is started and that CPS has to be distinguished from euthanasia. Enhance the patient’s 
autonomy by establishing an end-of-life care plan that will meet the patient’s goals, values, needs, and preference. 
Fulfil the preconditions for CPS for patients with existential suffering
Before	CPS	is	administered	in	patients	with	existential	suffering,	the	following	preconditions	should	be	fulfilled:	(1)	
an expert in psychosocial problems and meaning-of-life issues has been consulted; (2) intermittent sedation is initiated 
before CPS is attempted; (3) the patient has a life expectancy of a maximum of one to two weeks; (4) informed consent 
has	been	obtained;	and	(5)	existential	suffering	is	not	the	patient’s	sole	refractory	symptom.	
Be aware of personal values in end-of-life care decision making
Physicians should be aware that there can be subjectivity in determining the refractoriness of symptoms and that their 
own values may enter into the decision making for CPS.
Inform patients and relatives of the effectiveness of CPS before starting and monitor patients 
during CPS
Communicate	with	patients	and	their	relatives	that	CPS	is	in	general	a	fast-acting	and	effective	intervention	but	
also	that	CPS	is	not	a	one-size-fits-all	intervention.	Therefore,	monitoring	of	patient’s	discomfort	during	sedation	is	
essential. Communicate prior to the start of CPS regarding which signs of discomfort are looked for during sedation, 
the	individual	items	of	the	DS-DAT	(e.g.,	facial	expression,	body	language,	fidgeting	and	negative	vocalization)	can	
be used as parameters. 
Discuss the administration of artificial hydration during CPS 
In patients with a considerable intake before the start of CPS, the physician should discuss whether the administration 
of	artificial	hydration	during	palliative	sedation	will	improve	the	comfort	of	the	sedated	patient	or	not,	and	whether	a	
possible	life-shortening	effect	of	CPS	will	be	accepted	if	artificial	hydration	is	not	given.
Complement the Dutch national guideline on palliative sedation
The	 guideline	 should	 give	 more	 attention	 to	 the	 timely	 identification,	 communication	 with	 and	monitoring	 of	
patients at high-risk for CPS and should be more explicit on which signs of discomfort during CPS must be looked 
for. Additionally, the guideline should include intermittent sedation as a precondition for the use of CPS for treating 
refractory	existential	suffering.
 a High-risk patients are patients at younger ages, male patients, patients with a cancer diagnosis, patients with feelings 
of hopelessness, patients dying in a hospital, patients living in a French-speaking community setting in Belgium, patients 
who use opioids, and patients who use psycholeptics.
CPS = continuous palliative sedation; DS-DAT = Discomfort Scale–Dementia of Alzheimer Type
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Implications for further research
Although the studies described in this thesis provide important insight into the determinants, practice 
and outcome of the administration of CPS, there are still several aspects that deserve more attention in 
future research. These themes are discussed below.
Determinants of CPS
This thesis revealed some patient-related determinants of CPS (chapters 2 and 3). However, the research 
in this thesis reported only individual factors, and these factors did not cover all domains of palliative care 
extensively. It is plausible that clinical practice is more complex and that multiple physical, psychosocial 
and spiritual problems are present and interact. Additionally, this thesis showed that the mechanisms 
of these determinants are unclear and that other determinants could be present. Therefore, future 
prospective multicenter research should be performed to confirm the determinants of CPS reported in 
this thesis, using clearly outlined and similar definitions of CPS within multivariate models. To determine 
if the use of opioids and psycholeptics are truly independent determinants or that other underlying 
factors are present, the symptoms pain, dyspnea and delirium should be included in the multivariate 
model. Moreover, such a multivariate model should include not only individual factors but also clusters, 
e.g., the symptoms pain and exhaustion. Additionally, to control for clustering of patients and to exclude 
confounding of characteristics of residence or health care providers, the residence should be included in the 
multivariate model. Besides, it is preferably to perform such research in different settings and countries, as 
“country” has also been found to be an important factor in predicting the probability of receiving sedation, 
suggesting that cultural, social, legal, and organizational factors probably play a role.78 Furthermore, 
besides assessments at admission, assessments should also be performed during the whole admission 
at regular time intervals to determine whether the associations are time-sensitive. Finally, to determine if 
monitoring and appropriately applied interventions actually can alter the course of symptoms in high-
risk patients and the patients’ eventual need for palliative sedation, an interventional study should be 
performed in patients with clinically relevant determinants. Such research could also determine whether 
informing patients at high risk and their relatives about the indication and preconditions for CPS early 
in the palliative trajectory results in more effective communication at the moment refractory symptoms 
occur, and reduces concerns of relatives before and during the administration of CPS.  
Observer-based scale to monitor discomfort during
The DS-DAT has the potential to be a useful scale for measuring comfort during CPS. However, before 
the DS-DAT can be used in clinical practice, further research on the psychometric properties of the DS-
DAT is recommended. Such research should focus on the face validity of this tool, e.g., using the Delphi 
method. This effort should preferably be undertaken by a panel of experts from an internationally 
accepted organization, e.g., the European Association for Palliative Care. Only then is the widespread 
adoption by the palliative care community and implementation of a scale to monitor discomfort during 
the administration of CPS in clinical practice possible. Such a panel should discuss whether all the items 
of the DS-DAT are valid for measuring discomfort in sedated patients. For example, it is possible that 
an observer scores the item ‘noisy breathing’ in cases in which a ‘death rattle’ is present, whereas it is 
doubtful whether sedated patients actually experience discomfort from this symptom.83 Additionally, the 
DS-DAT includes positive items (content facial expression and relaxed body language). The aim of CPS 
is providing comfort; therefore it seems reasonable to include these positive items. However, the question 
arises whether this inclusion corresponds with clinical practice. Do physicians and nursed focus on signs 
of discomfort rather than signs of comfort, and therefore can a decrease of discomfort be interpreted as an 
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increase of comfort? Furthermore, the DS-DAT records the frequency, intensity, and duration of each of the 
behavioral characteristics. As a result of this measurement a more specific score of the level of discomfort 
is possible. However, the question arises whether a score of three on one item is equal to a score of one 
on three items. Finally, such a panel should discuss whether some items of the DS-DAT deserve more 
weight or not in determining discomfort during the administration of CPS. Future research should also 
focus on the inter- and intrarater reliability of the DS-DAT in a population of sedated patients. Moreover, 
to obtain some concurrent validity, comparison between simultaneously assessments using the DS-DAT 
and subjective assessments by physicians and nurses should be performed. Additionally, establishing a 
cut-off point for the DS-DAT that reflects comfort in patients with CPS could be helpful to determine if 
CPS provides sufficient relief of discomfort. Although there is no cut-off point for the DS-DAT that reflects 
comfort in patients with CPS, a score of eight is mentioned as the cut-off point for high versus not high 
discomfort in a population of confused elderly patients or patients with dementia.48,49 Future research 
should determine if a cut-off point can be established, although the interpretation of a (particular) score on 
an observational scale should not be separated from the subjective assessment of the health care provider.  
A score above a cut-off point could indicate that sedative dose escalation to alleviate discomfort is necessary. 
However, a score below a cut-off point may not always indicate that the patient is comfortable. Therefore, 
a clinical assessment by the physician or nurse should also always be performed. Finally, although it seems 
plausible that the use of an observational assessment instrument helps to ensure that the patient becomes 
comfortable while sedated, prevents unnecessary dose escalation and improves communication between 
health care providers and between professionals and the patients’ families,53,54 future research should 
also evaluate the impact of the use of the (revised) DS-DAT on these items. Some authors question the 
accuracy of observational scales in palliative patients because the ability to react with facial expressions or 
body movements may be diminished in the end-of-life stage.84 What if unresponsiveness is not equal to 
unawareness?45 Some authors therefore urgently recommend more research on the measurement of the 
level of awareness of patients who are continuously sedated until death by using electroencephalography 
derivates such as bispectral index (BIS), or on correlating BIS values with the clinical assessment of a 
physician.7 However, besides the fact that BIS is an invasive technique, a recent publication shows that 
the wide range of BIS values in deeply sedated and comfortable patients seems to hamper the use of BIS 
in daily clinical practice.84 Therefore, we have to rely on clinical assessments by physicians, nurses as well 
as relatives, in combination with observer-based scales such as the DS-DAT. Although the fact that the key 
notion ‘sedated patients do not suffer’ is never completely without doubt,79 it does not mean that sedated 
terminal patients do suffer. With the lack of evidence about the capacity of sedated patients to suffer, we 
have to assume that a sedated patient who looks comfortable and is no longer conscious does not suffer. 
In the future, if the DS-DAT shows good psychometric properties and the palliative care community 
adopts the (revised version of the) DS-DAT as a scale for measuring comfort during CPS, attention should 
also be paid to the implementation of this scale. First, the DS-DAT is a relatively complex scale, especially 
the scoring of the intensity, duration, and the number of items,85 therefore, training and regular use of this 
scale are required. Second, recommendations regarding which discipline should perform the assessment 
should be made. Although many disciplines may be involved in the administration of CPS, nurses often 
play a critical role in the observations and in the communication with relatives during CPS, and they seem 
to be the most suitable assessor. Third, these recommendations should also include what adequate time 
intervals for monitoring are, e.g., at least twice a day with closer intervals of 30 to 60 minutes during the 
initiation of CPS until adequate comfort is achieved.
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Determinants of discomfort during CPS
The results presented in this thesis showed that an intake of at least a small amount of fluid before 
sedation, the presence of the refractory symptom vomiting and the presence of multiple refractory 
symptoms were positively associated with a higher mean score on the DS-DAT during the last eight 
hours of life. Other characteristics, e.g., duration of CPS, gender, age, pain, dyspnea and delirium were 
not significantly associated. These results are in line with the findings of a previous prospective study.30 
However, a previous retrospective study reported contrasting findings regarding intake, duration and 
the presence of the refractory symptom vomiting.86 Therefore, the results presented in this thesis must 
be viewed as a first step in the identification of patients at risk for discomfort during CPS and could be 
supportive for future research. 
Euthanasia
The research presented in this thesis showed that close to one in five sedated patients with cancer 
had made a previous request of euthanasia (chapter 4). Additionally, having a previous request for 
euthanasia is significantly associated with the administration of CPS for existential suffering (chapter 5). 
These findings might indicate that CPS is used in these cases as an alternative to euthanasia. It has been 
suggested that physicians sometimes are vague towards patients regarding the possibility of euthanasia 
early in the palliative trajectory, telling patients later in the final phase of life that it is too late to initiate 
the procedures for euthanasia and then opting for CPS.87 Research also shows that some physicians 
choose CPS above euthanasia because ‘the best part is that you do not have to have anything arranged 
and it’s just always possible.’88 However, careful interpretation of the findings presented in this thesis is 
warranted. We did not ask physicians why a previous request for euthanasia was not granted. Plausible 
reasons for denying such a request could be present.21,69,89,90 There could be a lack of time to complete 
the euthanasia process: the patient could have postponed the formal euthanasia request until it was too 
late or the dying process could have been short. Additionally, the patient could have lost mental capacity 
during the formal euthanasia process. Moreover, requests for euthanasia are often made in advance.91 
Such a request early in the palliative trajectory could be made to keep in control, but could disappear at 
the end of life. Future research should illuminate the reasons behind decisions not to grant requests for 
euthanasia and to administer CPS instead. 
Existential suffering
Elderly care physicians often mention existential suffering and loss of dignity as an indication for CPS 
(chapter 4). However, the refractoriness of this type of suffering was not determined by investigating the 
etiology of each type of suffering, what types of treatment had been attempted, and how symptoms were 
recognized (especially in patients with dementia). Furthermore, in almost all cases refractory existential 
suffering occurs in conjunction with refractory physical symptoms. We did not determine what impact 
each of the symptoms had on the decision to administer CPS. It is possible that nonphysical symptoms 
may have exacerbated physical symptoms and could have compromised the patient’s endurance, 
without being the decisive refractory symptom. Further research is therefore needed on when, how, and 
by whom existential suffering at the end of life should be best treated. Research should also determine 
how existential suffering affects or is affected by other symptoms patients may be experiencing, and to 
clarify the impact of existential suffering on the decision to administer CPS.64
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Medication scheme of the national guideline for palliative sedation
The dose range and the mean dose of midazolam (chapter 4) was consistent with the recommendations of 
the Dutch national guideline.1 However, little is known about the pharmacokinetics of midazolam in a frail, 
elderly population, and the recommendations of the guideline are based on level three or four evidence, 
i.e., expert opinion and non-comparative studies. Furthermore, recently some comments on the revised 
medication table of the national guideline have been made.92,93 Therefore, further research is needed 
to establish the optimal medication scheme for CPS and to support the medication recommendations 
of the RDMA guideline. Such research should focus on which drugs are stopped at the start of CPS and 
which drugs are started, which doses are used and at what time intervals dose and drugs adjustments are 
required during CPS.  
Conclusions
This thesis showed that CPS decreases the level of discomfort within an acceptable timeframe and appears 
to be an effective intervention for refractory symptoms in the final days of a patient’s life. However, the 
administration of CPS should be considered as a palliative intervention of last resort. Additionally, CPS 
is not a one-size-fits-all intervention because some sedated patients still experienced higher levels of 
discomfort in the last hours of life. 
Therefore, both in clinical practice as well as in the national guideline on palliative sedation, more 
awareness for monitoring for signs of opioid toxicity, the presence and intensity of delirium, pain, dyspnea 
and feelings of hopelessness should be present in patients in the palliative trajectory. Adequate palliative 
care with careful assessment of potential reversible factors and non-sedating interventions should be the 
cornerstone of treatment before starting palliative sedation. Effective interventions in these patients could 
possibly prevent a refractory state for such symptoms, thereby possibly limiting the future need for CPS. 
Moreover, advance care planning and information on the indication and the preconditions of CPS early 
in the palliative trajectory are advisable in high-risk patients. This approach may prevent unforeseen 
situations and difficulties in communication at the bedside when problems arise. 
Furthermore, more attention should be paid to the suggested preconditions for administering CPS in cases 
in which existential suffering becomes an indication for CPS, especially the use of intermittent sedation 
and consultation with a palliative care consultant or spiritual counsellor. Additionally, in patients who 
have considerable oral intake before the start of continuous sedation, physicians should at least explicitly 
discuss the issue of artificial hydration and the possible concomitant life-shortening effect of CPS, or 
preferably should offer intermittent sedation. 
Finally, if an indication arises for the administration of CPS, it is important to communicate prior to the 
start of CPS which signs of discomfort are looked for during sedation. Currently, there is no validated 
and generally accepted scale for monitoring discomfort in sedated patients. Although further research on 
the psychometric properties of the DS-DAT is needed before this tool can be used in clinical practice, the 
individual items of this scale, e.g., facial expression, body language, fidgeting and negative vocalization, 
can already be used as parameters in clinical practice.
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Palliative sedation is defined as “the deliberate lowering of a patient’s level of consciousness in the 
last stages of life.” The objective of palliative sedation is to alleviate the patient’s discomfort caused by 
symptoms that do not respond (fast enough) to conventional modes of treatment and/or if these modes 
of treatment are accompanied by unacceptable side-effects, so-called refractory symptoms. The term 
“palliative sedation’’ encompasses two distinct types of intervention: brief or intermittent sedation and 
continuous sedation administered until death (CPS). 
Although CPS is increasingly accepted as part of medical practice, it is also considered as a last resort 
intervention. CPS not only takes away a patient’s suffering but also produces an impaired capacity to 
communicate, which takes away any potential positive and meaningful experiences a patient might have. 
In the last two decades, more and more attention has been paid to this intervention in the literature, and in 
2005, the Royal Dutch Medical Association (RDMA) described the conditions in which palliative sedation 
is good medical practice in a national guideline. Although the RDMA guideline gave a comprehensive 
framework for clinical decision-making and the administration of CPS, and literature provided more 
insight, it could not solve all the problems or answer all the questions regarding the increasing admi-
nistration of CPS. First, little is known about the early identification of patients at high risk for CPS. The 
identification of these determinants could improve advance care planning and quality of life for high-risk 
patients in a terminal phase. Second, little insight has been achieved into the practice of CPS by elderly care 
physicians in general and into the administration of CPS for existential suffering in particular. More insight 
is essential to contribute to the further development of guidelines and clinical practice. Finally, although 
the RDMA guideline states that monitoring of (continuous) palliative sedation is essential, the “how” of 
monitoring of the level of suffering during (continuous) palliative sedation is currently an open question. 
Accordingly, little is known about the efficacy of CPS and determinants of inadequate symptom relief 
during CPS. Therefore, the aim of this thesis was to provide more insight into these topics (chapter 1).
In chapter 2, we provide a systematic review of PubMed, EMBASE, and CINAHL on determinants 
of CPS. In total, eight papers fulfilled the inclusion criteria. The following nine factors were found to be 
associated with the administration of CPS: younger age, male sex, having cancer, feelings of hopelessness, 
dying in a hospital, living in a Dutch speaking community setting in Belgium, very nonreligious or 
extremely nonreligious physicians, physicians working in “other hospital’’ specialties, and physicians in 
favor of assisted death. Given the variation in study designs and the limitations of the included studies, 
the outcomes should be interpreted carefully. This review highlighted the need for further research, 
particularly regarding factors that can be influenced and that may alter the course of a patient’s symptoms 
and the patient’s eventual need for palliative sedation.
A prospective multicenter observational study was performed in six Dutch hospices and three nursing 
home-based palliative care units to explore which patient-related factors at admission are associated with 
receiving CPS later in the terminal phase of life (chapter 3). The following variables were analyzed: age, 
gender, diagnosis, use of opioids or psycholeptics, number of medications, Karnofsky performance status 
scale score, Edmonton symptom distress score and Glasgow coma scale score. Our findings showed that 
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only the use of opioids at admission was independently associated with the administration of CPS. In this 
group of high-risk patients, a comprehensive personalized care plan starting at admission is mandatory. 
This chapter shows that further research to identify other determinants of the administration of CPS and 
to investigate which early interventions will be effective to prevent the need for CPS in patients at high 
risk is needed.
In chapter 4, we investigated the practice of CPS by Dutch elderly care physicians. One thousand two 
hundred fifty-four registered members of the Dutch Association of Elderly Care Physicians and Social 
Geriatricians received a structured questionnaire concerning their last case of CPS. A total of 675 physicians 
responded (response rate 54%), and 316 patients were described. The majority of these patients had cancer 
or dementia. In almost all cases, symptom relief was the aim, and in close to one in five patients with 
cancer, a previous request for euthanasia had been reported. In addition to physical symptoms, anxiety, 
exhaustion, loss of dignity, and existential distress were often mentioned as refractory symptoms in the 
decision to start CPS by elderly care physicians. The dosage range of midazolam, the most frequently 
used drug in this study, fits the recommendations of the Dutch national guideline on palliative sedation. 
This chapter shows a need for prospective research about the acceptability and assessment of nonphysical 
symptoms as indications for CPS and about the reasons not to grant a preceding euthanasia request.
Some guidelines and recommendations identify existential suffering as a potential refractory symptom for 
which CPS can be administered under certain conditions. To provide insight into this specific indication 
for CPS, a subanalysis of the results of the questionnaire was performed (chapter 5). Existential suffering 
was a refractory symptom in 83 of the patients. For most of the patients with refractory existential 
suffering, other refractory symptoms were also reported, and the life expectancy was seven days or 
less; informed consent for initiating CPS had been obtained in all cases. Consultation and intermittent 
sedation before the start of CPS were far less frequently reported than one would expect based on the  
preconditions mentioned in guidelines and recommendations. Multivariate analysis showed that being 
male, having previously requested euthanasia, having a nervous system disease, or having an “other 
diagnosis” were positively correlated with the administration of CPS for existential suffering. We conclude 
that more attention should be paid to the suggested preconditions and to the presence of existential 
suffering in male patients or patients with a nervous system disease.
In chapter 6, we present a prospective observational multicenter study in nine hospices and palliative care 
units, to observe the course of discomfort in sedated patients and to identify determinants of discomfort  
during CPS. For monitoring of patient discomfort before and during CPS, the Discomfort Scale–Dementia of  
Alzheimer Type (DS-DAT) was independently assessed, and we compared the mean group score of 
discomfort between four predefined timeframes of CPS. A total of 130 patients were sedated, and the 
DS-DAT was completed in 106 patients at least once. This study showed that discomfort significantly 
decreased within 8 hours after the start of CPS and remained relatively stable until the moment of death. 
The patient’s intake of a small amount of fluid or more before CPS, the presence of vomiting or multiple 
symptoms were positively associated with a higher mean score of the DS-DAT during the last eight 
hours of life. This study shows that CPS is associated with a decrease in the level of discomfort within an  
acceptable timeframe, although in some sedated patients higher levels of discomfort in the last hours of life  
occurred. Although the DS-DAT seems to be of value for monitoring the level of discomfort during CPS, 
the results of this study should be interpreted within the constraints of the limitations, and further research 
on the psychometric properties of this tool is needed before the DS-DAT can be used in clinical practice. 
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The main findings of this thesis as well as the methodological considerations and implications for clinical 
practice and future research are discussed in chapter 7. This thesis showed that CPS decreases the level 
of discomfort within an acceptable timeframe and appears to be an effective intervention for refractory 
symptoms in the final days of a patient’s life. However, the administration of CPS should be considered 
as a palliative intervention of last resort. Additionally, CPS is not a one-size-fits-all intervention because 
some sedated patients still experienced higher levels of discomfort in the last hours of life. Therefore, 
both in clinical practice as well as in the national guideline on palliative sedation, more awareness 
for monitoring for signs of opioid toxicity, the presence and intensity of delirium, pain, dyspnea and 
feelings of hopelessness should be present in patients in the palliative trajectory. Adequate palliative 
care with careful assessment of potential reversible factors and non-sedating interventions should be the 
cornerstone of treatment before starting palliative sedation. Effective interventions in these patients could 
possibly prevent a refractory state for such symptoms, thereby possibly limiting the future need for CPS. 
Moreover, advance care planning and information on the indication and the preconditions of CPS early 
in the palliative trajectory are advisable in high-risk patients. This approach may prevent unforeseen 
situations and difficulties in communication at the bedside when problems arise. 
Furthermore, more attention should be paid to the suggested preconditions for administering CPS in cases 
in which existential suffering becomes an indication for CPS, especially the use of intermittent sedation 
and consultation with a palliative care consultant or spiritual counsellor. Additionally, in patients who 
have considerable oral intake before the start of continuous sedation, physicians should at least explicitly 
discuss the issue of artificial hydration and the possible concomitant life-shortening effect of CPS, or 
preferably should offer intermittent sedation. 
Finally, if an indication arises for the administration of CPS, it is important to communicate prior to the 
start of CPS which signs of discomfort are looked for during sedation. Currently, there is no validated 
and generally accepted scale for monitoring discomfort in sedated patients. Although further research on 
the psychometric properties of the DS-DAT is needed before this tool can be used in clinical practice, the 
individual items of this scale, e.g., facial expression, body language, fidgeting and negative vocalization, 
can already be used as parameters in clinical practice.
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Onder palliatieve sedatie wordt verstaan “het opzettelijk verlagen van het bewustzijn van een patiënt 
in de laatste levensfase”. Het doel van palliatieve sedatie is het verlichten van het lijden van de 
patiënt, veroorzaakt door de aanwezigheid van één of meer refractaire symptomen. Een symptoom 
is of wordt refractair als geen van de conventionele behandelingen (voldoende snel) effectief zijn en/
of deze behandelingen gepaard gaan met onaanvaardbare bijwerkingen. De term palliatieve sedatie 
omhelst twee verschillende vormen: kortdurend of intermitterend sederen en continu sederen tot het 
moment van overlijden (CPS). 
Hoewel CPS in toenemende mate wordt geaccepteerd als een mogelijke interventie binnen het nor-
maal medisch handelen, wordt CPS ook gezien als laatste redmiddel. CPS neemt niet alleen het lijden  
van de patiënt weg, maar zorgt ook voor een vermindering van de communicatieve vaardigheden. 
Hierdoor wordt de mogelijkheid bij de patiënt om potentieel positieve en betekenisvolle 
ervaringen te hebben weggenomen. In de laatste twee decennia is in de literatuur steeds meer 
aandacht gegeven aan deze interventie. Ook heeft de Koninklijke Nederlandsche Maatschappij tot 
bevordering der Geneeskunst (KNMG) in 2005 een richtlijn opgesteld waarin beschreven wordt 
wanneer palliatieve sedatie medisch gezien verantwoord is. Ondanks dat de KNMG richtlijn de 
indicatiestelling, de randvoorwaarden, het besluitvormingsproces en de uitvoering van palliatieve 
sedatie beschrijft en de literatuur steeds meer inzicht in de toepassing van CPS geeft, blijven 
in de praktijk nog vragen en knelpunten aanwezig over deze in toenemende mate toegepaste  
interventie. Ten eerste is weinig bekend over de vroegtijdige identificatie van hoog-risico patiënten 
voor de toepassing van CPS. De identificatie van dergelijke determinanten kan ervoor zorgen dat 
het verrichten van advance care planning bij hoog-risico patiënten verbetert, alsook hun kwaliteit 
van leven en sterven. Ten tweede is weinig bekend over de praktijk van de toepassing van CPS 
door specialisten ouderengeneeskunde in het algemeen en over de toepassing van CPS voor  
existentieel lijden in het bijzonder. Meer inzicht hierover geeft een belangrijke bijdrage aan de door-
ontwikkeling van richtlijnen en het verbeteren van het klinisch handelen in de dagelijkse praktijk.  
Als laatste, de KNMG richtlijn palliatieve sedatie beschrijft dat het monitoren van (continue)  
sedatie essentieel is, echter de wijze waarop het monitoren van lijden gedurende (continue) sedatie 
dient plaats te vinden blijft een open vraag. Hierdoor is weinig bekend over de effectiviteit van 
CPS en over determinanten van ontoereikende klachtenbestrijding gedurende CPS. Het doel van 
dit proefschrift was dan ook om meer inzicht in deze onderwerpen te verschaffen (hoofdstuk 1).
In hoofdstuk 2 wordt de uitkomst van een systematische review over determinanten van CPS 
beschreven. Deze review werd verricht met behulp van de zoeksystemen PubMed, EMBASE, en 
CINAHL. Acht artikelen voldeden aan de inclusiecriteria. De volgende negen factoren welke 
geassocieerd zijn met de toepassing van CPS werden gevonden: jongere leeftijd, mannelijk 
geslacht, het hebben van kanker, de aanwezigheid van gevoelens van hopeloosheid, het overlijden 
in een ziekenhuis, het woonachtig zijn in een Nederlands sprekende gemeenschap in België, de 
aanwezigheid van erg niet-religieuze of zeer niet-religieuze artsen, de aanwezigheid van artsen 
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werkzaam in een “ander” ziekenhuisspecialisme en de aanwezigheid van artsen welke voorstander 
zijn van hulp bij zelfdoding. Door de variatie in onderzoeksdesign en de beperkingen van de 
geïncludeerde studies dienen de resultaten van deze review met enige voorzichtigheid te worden 
geïnterpreteerd. Deze review laat zien dat nieuw onderzoek nodig is, met name naar factoren welke 
beïnvloed kunnen worden. Beïnvloeding van dergelijke factoren kan het beloop van de symptomen 
bij de patiënt veranderen, waardoor mogelijk ook de uiteindelijke noodzaak van de toepassing van 
CPS voorkomen kan worden.   
In zes hospices en drie palliatieve units van verpleeghuizen in Nederland werd een prospectief 
observationeel multicenter onderzoek verricht. Een doel van dit onderzoek was het exploreren 
welke patiëntgebonden factoren bij opname geassocieerd zijn met de toepassing van CPS in de 
laatste fase van het leven (hoofdstuk 3). De volgende variabelen werden geanalyseerd: leeftijd, 
geslacht, diagnose, gebruik van opioïden, gebruik van psycholeptica, aantal medicijnen, Karnofsky 
performance status scale score, Edmonton symptom distress score en Glasgow coma scale score. 
De resultaten laten zien dat enkel het gebruik van opioïden bij opname onafhankelijk geassocieerd 
is met de toepassing van CPS. In deze hoog-risico patiënten is reeds bij opname een uitgebreid 
persoonlijk zorgplan nodig. Dit hoofdstuk laat verder zien dat meer onderzoek nodig is om andere 
determinanten te identificeren en om te onderzoeken of vroegtijdige interventies bij deze hoog-risico 
patiënten effectief zijn in het voorkomen van de noodzaak van de toepassing van CPS. 
Hoofdstuk 4 beschrijft het onderzoek naar de praktijkvoering van CPS onder specialisten ouderen-
geneeskunde. Een gestructureerde enquête, met vragen over de laatste patiënt waarbij CPS werd 
toegepast, werd gestuurd naar 1254 leden van de vereniging van specialisten ouderengeneeskunde en 
sociaal geriaters. In totaal reageerden 675 artsen (respons 54%) en 316 patiënten werden beschreven. 
De meeste patiënten hadden kanker of dementie. In bijna alle casus was symptoombestrijding het 
doel van CPS. In bijna 1 op de 5 patiënten met kanker werd melding gedaan van een voorgaand 
euthanasieverzoek. Naast refractaire lichamelijke symptomen werden door specialisten ouderen-
geneeskunde ook refractaire symptomen als angst, uitputting, verlies van waardigheid en existentieel 
lijden benoemd als indicatie voor CPS. Midazolam was het meest gebruikte middel in deze studie en 
de genoemde doseringen komen overeen met de aanbevelingen van de landelijke KNMG richtlijn 
palliatieve sedatie. Dit hoofdstuk laat de noodzaak zien voor prospectief onderzoek. Met dergelijk 
onderzoek kan inzicht verkregen worden over de wijze waarop niet-lichamelijke klachten in kaart 
gebracht worden, over de aanvaardbaarheid van dergelijke klachten als indicatie voor CPS en de 
achterliggende redenen om een voorgaand euthanasieverzoek niet in te willigen.      
Sommige richtlijnen en aanbevelingen benoemen existentieel lijden als een potentieel refractair 
symptoom, waarvoor onder bepaalde voorwaarden CPS gegeven kan worden. Om meer inzicht te 
krijgen in deze specifieke indicatie voor CPS werd een subanalyse van de resultaten van het enquête 
onderzoek verricht (hoofdstuk 5). Existentieel lijden was een refractair symptoom bij 83 patiënten. 
Bij de meeste patiënten met existentieel lijden werd ook de aanwezigheid van andere refractaire 
symptomen beschreven en was de levensverwachting zeven dagen of minder. Bij alle patiënten was 
informed consent verkregen voor de start van CPS. Consultatie en het gebruik van intermitterende 
sedatie voor de start van CPS werden beduidend minder frequent beschreven dan verwacht zou 
worden op basis van de voorwaarden genoemd in richtlijnen en aanbevelingen. Multivariate analyse 
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laat zien dat het hebben van het mannelijke geslacht, een voorgaand euthanasieverzoek, een ziekte 
van het zenuwstelsel of een “andere” diagnose positief gecorreleerd zijn met de toepassing van CPS 
voor existentieel lijden. Meer aandacht dient uit te gaan naar de voorwaarden voor CPS bij deze 
indicatie en naar de aanwezigheid van existentieel lijden bij mannelijke patiënten en bij patiënten 
met een ziekte van het zenuwstelsel.
In hoofdstuk 6 wordt het prospectief observationeel multicenter onderzoek beschreven, waarin 
gekeken is naar het beloop van discomfort in gesedeerde patiënten en naar determinanten van 
discomfort tijdens de toepassing van CPS. Het onderzoek heeft plaatsgevonden in negen hospices 
en palliatieve units.
De Discomfort Scale–Dementia of Alzheimer Type (DS-DAT) werd onafhankelijk afgenomen om de 
mate van discomfort voor en tijdens de toepassing van CPS te meten. De gemiddelde groepsscore 
van de DS-DAT tussen vier vooraf gedefinieerde tijdframes werd vergeleken. In totaal werd bij 130 
patiënten CPS toegepast en werd bij 106 patiënten ten minste 1 meting van de DS-DAT verricht. De 
mate van discomfort daalde significant binnen 8 uur na de start van de sedatie en bleef aansluitend 
relatief stabiel tot aan het moment van overlijden. Een intake van een kleine hoeveelheid vocht 
of meer en de aanwezigheid van het symptoom braken of meerdere symptomen waren positief 
geassocieerd met een hogere gemiddelde score van de DS-DAT in de laatste acht uur van het leven. 
Deze studie laat zien dat de toepassing van CPS is geassocieerd met een verlaging van de mate van 
discomfort binnen een acceptabel tijdsbestek, alhoewel in de laatste uren van het leven bij sommige 
patiënten ook hogere scores van discomfort aanwezig waren. De DS-DAT lijkt van toegevoegde 
waarde om de mate van discomfort te monitoren gedurende CPS, echter de resultaten van deze 
studie dienen in het licht van de beperkingen van het onderzoek gezien te worden. Voordat de 
DS-DAT in de praktijk gebruikt kan worden, is verder onderzoek naar de psychometrische 
eigenschappen van deze schaal nodig.  
De hoofdresultaten van dit proefschrift, de methodologische overwegingen en de implicaties voor de 
praktijk en toekomstig onderzoek worden bediscussieerd in hoofdstuk 7. Dit proefschrift laat zien 
dat de toepassing van CPS een verlaging van de mate van discomfort geeft binnen een acceptabel 
tijdsbestek. CPS lijkt dan ook een effectieve interventie voor refractaire symptomen in de laatste 
dagen van het leven van een patiënt. Daarentegen dient CPS gezien te worden als laatste redmiddel 
en lijkt het niet een one-size-fits-all interventie, aangezien bij sommige gesedeerde patiënten nog 
steeds hogere scores van discomfort in de laatste uren van het leven worden gezien. Om deze reden 
dient zowel in de praktijk als in de landelijke richtlijn palliatieve sedatie meer bewustwording te 
komen voor het monitoren van tekenen van opiaatintoxicatie en de aanwezigheid van delier, pijn, 
dyspneu en gevoelens van hopeloosheid bij patiënten in de palliatieve fase. Voordat CPS wordt 
toegepast, dient adequate palliatieve zorg te worden gegeven, waarbij actief gezocht wordt naar 
reversibele oorzaken van klachten en waarbij niet sederende interventies worden ingezet. Effectieve 
interventies kunnen mogelijk het ontstaan van refractaire symptomen voorkomen, waardoor de 
noodzaak voor de toepassing van CPS mogelijk minder vaak aanwezig is. Bovendien is advance 
care planning en het geven van informatie over de indicatie en voorwaarden van CPS vroegtijdig 
in het palliatief traject aan te bevelen. Een dergelijke aanpak kan mogelijk onvoorziene situaties en 
problemen in de communicatie, op het moment dat problemen ontstaan, voorkomen.  
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Tevens dient meer aandacht te worden geschonken aan de voorgestelde voorwaarden voor de 
toepassing van CPS op het moment dat existentieel lijden de indicatie gaat vormen. Het gaat dan met 
name om de voorwaarde van het toepassen van intermitterende sedatie en het consulteren van een 
palliatief consulent of spiritueel verzorger voorafgaand aan CPS. Verder dient bij patiënten met een 
aanzienlijke intake voor de start van CPS het mogelijk levensbekortend effect van CPS en de voor- en 
nadelen van kunstmatige vochttoediening tijdens CPS te worden besproken, of dient bij voorkeur 
intermitterende sedatie te worden gegeven.  
Tot slot is het belangrijk dat als een indicatie voor de toepassing van CPS ontstaat, reeds voor de start 
van CPS te bespreken naar welke signalen van discomfort wordt gekeken gedurende de sedatie. 
Momenteel is nog geen gevalideerde en geaccepteerde schaal voor het monitoren van discomfort 
in gesedeerde patiënten aanwezig. Ondanks dat verder onderzoek naar de psychometrische 
eigenschappen van de DS-DAT nodig is voordat deze in de praktijk gebruikt kan worden, kunnen 
de individuele items van deze schaal al wel als parameters gebruikt worden. Hierbij kan gedacht 
worden aan de items gelaatsuitdrukking, lichaamstaal, bewegingsonrust en negatief stemgebruik.
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Dit hoofdstuk is 1 van de moeilijkste hoofdstukken uit het proefschrift, de angst dat ik iemand vergeet 
blijft aan mij knagen. Ik heb gepoogd om iedereen die een rol heeft gespeeld in het onderzoek, direct of 
langs de zijlijn, te benoemen. Mocht ik toch iemand vergeten zijn, spreek mij aan, en ik zal alsnog een 
persoonlijk woord van dank uitspreken!
Met de insteek om een bijdrage te leveren aan de verdere wetenschappelijke onderbouwing van de 
palliatieve zorg in het algemeen, en het vakgebied van de specialist ouderengeneeskunde in het bijzonder, 
ben ik het traject van promotieonderzoek begonnen. De keuze van het onderwerp was snel gemaakt. De 
toepassing van palliatieve sedatie heeft altijd mijn belangstelling gehad, zich al uitend in een publicatie 
over het onderwerp gedurende mijn opleiding tot verpleeghuisarts en mijn deelname aan de KNMG 
richtlijncommissie palliatieve sedatie. Enerzijds een behandeling om onbehandelbaar ondraaglijk lijden te 
bestrijden. Anderzijds een behandeling waarmee je het bewustzijn van een patiënt in de laatste levensfase 
vermindert. Hierdoor wordt de communicatie tussen patiënt en zijn omgeving beperkt of onmogelijk 
gemaakt, terwijl dit in deze belangrijke fase van iemands leven wel wenselijk zou zijn. Het is en blijft 
een boeiend onderwerp! Ik ben dan ook vol goede moed aan het onderzoek begonnen, waarbij ik al snel 
ontdekte dat de steun en betrokkenheid van vele mensen onmisbaar zijn in het verwezenlijken van een 
promotieonderzoek. Ik wil deze mensen dan ook hartelijk danken voor hun bijdrage en ondersteuning, 
zonder hen was het (afronden van het) onderzoek niet mogelijk geweest.
Om te beginnen wil ik alle patiënten en naasten bedanken welke een bijdrage hebben geleverd aan het 
prospectieve gedeelte van mijn onderzoek. In de laatste fase van het leven, waar ziekte niet alleen op 
lichamelijk, maar ook op sociaal en geestelijk vlak een grote impact heeft, hebben zij desondanks de 
tijd en moeite genomen om een bijdrage te leveren aan het verrichten van wetenschappelijk onderzoek. 
Daarnaast wil ik de specialisten ouderengeneeskunde (in opleiding), welke gereageerd hebben op de 
enquête, en verpleging en artsen van de deelnemende instellingen van het prospectieve gedeelte van 
mijn onderzoek bedanken, met een speciaal woord van dank voor Marleen van Casteren voor het lezen 
en becommentariëren van het laatste artikel. In de hectiek van alle dag, waarin verpleging en artsen 
met hart en ziel de zorg voor mensen in de palliatieve fase op zich nemen, hebben zij toch ruimte voor 
mijn onderzoek kunnen vrijmaken. Ook mijn dank aan de besturen van de deelnemende organisaties 
voor hun ondersteuning: Groenhuysen, Kalorama, Liemerije, Sevagram, Volckaert, De Waalboog, De 
Zorgboog en De Zorggroep.
Natuurlijk ook dank aan mijn promotoren! Raymond, aangezien je naast jouw rol als mijn promotor 
ook een collega van mij bent, wil ik je als eerste bedanken. Je was voor mij een steun en toeverlaat, als 
ik even in de put zat was je altijd beschikbaar en kon mij door jouw enthousiaste houding weer de 
benodigde energie geven. Altijd bereid om mee te denken, kritisch en constructief. Ook in discussies 
bij de gezamenlijke overleggen voelde ik vaak jouw steun, waarbij vermoedelijk onze gezamenlijke 
achtergrond als specialist ouderengeneeskunde een rol heeft gespeeld. Kris, jouw leerstoel laat zien waar 
jouw hart ligt: de palliatieve zorg, hetgeen ook terug te zien was in je inbreng tijdens de gezamenlijke 
overleggen. Bedankt dat je samen met mij dit traject bent aangegaan. 
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Daarnaast, en zeker niet onbelangrijk in de begeleiding van een promovendus, mijn waardering voor 
de copromotoren. Stans en Jeroen, een beter duo kun je als promovendus niet treffen! Daar waar het 
nodig was in het begeleidingstraject, vulden jullie elkaar. Stans met de klinische invalshoek, veel kennis 
van de materie en waarbij geen enkel detail uit het oog werd verloren, Jeroen met de helikopter view, 
zijn analytisch vermogen en degene die op een positieve manier iedereen terugfloot als we tijdens de 
overleggen (ruim 70 keer) afdwaalden van het onderwerp. Naast de (co)promotoren ook natuurlijk dank 
aan de leden van de manuscriptcommissie voor hun kritische blik en goedkeuring van het manuscript. 
Ook andere mensen hebben mij tijdens het onderzoek geholpen. Zeker in het eerste gedeelte heb ik erg veel 
steun mogen ervaren van Jeroen Krijnsen bij het ontwikkelen van de enquête en het invoeren, analyseren 
en uitwerken van de gegevens.  Helaas heb je het pad van het specialisme ouderengeneeskunde verlaten 
en ben je de kant van de klinische geriatrie opgegaan. Mocht je toch nog een keer terug willen komen op 
je keuze, je bent in het Limburgse altijd welkom! Ik wil Jenny van der Steen en Ann Hurley bedanken 
voor het beschikbaar stellen van de digitale versie van de DS-DAT en de daarbij behorende instructie, en 
Hella Brandt voor het beschikbaar stellen van voorbeelden van informatiebrieven voor patiënten. Ook 
een woord van dank aan Judith Duiker van het Integraal Kankercentrum Nederland, artikelen welke 
ik zelf niet kon bemachtigen werden meestal door jou wel gevonden, en vaak binnen een zeer kort 
tijdsbestek. Daarnaast mijn dankbetuiging aan Jeroen Fokke, welke heeft opgetreden als onafhankelijke 
arts tijdens mijn onderzoek en gelukkig niet veel te doen heeft gehad. Ook wil ik Daphne van den Berg 
bedanken, jouw ondersteuning bij het invoeren van de gegevens in SPSS heeft mij veel tijd en kopzorgen 
bespaart. Als laatste van deze mensen wil ik Hans Bor bedanken. Als een arts onderzoek uitvoert, is de 
aanwezigheid van een statisticus onontbeerlijk. Hans, bedankt voor je eindeloos geduld met mij, je altijd 
duidelijke uitleg en je snel reageren op mijn vele e-mails. 
Natuurlijk wil ik ook mijn directe collegae bedanken. Jullie hebben me af en toe voor de gek gehouden (is 
het nu nog niet klaar…), maar jullie zijn zeker voor mij altijd een steun geweest, met name in de perioden 
waar het even wat moeizamer ging. Het is fijn om met zo’n betrokken en gezellige collegae te werken! 
Ook wil ik mijn opdrachtgever, de Zorggroep, niet vergeten! Ondanks de huidige maatschappelijke 
ontwikkelingen, waarin het soms moeizaam is om binnen de steeds kleiner wordende financiële kaders 
kwalitatief optimale zorg te kunnen blijven leveren in onze sector, is het lovenswaardig dat binnen De 
Zorggroep ook aandacht uitgaat naar de verdere wetenschappelijke onderbouwing van het specialisme 
ouderengeneeskunde en de palliatieve zorg in het bijzonder.
Ik wil het toepclubje, de matties van het thaiboxen, de Ranso’s, (ex)trainers en leiders van de Venlosche Boys, 
de Höltjes, Stijn en Myriam, Rob en Marianne en alle andere vrienden bedanken voor de belangstelling 
en het aanhoren van mijn geklaag. Een speciaal woord van dank voor Rob voor het meehelpen met het 
versturen van de enquêtes (toch een behoorlijk werk als je alles opnieuw moet doen…) en voor Marc voor 
het opmaken van dit proefschrift. 
Tot slot wil ik mijn naaste familie danken. Mijn vader, trots op zijn “lievelingetje” (zoals mijn broers mij 
altijd beschreven) vanwege het promotietraject. Je hebt het traject grotendeels mee kunnen maken, maar 
helaas niet mee af kunnen sluiten, hetgeen je net voor je overlijden aangaf erg jammer te vinden. Papa, 
ik weet zeker dat je van boven met een goed gevoel naar ons aan het kijken bent, de befaamde uitspraak 
in de laatste dagen van je leven siert nu dit proefschrift. Mama, altijd bezorgd! De vele telefoontjes, het 
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lezen van de artikelen en je grote interesse in mijn onderzoek en welzijn hebben mij altijd goed gedaan. 
Hay en Jannie, mijn schoonouders, naast jullie emotionele steun hebben jullie, samen met jullie zoon 
en mijn zwager Jan, zelfs nog fysieke arbeid moeten verrichten bij het verzenden van de enquête. Mijn 
broers, Teun en Willem-Jan, wil ik bedanken. Naast jullie steun tijdens het onderzoek waren jullie ook 
bij de life events de afgelopen periode voor mij een steun in de rug. Mijn schoonzussen Ellen en Barbara 
wil ik natuurlijk niet vergeten (achter elke belangrijke man staat nog een belangrijkere vrouw, hetgeen 
natuurlijk ook voor mijn broers geldt), ik heb meerdere malen dankbaar gebruik gemaakt van Barbara 
haar vaardigheden op het gebied van de Engelse taal. 
Aan het einde van de rij met dankzeggingen wil ik graag mijn oogappels benoemen: mijn kinderen Tom, 
Anne en Bas. Bedankt dat jullie (meestal) rustig waren op de momenten dat ik op het zolderkamertje 
achter de computer aan het zweten was en voor het meerekenen tijdens de analysefase (waar zit toch 
het knopje op het rekenmachine van de macht tot de 10e…). Gedurende het promotietraject zijn jullie 
letterlijk en figuurlijk als personen gegroeid. Ik ben trots op jullie! Als allerlaatste mijn vrouw Ans, mijn 
steun en toeverlaat. Bedankt voor je bemoedigende woorden in de momenten dat ik het even niet meer 
zag zitten, bedankt voor de ruimte welke je mij gaf om dit traject aan te gaan en af te kunnen ronden en 
bedankt voor je altijd vertrouwde aanwezigheid!
Dankwoord
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Rogier van Deijck (16 maart 1972) is geboren en getogen in Breda en haalde in 1990 daar zijn Atheneum-B 
diploma aan de Nassau Scholengemeenschap. In hetzelfde jaar startte hij met de studie geneeskunde aan 
de Katholieke Universiteit Nijmegen. In 1998 behaalde hij zijn artsexamen. In afwachting van de start van 
de vervolgopleiding tot huisarts ging hij werken bij De Zorggroep, destijds de Professor Dubois Stichting 
geheten. Tijdens de werkzaamheden in het verpleeghuis ontstond zijn interesse in de palliatieve zorg en 
het multidisciplinair werken. Het deed hem besluiten om de switch te maken naar het volgen van de 
opleiding tot verpleeghuisarts aan de Katholieke Universiteit Nijmegen. Deze opleiding voltooide hij in 
2002, sindsdien is hij als specialist ouderengeneeskunde bij De Zorggroep werkzaam. 
Hij heeft zich verder ontwikkeld op het gebied van de palliatieve zorg middels de kaderopleiding 
palliatieve zorg aan de Vrije Universiteit en de Universiteit van Amsterdam te Amsterdam. Deze 
opleiding heeft hij in 2007 met goed gevolg afgerond. Naast de werkzaamheden als arts voor mensen in 
de palliatieve fase, is hij ook als consulent bij het Integraal Kankercentrum Nederland en het Transmuraal 
Palliatief Team Noord-Limburg werkzaam. Ook was hij betrokken bij het maken van diverse richtlijnen 
op het gebied van palliatieve zorg. Een richtlijn waar hij ruim 11 jaar bij betrokken is geweest, is de richtlijn 
palliatieve sedatie van de Koninklijke Nederlandsche Maatschappij tot bevordering der Geneeskunst.
In 2009 is hij gestart met zijn promotieonderzoek met palliatieve sedatie als onderwerp, onder begeleiding 
van Prof. Dr. R.T.C.M Koopmans, Prof. Dr. K.C.P. Vissers, Dr. C.A.H.H.V.M. Verhagen en Dr. G.J. Hasselaar. 
Van dit onderzoek wordt verslag gedaan in het proefschrift dat voor u ligt. Hij hoopt na afronding van zijn 
promotie de vruchtbare samenwerking voort te zetten, om zo de nog aanwezig data van het prospectieve 
gedeelte van zijn onderzoek openbaar te maken. Daarnaast hoopt hij weer meer tijd vrij te kunnen maken 
voor de patiëntenzorg.
Rogier van Deijck is sinds 1998 getrouwd met Ans Gielen, samen hebben ze 3 kinderen: Tom (1999),  
Anne (2001) en Bas (2002).
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